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Coronary heart disease (CHD) and depression are very common and often co-existing 
disorders. The prevalence of depression among patients with CHD is considerably higher 
as compared to the general population. Depression exacerbates adverse cardiac outcomes 
in CHD patients increasing the risk of cardiovascular morbidity and mortality, besides 
worsening the psychological and social morbidity. Inflammation has been recognised to 
be involved in the association between these two debilitating disorders.  
Therefore, the present PhD thesis aimed to evaluate inflammatory responses and to 
investigate the pathophysiological mechanisms underlying the inflammatory activation in 
CHD patients with and without depression by assessing the function of two important 
biological factors regulating inflammation: the hypothalamus-pituitary-adrenal (HPA) 
axis and the glucocorticoid receptor (GR). Serum C-reactive protein (CRP), and plasma 
and salivary cortisol were measured using commercially available ELISA kits. Gene 
expression of GR and inflammatory biomarkers were analysed by means of quantitative 
real time PCR. GR function was assessed in vitro in isolated peripheral blood 
mononuclear cells using the dexamethasone inhibition of lipopolysaccharide-stimulated 
IL-6 production method. Serum levels of kynurenine pathway of tryptophan metabolism 
metabolites were measured using high performance liquid chromatography.  
CHD patients with depression showed higher CRP levels and IL-6 gene expression 
compared with CHD non-depressed. Both plasma cortisol levels and salivary cortisol 
awakening response were significantly lower in patients with depression when compared 
with CHD alone. The CHD depressed group exhibited a reduction in GR expression and 
function. Tryptophan levels were significantly lower in patients with depression who also 
showed an increased kynurenine/tryptophan ratio, which in turn was associated with an 
increased in 3-hydroxykynurenine level.  
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In CHD patients, depression was accompanied by elevated levels of inflammation in the 
context of HPA axis hypoactivity, GR resistance, and increased activation of the 
kynurenine pathway. Reduced cortisol bioavailability and attenuated glucocorticoid 
responsiveness due to decreased numbers and sensitivity of GR may lead to insufficient 
glucocorticoid signalling and thus elevation of inflammation in CHD patients with 
depression. An increased inflammatory response may in turn lead to a diversion of the 
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1.1 Major Depressive Disorder (MDD) 
 
1.1.1 Definition and Epidemiology of Depression 
Major depressive disorder (MDD) or clinical depression is a very common mental 
disorder characterized by distinct low mood and persistent emotions of sadness, 
hopelessness, emptiness, or irritability; and accompanied by loss of interest to enjoyable 
activities and diminished ability to response to pleasurable stimuli (anhedonia). Patients 
with major depression display clinically significant behavioural, cognitive, and 
psychophysiological changes. The symptoms include low energy, appetite impairments 
(weight gain or loss), sleep disturbances (such as insomnia or hypersomnia), and 
alteration in sexual desire. In addition, depressed people experience poor memory and 
concentration, slowing of actions and speech, difficulties making decisions and engaging 
or holding conversations, and attention deficits. Crying, feelings of regret, worthlessness 
or inappropriate guilt, and recurrent suicide thoughts are other symptoms present in 
depression. According to American Psychiatric Association (APA) stated in fifth edition 
of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) at least five of the 
symptoms of major depressive episodes must persist for a minimum of two weeks and 
nearly every day, to meet the diagnostic criteria for MDD considering that one of the 
symptoms must be either depressed mood or loss of interest/pleasure (APA, 2013, 
Belmaker and Agam, 2008).    
 
Depression, in general, is a complex and heterogeneous condition with no one established 
aetiology, variable course, and inconsistent response to treatment (Belmaker and Agam, 
2008, Stetler and Miller, 2011). Depression can be a chronic and highly episodic disorder. 
Some patients experience MDD only in a single episode with almost two-thirds being 
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recovered within first year. However, the majority of patients, almost more than 75%, 
develop recurrent episodes usually within two years of recovery (Mueller et al., 1999, 
Solomon et al., 2000). Based on the clinical presentation and neurovegetative symptoms, 
MDD has been defined into various subtypes. For instance, melancholic depression is 
markedly characterised by pervasive anhedonia, diurnal variation of mood being worse in 
the morning, psychomotor retardation, early morning waking, decreased appetite and 
weight loss (Uher et al., 2011). In contrast, depression with atypical features is mainly 
marked by mood reactivity, extreme lethargy and fatigue, interpersonal rejection 
sensitivity, hypersomnia, weight gain and increased appetite (Gold and Chrousos, 2002, 
O'Keane et al., 2012).   
 
Amongst all psychiatric conditions, depression is the most prevalent one affecting 4% to 
7% of the general population (Eaton et al., 2007, Kessler, 2002). While the prevalence of 
depression is about 6% in men at any one time and 7%-12% lifetime incidence risk, the 
rates are higher in women to up to 18% with the lifetime risk of 20%-25% (Kemp et al., 
2003, Kessler, 2003). Results from the International Consortium of Psychiatric 
Epidemiology (ICPE) Surveys revealed that being female and unmarried are the two 
major consistent socio-demographics that correlate with depression (Andrade et al., 
2003). Depression is a universal human condition which affects individuals of all 
ethnicities and cultures.  The disorder is also observed in all age groups. In the past, 
depression was mainly considered as a disorder of adulthood. However, after large 
evidence from epidemiological studies including adolescents as well as improvement in 
diagnoses of depression in children, it is now known that in many cases depressed adults 
experienced their first depressive symptoms in their adolescence (Burke et al., 1990, 
Kessler, 2002). With a growing elderly population, late-life depression is also a cause of 
concern. Specifically because the elderly tend to escape the strict criteria of the DSM of 
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clinical depression, since they often only display some symptoms of depression that 
clinically are believed to be associated with increased risk of disability and mortality in 
this population (Beekman et al., 2002, Kohn and Epstein-Lubow, 2006, Mulsant and 
Ganguli, 1999).    
 
1.1.2 Depression in the Medically-ill  
While depression affects millions of people worldwide, the prevalence rate greatly 
increases when comorbid with chronic physical conditions and medical illnesses. 
Prolonged physical illnesses such as asthma, diabetes, arthritis, heart disease, cancer, 
Alzheimer's and Parkinson’s diseases are all associated with a high risk of comorbid 
depression (Cowles et al., 2009, Moussavi et al., 2007). Studies argue possible 
mechanisms underlying comorbidity of chronic medical conditions and depression such 
as physiological mechanisms, behavioural and environmental factors, and/or common 
genetic vulnerabilities (Licinio et al., 2002, Voinov et al., 2013). Many lines of evidence 
also suggest there is an association between medications and therapies related to medical 
illnesses and increased risk of developing depression. For example, interferon-α (INF-α) 
treatment for hepatitis C and cancer has been shown to be associated with development of 
depressive symptoms (Dieperink et al., 2003, Hauser et al., 2002, Wichers et al., 2005). 
 
Depression has a huge impact on medically ill patients’ health status leading to poorer 
quality of life and loss of productivity, and also increasing the risk of illness 
complications and death (Carney and Freedland, 2003, Noel et al., 2004).  In addition, 
medically ill patients with comorbid depression are less able to cope with their physical 
symptoms related to their condition than patients without depression. In fact, depression 
seems to adversely affect the adaptation process in these patients (Cowles et al., 2009). 
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Furthermore, poor adherence to medication is another challenging issue associated with 
comorbidity of depression in patients with chronic illnesses (Grenard et al., 2011). 
Moreover, severe consequences of comorbid depression not only affect the health and 
social welfare of the patient as an individual, but also their families as well as having 
substantial economic and social impact on the wider community (Louch, 2009, Moussavi 
et al., 2007). 
 
Unfortunately, depression in medically ill patients is generally under-recognized and 
consequently under-treated by health organizations. In fact, the presence of depressive 
symptoms is sometimes considered to be an understandable psychological reaction and 
natural response to the long term medical disorder the patient is dealing with. Thus, 
depression often can be normalized by the general practitioners, one of the main barriers 
in the management of depression in patients with chronic conditions (Coventry et al., 
2011, Cowles et al., 2009).  
 
1.1.3 Heart Disease and Depression 
Heart disease and depression are two very common and often co-existing disorders 
affecting the population worldwide. According to the World Health Organization Global 
Burden of Disease Survey, coronary heart disease (CHD) and major depression are 
currently the first and second causes of disability in developed countries, and it is 
estimated that this will apply to all countries throughout the world  by the year 2020 
(Blazer, 2000, Licinio et al., 2002). The prevalence of depression among patients with 
established CHD is considerably higher as compared to the general population (Carney 
and Freedland, 2003). More than 50% of all heart disease patients experience symptoms 
of depression. Approximately, 17%-27% of outpatients and 35%-70% of inpatients with 
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CHD meet criteria for major depression compared to 4%-7% in the general population 
(Carney and Freedland, 2008, Rudisch and Nemeroff, 2003, Rutledge et al., 2006). In a 
study by Polsky et al., following up patients for eight years after new diagnosis of a 
medical illnesses, heart disease patients were found to have consistently higher risk for 
development of depressive symptoms compared to patients diagnosed with chronic lung 
disease, arthritis, diabetes, and cancer (Polsky et al., 2005). 
 
In addition to psychological and social morbidity, depression exacerbates adverse cardiac 
outcomes in CHD patients. The study by Frasure-Smith and colleagues in 1993 
introduced major depression as a significant predictor and risk factor for mortality in 
patients hospitalised following myocardial infarction (MI) (Frasure-Smith et al., 1993). 
Indeed, after several epidemiological and meta-analysis studies since then, depression is 
now recognized as a negative prognostic indicator and an independent factor greatly 
increasing the risk of cardiovascular related morbidity and mortality, regardless of 
aetiology and other known cardiac risk factors (Jiang et al., 2002, Meijer et al., 2011, 
Miller et al., 2002). However, the pathophysiological mechanisms underlying the 
increased incidence of depression in patients with CHD are yet to be understood, despite 
the severe consequences for the patients’ health. 
 
The relationship between heart disease and depression is bidirectional and multifaceted 
(Lippi et al., 2009). The mechanisms associated with the link between the two diseases 
are not completely understood and identifying the underlying mechanisms remains a big 
challenge (Whooley and Wong, 2013). Various genetic and biological approaches 
suggested the possibility of shared genetic substrates (see page 191) and/or outcome of 




Despite the findings in regards to bidirectional association between these two devastating 
disorders, and that the depression is a robust and independent risk factor for heart disease, 
both aetiologically and prognostically, clinical recognition of depression in heart disease 
patients is generally complex and a significant concern. Indeed, depression in heart 
disease patients in more likely to be under-diagnosed compared with those who only 
suffer from depression (Jiang et al., 2002). This brings the importance of screening and 
monitoring of depression in patients with heart disease, applying appropriate treatment 
plan, and whether the treatment of depression would ease and improve the prognosis of 
their cardiac condition. 
 
Up-to-date there is no one established mechanism that can explain the increased incidence 
of depression in heart disease. There seems to be, however, shared vulnerability factors 
between these two disorders. Identification of biomarkers that predict future development 
of depressive symptoms in heart disease patients would help in the early diagnosis and 
treatment of depression, and could potentially decrease the early morbidity and mortality 
associated with depression in this population. This would be in turn possible through 
identifying exact pathways underlying the association between these two common mental 
and physical disorders.  
 
Therefore, the present PhD thesis focuses on the potential mechanisms underlying the 
pathophysiology of depression in heart disease patients trying to advance further the 
current understanding of the link between these two debilitating conditions by 
investigating the possible biological pathways involved and exploring the consequences 





In the next section, major theories proposed the behind pathogenesis of depression will be 
described followed by a review of current knowledge in relation to the mechanisms 
associated with development of MDD in general that would in turn help us to better 
























1.2 The Biological Basis of Depression 
 
1.2.1 Major Theories Behind Pathogenesis of Depression 
There have been mounting lines of investigations trying to understand the biological 
mechanisms underlying the causality and pathogenesis of major depression. In spite of 
various theories proposed, there is no one established mechanism associated with 
depression due to the complexity and heterogeneous nature of this disorder. Some of the 
main approaches in this regard are being mentioned in the following paragraphs. 
 
The genetic approach elucidates the heritability of depression considering the evidence of 
specific associated genes, dependent or independent heritable depression prone 
personality traits, and also family history of depression as one of the strong predictor 
(Kendler et al., 2006, Levinson, 2006). However, heritability of MDD is only moderate 
and to develop depression environmental factors and major life stressors interact with 
genetic vulnerability (Firk and Markus, 2007).  
 
The monoamine-deficiency hypothesis as one of the major theories of depression claims 
depletion in monoamine neurotransmitters serotonin and norepinephrine in the brain in 
depressed people (Schildkraut, 1965). The hypothesis attempted to explain the efficacy of 
early antidepressants: tricyclic antidepressants and monoamine oxidase inhibitors, which 
increase the availability of the monoamine neurotransmitters in the synapse (Belmaker 
and Agam, 2008, Kalia, 2005). More recent studies have shown that it is in fact the 
interaction between serotonin reduction with other neurotransmitters and their associated 
proteins that is implicated in the pathophysiology of depression rather than just the 
serotonin deficiency (Kalia, 2005). Furthermore, alterations in serotonin receptor 
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expression and function are also implicated in MDD (López-Figueroa et al., 2004, Pierz 
and Thase, 2014). 
 
Another approach in understanding the biological basis of depression is coming from 
studies on communication between the endocrine and immune systems and the brain, and 
indeed the association between immune alteration and depression (Blalock, 1994, 
Hopkins and Rothwell, 1995). The macrophage theory of depression proposed by Smith 
hypothesized excessive secretion of macrophage monokines as a cause of depression 
(Smith, 1991). In addition, the hypothalamic-pituitary-cortisol hypothesis suggests the 
alteration in cortisol response to stress as an underlying mechanism of pathophysiology of 
depression (Belmaker and Agam, 2008).  
 
In fact, the more recent psychiatric approaches on mechanisms involved in the 
pathogenesis of MDD are focusing on the developments in psychoneuroimmunology 
research considering the neural-immune interaction and involving the role of 
inflammatory processes. The theory is now known as cytokine hypothesis of depression 
developed by consistent findings of elevated levels of pro-inflammatory cytokines, and 
their action as neuromodulators, in MDD patients (Schiepers et al., 2005). The latest 
theory has led to the inflammatory and neurodegenerative hypothesis by Maes et al. 
stating that inflammatory processes are associated with depression leading to the 
diminished neurogenesis and increased neurodegeneration observed in MDD patients 
(Maes et al., 2009).   
 
Taking into the consideration all the theories mentioned above, this PhD thesis, has 
particularly focused on the role of inflammation in the pathogenesis of depression trying 
to better understand the pathophysiological mechanisms underlying inflammatory 
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activation, their association with adrenocortical and serotonergic system, and their 
consequences as a comorbid condition. The following sections describe the main 
physiological systems responsible for the regulation of immune and inflammatory 
response and their involvement in pathophysiology of depression.  
 
1.2.2   Hypothalamic-Pituitary-Adrenal (HPA) Axis 
Involvement of the hypothalamic-pituitary-adrenal (HPA) axis in depression has been 
reported consistently by various studies (Pariante and Miller, 2001). HPA axis is a main 
physiological circuit which connects the brain with the endocrine system and plays a 
fundamental role as a regulatory system in stress responses. In response to psychological, 
physical, and/or environmental stress stimuli, HPA system (Figure 1.1) is activated by 
stimulation of hypothalamus secreting corticotrophin-releasing hormone (CRH) and 
arginine vasopressin (AVP) peptides secreted by the parvocellular neurons of the 
hypothalamic paraventricular nucleus (PVN). These neuropeptides exert their effect on 
the pituitary gland promoting the release of adrenocorticotropic hormone (ACTH) from 
the anterior lobe of the gland into the bloodstream. Circulating ACTH in turn triggers the 
biosynthesis and secretion of glucocorticoids (GCs) from the adrenal cortex via acting on 
type 2-melanocortin receptor (Breedlove et al., 2007, McQuade and Young, 2000).  
 
GCs, cortisol (mainly in human and primates) and corticosterone (mainly in rodents), are 
the final product of the HPA axis. These steroid hormones are synthesized from 
cholesterol and exhibit a critical role in restoring and maintaining bodily stress-related 
homeostasis, modulating neuroendocrine and immune responses, regulating energy 
metabolism and inflammatory reactions, and influencing cardiovascular function 
(Breedlove et al., 2007, McQuade and Young, 2000).  
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The physiological function of the endogenous GCs, both central and peripheral effect, is 
mediated upon their interaction with specific intracellular receptors expressed in target 
tissues including the HPA axis itself where they play a critical role in maintaining the 
intrinsic homeostasis of the axis activity. In fact, the receptors facilitate regulation of 
HPA axis activity through GC-mediated negative feedback mechanisms inhibiting the 
secretion of ACTH from the pituitary as well as CRH from the hypothalamus (De Kloet 
et al., 1998, de Kloet et al., 2005).    
 
Due to the central role of the HPA axis in the regulation of stress responses, and extensive 
evidence indicating the involvement of the system in the pathophysiology of stress-
related disorders including MDD that will be discussed shortly in section 1.2.4 , in this 
PhD thesis, HPA axis is assessed by measuring the concentrations of circulating cortisol 
in plasma and also free cortisol levels in saliva. Disturbances in the HPA axis activity 
could be reflected in alterations in the levels of cortisol as the end product of the circuit 
that is investigated in this PhD thesis together with assessing the function of their specific 
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Figure 1.1 Schematic Diagram of the HPA Axis and Glucocorticoid Mediated 
Negative Feedback Regulation (McQuade and Young, 2000).  
In response to the stress stimuli, hypothalamic-pituitary-adrenal (HPA) axis is activated by 
stimulation of corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) secreted 
by hypothalamic paraventricular nucleus (PVN) which receives neuronal inputs from various 
brain regions including hippocampus, amygdala, and midbrain. CRH and AVP then promote the 
release of adrenocorticotropic hormone (ACTH) from the pituitary gland. ACTH in turn triggers 
the secretion of glucocorticoids (GCs) from the adrenal cortex. GCs, cortisol in human, are the 
final product of the HPA axis, and mediate their effect upon their interaction with glucocorticoid 
receptors (GRs). The specialised receptors are expressed in target tissues including the 
hippocampus and the HPA axis tissues where they facilitate regulation of HPA axis activity 
through GC-mediated negative feedback mechanisms by inhibiting the secretion of ACTH from 
the pituitary as well as CRH from the hypothalamus. 
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1.2.3 Glucocorticoid Receptor (GR) 
There are two distinct steroid hormone receptor subtypes: type I or mineralocorticoid 
receptor (MR) and type II or GC receptor (GR) that are involved in the feedback 
regulation of the HPA axis. These specialised intracellular ligand-binding receptors are 
the members of the superfamily of nuclear transcription factors, and are involved in 
modulating the transcription of target genes. Under normal physiological conditions, MR 
is expressed in heart, intestine, and renal tissue as well as limbic brain regions, while GR 
is found in almost all tissues and organs in the human body (Anacker et al., 2011a, 
Marques et al., 2009).  
 
Compared to MR, GR has lower affinity for endogenous corticosteroids such as cortisol, 
and it is activated when the GC levels are high. GR also shows high affinity for 
dexamethasone which is a synthetic cortisol, and only binds to GR and not to MR. While 
MR is mainly associated with circadian regulation of cortisol, GR plays a role in the 
modulation of peak morning response. In addition, GR activity appears to be more crucial 
in regulating stress-related responses when specifically there are elevated levels of 
endogenous GCs (De Kloet et al., 1998, Joels et al., 2008, Juruena et al., 2004, Pariante, 
2004).   
 
As illustrated in Figure 1.2, according to the Nucleocytoplasmic Traffic Model of GR 
(Juruena et al., 2004), inactivated GR primarily resides in the cytoplasm. The unbound 
cytosolic receptor is stabilized within an assembly of chaperone proteins such as heat 
shock proteins (HSPs): HSP56 and HSP90, and immunophilins. (Grad and Picard, 2007). 
GR is a ligand dependent transcription factor and is activated following binding to GC 
which passively diffuses across the cell membrane. Upon activation, GR undergoes 
conformational changes, dissociates from HSPs, and translocate to the nucleus where it 
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regulates gene expression. In fact, GR positively or negatively alters gene transcription 
either directly by interaction of its DNA binding domain with particular promoter 
sequence of the DNA known as GC responsive elements (GREs), or indirectly via 
binding with other transcription factors (protein-protein interaction) which in turn bind to 
the DNA response elements (Marques et al., 2009, Pariante and Miller, 2001).  
 
GR sensitivity to GC is crucial in order to produce an appropriate response that is 
determined by the number, affinity, and function of the receptor including the ability of 
GR to bind the ligand, to translocate from cytoplasm into the nucleolus, and to interact 
with other signal transduction pathways (Marques et al., 2009).  
 
Activation of gene expression by GR is known as transactivation in which GR stimulates 
transcription rate of a respective target gene, while negative alteration of gene expression 
by GR is called transrepression in which GR suppresses the other transcription factors 
activity. The crucial immunosuppressive and anti-inflammatory roles of GC are in fact 
mediated through GR-dependent transrepression which targets the genes associated with 
inflammatory cytokines including interleukins (Anacker et al., 2011a, De Bosscher and 
Haegeman, 2009). Pharmacologically, the gene-repressing properties of GR are targeted 
for treatment of inflammatory and autoimmune disorders using exogenous GCs (De 
Bosscher and Haegeman, 2009). However, the desired therapeutic use of these steroid 
agents is usually followed by adverse side effects mainly associated with gene-activating 





Figure 1.2 Schematic Representation of GR Activation and Function 
(Nucleocytoplasmic Traffic Model) (Juruena et al., 2004). 
GR is primarily resides in the cytoplasm in an inactivated form and in a complex assembly of 
chaperone proteins such as heat shock proteins. GR is activated following binding to GC which 
passively diffuses across the cell membrane. Upon activation, GR undergoes conformational 
changes, dissociates from HSPs, and translocate to the nucleus where it negatively or positively 











There are two homologous isoforms associated with human GR that are encoded by GR 
gene: GRα and GRβ. GRα is the cytoplasmic ligand-binding isoform, which is the classic 
GR and regulates gene transcription. In contrast, GRβ, which is the nuclear localized 
isoform, does not seem to bind to any ligand, but is known to affect GRα by attenuating 
its transcriptional activity. Elevation in inflammatory responses and specifically pro-
inflammatory cytokines increase expression of the GRβ leading to accumulation of this 
relatively inert isoform that results in decreased in GRα function (Webster et al., 2001, 
Wichers and Maes, 2002).  
 
Taking into consideration the crucial role of GR in negative feedback regulation of HPA 
axis and also its anti-inflammatory effect through transrepression activity, both 
expression and function of GR are assessed in this PhD thesis.   
  
1.2.4  HPA axis, GR, and Depression 
Generally, depressed patients tend to exhibit dysfunction of the immune system. The 
immune system disturbance in MDD patients is characterized by an overactivation of 
inflammatory responses (Empana et al., 2005, Raison et al., 2006) as well as a failure of 
the regulatory processes that maintain the balance, thus leading to a dysregulation in the 
control of inflammation (Holsboer, 2000, Pace et al., 2007, Pariante, 2006, Pariante and 
Miller, 2001). Disturbances in the HPA axis as a central regulatory system are implicated 
in the manifestations of psychosomatic and psychiatric disorders. HPA axis 
disfunctionality includes both hyperactivity and hypoactivity of the system leading to 




Alteration of the HPA axis and elevated level of GCs are two well-documented features 
observed in a significant proportion of patients with major depression and are assumed to 
be involved in both aetiology and pathogenesis of the disease (Pariante and Miller, 2001, 
Plotsky et al., 1998). Indeed, almost half of the depressed patients show increased level of 
cortisol in cerebrospinal fluid, plasma and urine, consistent with overactivity of the HPA 
axis; and enlargement of pituitary and adrenal glands (Otte et al., 2004, Pariante and 
Miller, 2001, Stewart et al., 2009). However, the association between depression and the 
increased cortisol levels is mostly observed in older and/or more severely depressed 
individuals (Burke et al., 2005) and also in medically ill patients (Otte et al., 2004).  
 
The hyperactivity of the HPA axis seems to reflect an impaired ability of GC hormones to 
exert their physiological effects (glucocorticoid resistance), including the negative 
feedback on the HPA axis itself as well as the anti-inflammatory effects at the peripheral 
level (Pariante, 2006, Pariante and Miller, 2001). In fact, the inflammatory response, 
which is regulated by the effect of GC hormones in normal conditions, cannot be 
terminated due to GR resistance and diminished sensitivity of immune cells to the 
hormones (Marques et al., 2009, Stark et al., 2001).  
 
Evidence suggests that GC resistance is observed in more than half of the patients with 
major depression and is associated with dysfunction of negative feedback pathway which 
is normally regulated by the effect of cortisol suppressing CRH production. Therefore, 
one of the reasons for CRH hyperactivity is due to the resistance to the GCs inhibitory 
effects (Holsboer, 2000, Nemeroff, 1996). Indeed, it has been shown that MDD patients 
have HPA axis hyperactivity in the presence of GR resistance (Carvalho et al., 2008). 
Although the aetiology of presence of GC resistance found in depression is not known, 
some studies suggest that prolonged inflammation has a direct effect in reducing GR 
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sensitivity through the interaction of cytokine signalling pathway with GR signalling 
pathway, thereby disruption of functional properties of the receptor (Miller et al., 1999).  
 
Alteration in GR function could explain impairment of the GC-mediated negative 
feedback regulation on HPA axis. In addition, a reduction in the number of GR has been 
also reported in the depressed patients (Pace et al., 2007, Pariante and Miller, 2001). 
Studies on therapeutic strategies using antidepressants report that some of these 
medications exert their effect directly on GR through increasing expression and 
modulating function of these receptors, hence the regulation of GR-mediated HPA axis 
activity. Since excessive inflammatory processes are involved in the pathogenesis of 
depression, some antidepressants also appear to exhibit beneficial effects through 
reducing levels of inflammatory biomarkers and modulating inflammation-induced 
depression (Carvalho et al., 2010, Pariante and Miller, 2001). 
 
Despite the extensive evidence in regards to HPA axis hyperactivity and overproduction 
of GCs that can disrupt cellular functioning as well as damage to the brain structure and 
therefore association with stress related conditions, insufficient GC signalling is also 
believed to contribute to the pathogenesis of such disorders. The evidence suggests that 
inadequate signalling capacity of GCs could be not only due to GR-mediated signal 
transduction, but also reduced GC bioavailability itself (Raison and Miller, 2003).  
 
Hypocortisolism has been observed in stress related disorders since 1960s, first in a study 
in which decreased plasma and urinary cortisol levels were reported in individuals 
exposed to chronic stress (Friedman et al., 1963). Patients suffering from post-traumatic 
stress disorder (PTSD) also exhibit low levels of cortisol (Yehuda, 2001). Disturbances in 
HPA activity and decreased cortisol production and/or release have been reported in 
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women with a history of childhood abuse (Heim et al., 2000, Heim et al., 2003), and also 
in patients with chronic fatigue syndrome and fibromyalgia (Crofford et al., 1994, 
Demitrack and Crofford, 1998, Demitrack et al., 1991). Atypical depression is also 
associated with hypoactivity of the HPA axis (Gold et al., 2002). 
 
1.2.5 Cytokines, Inflammation, and Depression 
Elevation of the inflammatory biomarkers is implicated in depression. Research over the 
last few years has consistently shown that patients with major depression exhibit evidence 
of activated inflammatory responses and significantly high levels of inflammatory 
biomarkers. For example, elevated levels of innate immune cytokines such as tumour 
necrosis factor-α (TNF-α), peripheral pro-inflammatory cytokines including interleukin 6 
(IL-6) and downstream acute phase reactants more notably C-reactive protein (CRP) are 
the inflammatory biomarkers associated with major depression (Empana et al., 2005). As 
mentioned before, based on the macrophage theory of depression introduced by Smith, 
and then followed by Maes, cytokines play a role in depression. (Maes et al., 1995, Smith, 
1991). The theory suggests the critical effect of elevation of pro-inflammatory cytokines 
that follows the acute phase reactions as a consequence in depressed individuals. The 
phenomenon is linked to the alteration of central nervous system (CNS) and contributes 
to symptoms of depressive disorder including insomnia and fatigue (Irwin and Miller, 
2007).   
  
Cytokines, in general, are proteins that are secreted by various cells and have a critical 
role in regulating immune response by acting as signalling molecules. They exhibit either 
pro- or anti-inflammatory activity. Pro-inflammatory cytokines such as IL-1, IL-6, and 
TNF serve to enhance the immune response, while anti-inflammatory cytokines such as 
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Il-4, IL-10, and IL-13 are responsible for reducing the immune response and inhibiting 
the synthesis of other cytokines. The cascade of cytokine production acts in a way that 
early cytokines stimulate the release of later cytokines. For example IL-1 induces the 
production of IL-2, IL-6, and TNF. The major sources of these cytokines are activated 
monocytes and macrophages (Dinarello, 1990). In addition, cytokines and their receptors 
are detected in the brain tissue. They are mainly produced by astrocytes and microglia 
cells and even under certain conditions by neurons (Kronfol and Remick, 2000, Schobitz 
et al., 1994).  
 
Although once it was believed that due to presence of the blood-brain-barrier (BBB), the 
brain is protected from peripheral inflammatory activation level, the concept has been 
challenged due to the development in neuroimmunology research and evidence showing 
the presence of inflammatory responses within the CNS. In fact, cytokines may not 
passively cross the BBB due to their size and hydrophilic nature, at least under 
physiological conditions, but studies reveal that they in fact are able to penetrate the brain 
via specific mechanisms. The communication between cytokine and the brain can be 
facilitated by: active transport mechanisms, passive diffusion at circumventricular sites 
where the BBB is deficient, induction of specific adhesion molecules, and finally 
activation of peripheral afferent nerve terminals to release cytokines (Kronfol and 
Remick, 2000, Wichers and Maes, 2002). 
 
Cytokine mediated inflammatory responses have been suggested to associate with 
behavioural alteration and development of depressive symptoms. Cytokine therapy is 
widely used as an effective treatment for medical conditions. However, it has been shown 
that for example IFN-α treatment in patients with cancer and hepatitis C as a therapeutic 
strategy for their condition is accompanied by neuropsychiatric side effects with 
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approximately half of the recipients developing clinically significant depressive 
symptoms (Capuron et al., 2002, Dieperink et al., 2003, Hauser et al., 2002). As revealed 
by animal studies, cytokine induced sickness behaviour, resembling symptoms of 
depression in human, is another feature observed following central or peripheral 
administration of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α (Wichers 
and Maes, 2002).  
 
Various mechanisms have been studied to explain the role of cytokines in the 
pathophysiology of mood disorders. Cytokines influence the neuroendocrine function by 
having an impact on the HPA axis activity.  The effect has been reported to be through 
stimulation of CRH and ACTH expression and release as well as cortisol (Miller et al., 
2009, Pariante and Miller, 2001). In addition, pro-inflammatory cytokines may generate 
GC resistance by directly affecting functional capacity of GR at multiple levels. Apart 
from induction of inert GRβ over active GRα isoform as described before, cytokines 
trigger GC resistance by reducing GR ligand and DNA binding capacities, inhibiting GR 
translocation to the nucleus and influencing GR protein-protein interactions as seen for 
example by activating the mitogen-activated protein kinase (MAPK) signalling pathway 
in cytoplasm which leads to phosphorylation of the receptor protein, thus diminishing GR 
transcriptional activity (Pace et al., 2007, Raison and Miller, 2003). Furthermore, in 
animal models exposed to either acute or chronic stress, excessive production of 
cytokines causes diminished neurotrophic support and neurogenesis (Ben Menachem-
Zidon et al., 2008, Koo and Duman, 2008), the two features which are enhanced by 
cytokines within the physiological range (Goshen et al., 2007). Moreover, neuro-
inflammatory activation enhances oxidative status in the CNS stimulating the production 
of nitric oxide, the characteristic that is observed in the neuropathophysiology of 
depression (Ida et al., 2008, Li et al., 2008).  
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In the present PhD thesis the immune system is assessed by measuring the circulatory 
levels of CRP and also the expression of the candidate genes associated with 
inflammation in order to investigate the activation of inflammatory response followed by 
identifying potential causes and consequences of such dysregulation.   
 
1.2.6   Serotonin, Inflammation, and Depression 
Serotonin (5-hydroxytryptamine or 5-HT) is a neurotransmitter synthesized from the 
amino acid tryptophan. The brain transmitter is critically implicated in a wide range of 
neurobehavioral phenomena such as mood, cognition, emotion, anxiety, sleep, or sexual 
activity (Belmaker and Agam, 2008). Indeed, as mentioned before, the monoamine 
hypothesis as a major theory of depression suggests the deficiency of brain serotonin as a 
main factor contributing to depression, and targeting the serotonin neurotransmission by 
medications is widely used as an effective treatment for mood and anxiety disorders, and 
specifically depression (Nemeroff and Owens, 2002).   
 
One of the main factors influencing serotonergic transmission in the brain is the serotonin 
transporter (5-HTT) responsible for the reuptake of serotonin from the synaptic cleft into 
the presynaptic neurone (Breedlove et al., 2007). 5-HTT is encoded by a single gene 
known as SLC6A4 whose transcriptional activity is particularly modulated by SLC6A4–
linked polymorphic region (5-HTTLPR), a repetitive sequence consisting of two 
prevalent alleles: short (S) and long (L) allele variants. The S allele of the 5-HTTLPR has 
been shown to reduce transcription efficiency of this gene, decrease expression of 5-HTT, 
and reduce serotonin reuptake from the synaptic cleft (Canli and Lesch, 2007, Collier et 
al., 1996). Carrying two copies of the “high transcription” L allele has been reported as a 
protective genotype against depression (Caspi et al., 2003). The “low transcription” SS 
42 
 
polymorphism is also associated with HPA axis hyperactivity, and predicts high stress-
induced cortisol response (Mueller et al., 2011). Studies also suggest an interaction 
between the IL-6 and the 5-HTTLPR genes. Specifically, the protective effect of the 
“high transcription” L allele has been shown only in the presence of the “low IL-6” 
synthesizing (CC) genotype and, thus, low inflammation (Bull et al., 2009). 
 
The central serotonergic system is involved in the activation and negative feedback 
regulation of HPA axis, and the communication between the two systems is observed 
during both development and adulthood (Andrews and Matthews, 2004, Lowry, 2002). 
Animal studies reveal that serotonin has a direct effect on hippocampal GR binding in rats 
(Mitchell et al., 1990) as well as the expression of GR mRNA in hippocampal neurons 
(Erdeljan et al., 2001). Therefore, an alteration in the serotonergic system adversely 
affects the regulation of HPA axis function.  
 
Activated inflammatory responses have been suggested to induce depressive symptoms 
not only by directly affecting the brain but also modulating the serotonergic system 
suggesting a causal relationship between altered inflammation and disturbances in the 
serotonergic system (Dantzer et al., 2011, Wichers and Maes, 2004). The monoamine 
hypothesis is linked with the activation of inflammatory responses. Indeed, the 
availability of tryptophan synthesizing serotonin is regulated by indoleamine-2,3- 
dioxygenase (IDO) enzyme whose expression is altered by the activation of inflammatory 
cytokines (Wirleitner et al., 2003a).  
 
Disturbances of the serotonergic system have been suggested to be associated with 
alteration in tryptophan metabolism. As proposed by the Lancet paper in 1969, 
introducing another major aetiological factor underlying development of depression, 
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tryptophan metabolism could be shunted away from the serotonin synthesis pathway, and 
instead shifted towards the formation of kynurenine metabolite (Lapin and Oxenkrug, 
1969).  
 
1.2.7 Tryptophan Metabolism, Inflammation, and Depression 
Tryptophan (TRP), which is a precursor of serotonin, is an essential amino acid supplied 
through dietary intake of dairy products, meats, egg whites, nuts, and chocolate. The 
synthesis of serotonin occurs within the brain; hence TRP needs to be transported across 
the BBB. In fact, TRP availability to the brain relies on the peripheral determinants, as the 
synthesis of TRP does not occur in the brain (Badawy, 2010, Watts et al., 2012). The 
bioavailability of tryptophan can be affected by other competing amino acids (CAA) 
including leucine, isoleucine, valine, tyrosine, and phenylalanine; the association which is 
implicated in depression relapse in susceptible individuals (Salomon et al., 2003, Young 
and Leyton, 2002). Indeed, depressed patients show 20%-29% decreased in plasma 
tryptophan as well as 16%-36% reduced in tryptophan availability to the brain as 
expressed by the TRP/CAA ratio which is in fact the result of lower tryptophan rather 
than higher CAA  (Badawy, 2010).  
 
The decrease in tryptophan concentration in MDD patients is explained by acceleration in 
the degradation of this amino acid. Kynurenine pathway of tryptophan metabolism is 
known as one of the major mechanisms that lead to the increased tryptophan degradation 
(Badawy, 2013). Independently of serotonin, tryptophan metabolites also contribute to the 




There are two metabolic pathways associated with TRP in humans: the kynurenine 
pathway and the methoxyindoles pathway. In normal conditions, about 5% of TRP is 
metabolized via the serotonin pathway, while the majority of around 95% is being 
shuttled through the kynurenine pathway in the liver. The fate of TRP depends on the 
comparative activities of the rate-limiting enzymes associated with each pathway (Gal 
and Sherman, 1980, Oxenkrug, 2007, Stone and Darlington, 2002). 
 
As illustrated in Figure 1.3 the methoxyindoles pathway leads to serotonin biosynthesis 
by the catalytic activity of the enzyme tryptophan-5-hydrohylase (TPH) and an important 
cofactor tetrahydrobiopterin, resulting in hydroxylation of TRP and the formation of the 
5-hydrohytryptophan (5-HTP) metabolite. The following decarboxylation converts 5-HTP 
into 5-HT. 5-HT then is either converted to a stable metabolite known as 5-hydroxyindole 
acetic acid (5-HIAA) catalyzed by monoamine oxidase and aldehydrogenase, or as a 
melatonin substrate first is converted to N-acetyl-serotonin (NAS) catalyzed by 5-HT N-
acetyl transferase, and then in turn results in melatonin (5-methoxy-N-acetyltryptamine) 
synthesis via O-methylation. The deficiencies of the methoxyindoles pathway metabolites 
contribute to depressive symptoms (Gal and Sherman, 1980, Oxenkrug, 2010). 
 
The kynurenine pathway of tryptophan metabolism is activated by the activity of two 
enzymes: tryptophan-2,3-dioxydase (TDO) found exclusively in the liver with high 
specificity for TRP, and IDO found in most tissues and organs throughout the body 
except the liver with less substrate specificity. Degradation of TRP by these rate-limiting 
enzymes induces the formation of kynurenine (KYN) as an intermediate substrate which 
can be converted to other catabolic products of the two distinct routes: either 
neuroprotective or potentially neurotoxic (Guillemin et al., 2007, Moffett and 
Namboodiri, 2003). In addition, KYN itself can induce IDO activation and influence TRP 
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availability by inhibiting its transport via BBB as observed in animal models of anxiety 
(Lapin, 2003). 
 
In normal physiological conditions, TDO is the enzyme activated metabolizing TRP into 
KYN in the liver. However, under stress related situations including infections, oxidative 
stress, and especially inflammatory conditions, IDO is the first rate-limiting enzyme 
which is activated.  It is believed that the activity of IDO enzyme is modulated by the 
activation of inflammatory responses and the balance between pro- and anti-inflammatory 
cytokines. Pro-inflammatory cytokines such as INF-γ, IL-1, IL-6, TNF-α, and CRP can 
enhance the activity of IDO enzyme, therefore, shifting TRP metabolism towards 
formation of KYN rather that serotonin synthesis (Halaris, 2013, Wichers et al., 2005). 
On the other hand, anti-inflammatory cytokines such as IL-4 have an inhibitory effect on 
IDO activity (Musselman et al., 2001). Evidence suggests that alterations in the levels of 
interleukins associated with KYN metabolism have been implicated in psychiatric 
conditions including bipolar (Kim et al., 2004) and major depressive disorders (Myint et 
al., 2007). Inflammatory induced IDO overstimulation is also associated with depressive 
symptoms as it leads to TRP depletion that in turn results in serotonin deficiency 
(Wichers and Maes, 2002). 
 
As demonstrated in Figure 1.3, KYN as a substrate is competed by two different 
pathways. The neuroprotective pathway facilitated by KYN aminotransferase (KAT) 
converts KYN into kynurenic acid (KYNA) which is an endogenous N-methyl-D-
aspartate (NMDA) receptor antagonist and glutamate receptor blocker, therefore 
potentially neuroprotective metabolite. The neurotoxic pathway leads to the 
transformation of KYN into 3-hydroxykynurenine (3-HK) catalysed by kynurenine 3-
monooxydase (KMO) or KYN 3-hydroxylase. The subsequent step is facilitated by 
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Kynureninase (KYNU) to form 3-hydroxyanthranilic acid (3-HAA), the precursor of the 
quinolinic acid (QUIN) which is a NMDA receptor agonist and induces oxidative stress, 
thus neurotoxic metabolite that can potentially lead to CNS excitotoxicity (Gabbay et al., 
2010, Miller et al., 2009, Oxenkrug, 2010). In the competition for conversion of KYN 
into its metabolites, the activity of the KMO directing the pathway through QUIN 
formation overcomes the KAT activity (Wichers et al., 2005). Elevation of the 
neurotoxins of the KYN pathway has been shown to be associated with 
hyperglutamatergic status in depression (Muller and Schwarz, 2008).                       
 
Depending on which cell type KYN is produced or transported, it is degraded into 
different metabolites. In the brain, the formation of neurotoxic 3-HK and QUIN occurs in 
microglia cells, while neuroprotective KYNA is mainly produced by astrocytes (Dantzer 
et al., 2011). Peripheral KYN is transported through BBB by a protein carrier to reach the 
CNS where it degrades into the neurotoxic metabolites when taken up by glia cells 
leading to neurodegeneration (Fukui et al., 1991). The switch of KYN neuroprotective 
pathway towards neurotoxic route has been proposed to be the result of inflammatory 
induced IDO overstimulation, the challenge that can explain the neurodegeneration 
hypothesis of depression (Myint and Kim, 2003). The hypothesis has been suggested to 
be associated with depression when microglial KYN degradation is dominant over the 
astrocytic metabolism (Muller and Schwarz, 2008). 
 
Due to the effect of inflammation on tryptophan metabolism, and in turn the implication 
of the disturbed system in pathophysiology of depression the present PhD assesses the 
tryptophan metabolism pathway concentrating mainly on the kynurenine diversion of the 
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              IDO/TDO             TPH 
   
                    KYN           5-HTP                   5-HT (serotonin)                    
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     3-HK              KYNA                  5-HIAA          NAS 
               KYNU                                                   5-hydroxyndole   O-methyltransferase 
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                3-HAA oxygenase 
 
      QUIN            
Figure 1.3 Kynurenine and methoxyindoles pathways of tryptophan metabolism 
IDO, indoleamine-2,3-dioxygenase; NAS, N-acetyl serotonin; QUIN, quinolinic acid; KAT, kynurenine 
aminotransferase; KMO, kynurenine 3-monooxydase or kynurenine 3-hydroxylase; KYN, Kynurenine; 
KYNA, Kynurenic acid; KYNU, Kynureninase; TDO, tryptophan-2,3-dioxygenase; TPH, tryptophan-5- 
hydroxylase; TRP, tryptophan; 3-HAA, 3-hydroxyanthranilic acid; 3-HK, 3-hydroxykynurenin; 5-HIAA, 5-
Hydroxyindole acetic acid; 5-HT, 5-hydroxytryptamine; 5-HTP, 5-hydrohytryptophan.         
The schematic diagram above illustrates kynurenine and methoxyindoles pathways, the two 
metabolic pathways associated with TRP metabolism. The methoxyindoles pathway leads to 
serotonin biosynthesis by the catalytic activity of the enzyme TPH resulting in hydroxylation of 
TRP and the formation of the 5-HTP metabolite. The following decarboxylation converts 5-HTP 
into 5-HT. 5-HT then either is converted to a stable metabolite 5-HIAA catalyzed by monoamine 
oxidase and aldehydrogenase, or as a melatonin substrate first is converted to NAS catalysed by 
5-HT-N-acetyl transferase, and then in turn results in melatonin synthesis via O-methylation. The 
kynurenine pathway is activated by the activity of two rate-limiting enzymes TDO and IDO. 
Degradation of TRP by these enzymes induces the formation of KYN, an intermediate substrate 
which is competed by two different pathways. The neuroprotective pathway facilitated by KAT 
enzyme converts KYN into KYNA which is an endogenous N-methyl-D-aspartate (NMDA) 
receptor antagonist and glutamate receptor blocker, therefore potentially neuroprotective 
metabolite. The neurotoxic pathway leads to the conversion of KYN into 3-HK catalysed by 
KMO, and then formation of 3-HAA, the precursor of the QUIN which is a NMDA receptor 





Antidepressants are clinically used for treatment of MDD and also some other conditions 
such as chronic pain, anxiety and sleep disorders. The major classes of these drugs that 
are effectively used include the early antidepressants: tricyclic antidepressants (TCAs) 
(e.g. clomipramine) and monoamine oxidase inhibitors (MAOIs) (e.g. phenelzine), and 
the newer generation: selective serotonin reuptake inhibitors (SSRIs) (e.g. citalopram, 
fluoxetine, sertraline) and serotonin-norepinephrine reuptake inhibitors (SNIRs) (e.g. 
venlafaxine) (Nemeroff and Owens, 2002). However, the exact mechanisms of actions of 
these antidepressants are still under investigations. 
 
Despite the development of various medications as antidepressants and all the 
investigations trying to understand the mechanisms of their action, drug resistance 
remains the huge challenge in treatment of depression. The concept is defined as 
treatment-resistant depression (TRD) when there is an inadequate response following 
pharmacotherapy of MDD by antidepressants. TRD leads to the condition becoming 
chronic, more severe and recurrent (Fava, 2003). It is relatively common affecting more 
than half of depressed individuals who fail to achieve remission (Greden, 2001). As 
reported by a systematic review, TRD is found to be associated with poorer clinical 
outcome especially where the multiple antidepressants are applied (Fekadu et al., 2009). 
Development of new strategies through identification of specific risk factors and targets 
seems to be a crucial step to prevent recurrence depression and if at all possible its initial 
development (Gotlib and Hammen, 2002). 
 
In regards to inflammation that is involved in the pathogenesis of depression, studies on 
therapeutic strategies using antidepressants report that some antidepressants appear to 
exhibit beneficial effect through reducing levels of inflammatory biomarkers and 
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modulating inflammation-induced depression (Tousoulis et al., 2009). TCAs and 
noradrenaline reuptake inhibitors have been reported to attenuate neuro-inflammatory 
activation in depression by inhibiting the over expression of pro-inflammatory cytokines 
and also inducible nitric oxide synthase leading to reduced inflammatory reactions and 
oxidative stress (Lu et al., 2010, O'Sullivan et al., 2009). 
 
Effective antidepressant treatment has been shown to resolve HPA axis dysregulation 
(Pariante and Miller, 2001). In fact, as reported by both in vitro and in vivo studies, these 
medications exert their effect directly to GR through increasing expression, promoting 
translocation, and enhancing function of these receptors, hence regulation of GR-
mediated HPA axis activity (Carvalho et al., 2008, Carvalho et al., 2010, Pariante, 2004, 
Pariante and Miller, 2001). The effect of antidepressants on enhancing hippocampal 
neurogenesis has been also proposed by studies in animals as well as in humans (Boldrini 
et al., 2009, Duman, 2004, Wang et al., 2008), that are suggested to be via GR dependent 
mechanisms associated with modulation of GR phosphorylation and transcription 
(Anacker et al., 2011b). 
 
Therefore, treatment of depression as a complex and multifaceted disorder requires more 
specific understanding about the underlying mechanisms involved in the pathogenesis of 
the disorder including cytokine induced complications, GR mediated HPA axis 
dysregulation, and/or neurogenesis related disturbances associated with MDD. 
 
The present thesis analyses the effects of antidepressants in vivo on the various biological 
systems investigated, by comparing depressed patients who are drug free and patients 
who are on antidepressants. Moreover, it directly assesses the in vitro effects of 
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antidepressants on the GR and immune function directly on peripheral mononuclear white 
blood cells. 
 
1.2.9 Polyunsaturated Fatty Acids (PUFAs) 
N-3 or omega-3 polyunsaturated fatty acids (PUFAs) are derived from fish oil and 
considered as safe therapeutic compounds in treatment of rheumatic arthritis, Crohn’s 
disease, cardiovascular disorders, and other systemic inflammatory conditions (Calder, 
2006, Farzaneh-Far et al., 2009). In fact, omega-3 fatty acids display anti-inflammatory 
properties. An independent and inverse association between omega-3 levels and 
inflammatory biomarkers including IL-6 and CRP has been reported in patients with 
coronary artery disease (Farzaneh-Far et al., 2009).  
 
Evidence suggests the relationship between omega-3 and depressive disorders indicating 
both protective and therapeutic effects of these agents (Su et al., 2000). Indeed, countries 
with higher consumption of fish oil have a lower prevalence of depression (Hibbeln, 
1998). Dietary intake of omega-3 is thought to be essential since neuronal cell membrane 
in the CNS require high concentration of this group of fatty acids whose alteration either 
in terms of concentration or molecular composition can adversely affect the 
microstructure of cell membrane and disturbance in the signalling pathways. The 
mechanism has been suggested to be associated with immunological dysregulation and 
development of depression (Lin and Su, 2007, Logan, 2003).   
  
MDD patients exhibit decreased levels of omega-3 in serum, red blood cells as well as fat 
tissue (Maes et al., 1999, Mamalakis et al., 2006, Peet et al., 1998). A therapeutic trial in 
MDD where omega-3 has been added to maintenance antidepressant therapy, showed a 
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significant improvement in symptoms of depression more specifically low mood, 
insomnia, and feelings of worthlessness and guilt (Nemets et al., 2002). The therapeutic 
effect of omega-3 has been also been shown in patients with TRD (Puri et al., 2002).  
 
Due to potential effect of PUFAs as an anti-inflammatory and antidepressant agent, the 
present thesis investigates the effects of PUFAs in vitro on the GR and immune function 
in peripheral blood mononuclear cells (PBMC) to better understand the mechanisms by 



















1.3 Coronary Heart Disease, Inflammation, and Depression  
The association between heart disease and depression is extensively evidenced in both 
epidemiological and experimental studies (Davidson, 2012, Jiang et al., 2002, Kemp et 
al., 2003, Whooley and Wong, 2013). Inflammation is recognised to be involved in this 
association (Halaris, 2013, Kop and Gottdiener, 2005, Maes et al., 2011, McCaffery et al., 
2006). 
  
Heart disease refers to disorders of cardiovascular system involving heart and/or blood 
vessels, and CHD is the most common type in which the atherosclerotic plaques develop 
progressively. Atherosclerosis is in fact an inflammatory disease. Inflammation plays a 
central role in pathogenesis of CHD and is involved in all stages of atherosclerosis 
including initiation, propagation, and activation of atherosclerotic plaque leading to clot 
formation or thrombogenesis. Inflammation in the plaques is indeed crucial for 
occurrence of cardiac events such as myocardial infarction or heart attack (Hansson, 
2005b, Libby, 2006).  
 
The inflammatory response in CHD involves activation of immune cells which initiate the 
cytokine cascade by producing pro-inflammatory cytokines including IL-1, TNF, and INF 
that in turn produce IL-6 in large amounts leading to production of high levels of CRP. 
Indeed, elevated levels of circulating inflammatory biomarkers such as IL-6 and CRP are 
reported in patients with CHD that has been shown to be correlated with poor prognosis 
as well as increased risk of future cardiac events and sudden death (Hansson, 2005b, 
Pearson, 2003, Vasan et al., 2003, Willerson and Ridker, 2004).  
 
On the other hand, excessive inflammation due to the impaired GR functioning and GC 
resistance has been found consistently in patients with MDD (Pace et al., 2007, Stewart et 
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al., 2009). However, it is postulated that GC resistance itself may occur as a result of 
chronic stress and prolonged exposure to inflammatory cytokines (Miller et al., 1999).  
 
Failure of regulatory responses in the control of inflammation could be particularly 
important in the development of depression in CHD patients when the immune system 
fails to shift through anti-inflammatory induction to inhibit excessive pro-inflammatory 
release (Davidson, 2012). Downregulation of anti-inflammatory cytokine IL-10 and 
upregulation of pro-inflammatory cytokines IL-6 and TNF-α have been reported in 
chronic heart failure patients with depressive symptoms (Parissis et al., 2004). Another 
study in patients with myocardial infarction demonstrated that increased plasma IL-6 and 
CRP concentrations and so altered response to the anti-inflammatory properties of GCs 
independently correlate with depressive symptoms (Pizzi et al., 2008). However, it is still 
not known whether inflammation in patients with CHD is a “state” biomarker that follows 
the development of depression, or an “at risk” biomarker that confers vulnerability to 
develop depression.  
 
A series of studies have contributed to answering this question and provided evidence that 
the activated inflammatory responses are indeed biomarkers of both vulnerability to 
develop depression and of the presence of a more severe form of depression, those less 
responsive to antidepressants. For example, severe treatment resistant inpatients with 
major depression show increased plasma levels of IL-6 in the presence of resistance of the 
peripheral blood GR to the anti-inflammatory action of GCs (Carvalho et al., 2008). 
Moreover, and consistent with the case that inflammation is indeed a vulnerability 
marker, Danese et al. have shown that early childhood trauma, a well-known risk factor 
for the future development of depression, is associated with increased levels of CRP in 
adulthood, even in the absence of adult depression (Danese et al., 2007). One study has 
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also found that the persistence of inflammation in people with a history of depression 
even in the absence of their depressive symptoms, again supporting the notion of 





















1.4 Aims and Hypotheses of the Study 
The INFLAME-BEAT project is the first clinical study directly investigating 
inflammatory-induced depression in CHD patients. The goal of the study is to directly test 
the hypothesis that inflammation in patients with CHD is a state biomarker of depression. 
Therefore, the aim of the present thesis, as part of the INFLAME-BEAT study, is the 
investigation of the pathophysiological mechanisms underlying the inflammatory 
activation in CHD patients with and without depression. Indeed, the present project 
evaluates inflammatory response in patients with CHD and with current depression and 
compares to those without depression at baseline. Considering the presence of GC 
resistance in patients with depression and the idea that chronic inflammation may induce 
depression through alteration in GR functional properties, this PhD thesis aims to 
investigate also two important biological elements in the pathogenesis of major 
depression in CHD patients; namely the HPA axis activity and GR function. Furthermore, 
this PhD project intends to explore the adverse consequences of inflammation and 
depression in CHD patients by examining the kynurenine pathway of tryptophan 
metabolism in this population. 
 
The hypotheses that the present thesis is trying to test are as follows: 
As compared to CHD patients without depression, CHD individuals with depression: 
1) Have higher circulating levels of CRP as a clinical inflammatory marker. 
2) Have higher expression levels of cytokines as markers of inflammation.  
3) Display lower expression of inflammatory related genes in those who are on 
antidepressant treatment. 




5) Exhibit GR resistance displaying lower expression and sensitivity of GR.   
6) Show improvement in GR sensitivity following in vitro effect of antidepressants 
and omega-3 fatty acids.   
7) Demonstrate disturbances in tryptophan metabolism pathway showing activation 
of IDO enzyme and production of neurotoxic metabolites of the kynurenine 
pathway. 
8) Have higher levels of circulating VEGF. 
  
Comprehensive understanding of the cause(s) and targeting directly the specific 
mechanisms involved in the pathogenesis of depression as a complex multifactorial 
disorder are essential to achieve effective treatment of depression, probably through 
multipotential therapy. In addition, uncovering the mechanisms underlying the 
inflammatory activation in patients with heart disease will help develop strategies of 
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2.1 Study Design, Subjects and Sample Collection 
This project, INFLAME-BEAT, was conducted in collaboration with an existing and on-
going study called UP-BEAT led by Prof. Andre Tylee (Institute of Psychiatry, IOP; 
KCL) examining patients with CHD (recruited through primary care services in South-
East London) and evaluating psychosocial, but not biological, predictors of depression in 
CHD. The purpose of the INFLAME-BEAT study was to evaluate underlying biological 
mechanisms involved in development of depression in CHD patients. INFLAME-BEAT 
utilized a four-year prospective cohort design while the biological analysis was conducted 
only once at baseline. The present PhD is a cross-sectional study where CHD patients 
without depression were compared to CHD patients with depression for their circulatory 
inflammatory biomarkers, HPA axis assessments, GR sensitivity, expression of genes 
associated with inflammation and GR as well as kynurenine pathway of tryptophan 
metabolism. 
 
UP-BEAT participants comprised 800 patients who were registered on the CHD Quality 
and Outcomes Framework (QOF) from participating practices. All volunteers who scored 
positive in the patient health questionnaire-2 (PHQ2) scale for depression had baseline 
psychiatric evaluation of mental state and previous psychiatric history assessed by UP-
BEAT group using the Clinical Interview Schedule-Revised (CIS-R) (Lewis et al., 1992). 
As part of the UP-BEAT study, CHD patients were clinically assessed once at baseline 
and then followed up every 6 months for 4 years for development of depression. 
  
INFLAME-BEAT subjects were recruited from UP-BEAT study participants who were 
interested to take part in other related studies and gave permission to be contacted by 
associated studies. The volunteers randomly were contacted and invited to participate in 
the INFLAME-BEAT project (see appendix-A/-B). The priori exclusion criteria included 
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patients taking corticosteroid medications such as prednisolone. In addition, patients with 
medical co-morbidity including asthma, cancer, and arthritis as well as those suffering 
from acute illnesses or infections were excluded. Furthermore, patients with other 
psychiatric conditions according to the CIS-R assessment were also excluded. The 
conditions included panic, obsessive–compulsive disorder (OCD), phobias (social phobia, 
specific phobias, agoraphobia), generalised anxiety disorder, and mixed depression 
anxiety disorder. The flowchart below demonstrates recruitment procedure carried out by 
this study. 
 
                         UP-BEAT Participants (n=800) 
                                                                        
Patients who gave consent to be contacted by related studies (n=395) 
                                                            n=7 excluded based on priori exclusion 
                              n=3 lost contact 
                           Eligible patients (n=385) 
            
          Patients who were randomly contacted (n=262) 
                                                           n=109 refused to participate          
                 INFLAME-BEAT Volunteers (n=153)  
                                                           n=10 excluded due to medical co-morbidity  
                                                           n=13 excluded due to psychiatric co-morbidity    
                                                           n=9 excluded due to acute illnesses or infections    
                                                           n=6 missing depression scores 
                                                           n=32 excluded CIS-R (-) but BDI (+) 
                            Total Study Sample (n=83)                   
Figure 2.1 Flowchart of recruitment procedure 
61 
 
2.1.1 Depression Assessments 
CHD patients with and without depression were recruited. The subjects were categorized 
into the two groups: group 1 were patients with symptomatic CHD and without current 
depression; and group 2 were those with CHD and currently depressed. The depression 
status was defined based on the CIS-R assessment (Lewis et al., 1992) for diagnosis of 
depression obtained from UP-BEAT database; as well as the presence of depressive 
symptoms that were quantified using the Beck depression inventory (BDI) score (Beck et 
al., 1961) obtained at the time of the biological sample collection. The cut-off BDI scores 
≥10 was used indicating the presence of depressive symptoms (Beck et al., 1988), that has 
been used previously by various studies (Bull et al., 2009, Meurs et al., 2012). Therefore, 
CHD patients who were both CIS-R and BDI positive were categorized as CHD 
depressed (CHD-D), and CHD patients who were both CIS-R and BDI negative were 
categorized as CHD non depressed (CHD).  
 
Apart from the PBMC cell culture (section 2.5.3); all the experiments described here in 
the following sections were preformed blind to the subjects’ depression status. The 
advantage of using frozen PBMC cells was that in vitro assessment of GR function could 
be performed in parallel for depressed and non-depressed CHD individuals. 
 
2.1.2 Blood Samples 
On attendance at Kings College Hospital London, patients were interviewed, and asked to 
complete the BDI (see appendix-E). The information in regards to their medication was 
recorded, and blood pressure, heart rate, height, and weight were measured (see appendix-
D). Informed consent was obtained from each participant (see appendix-C) followed by 
collecting peripheral venous blood (simple venepuncture): 4 sodium-heparin containing 
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tubes for collecting plasma and isolation of PBMC, a clot activator containing tube for 
collecting serum, and a PAXgene tube for isolation of RNA. The blood samples were 
collected between 8:30 am to 10:30 am. 
 
In addition, 12 healthy controls were recruited (at the University of Roehampton) without 
any history of heart disease and depression. Heparinised whole blood was obtained from 
healthy donors to be used for optimizing the PBMC cell culture protocol. 
 
2.1.3 Saliva Samples 
Saliva samples were collected from participants to measure their salivary cortisol during 
the day according to a previously published procedure (Mondelli et al., 2010). 
Participants were issued with the materials and instruction for collecting the saliva 
samples at 6 time points in a single day (see appendix-F/-G/-H). The self-collection of 
samples was carried out at home, and patients agreed to follow the procedure accurately. 
Patients were required to wake up before 10 am on the day, and obtain saliva samples 
immediately upon awakening (0 minutes) while still in bed, and then at 15, 30, and 60 
minutes post awakening, and again at 2 pm and bedtime at around 10 pm. To obtain 
saliva samples, subjects were issued 6 labelled salivette sampling devices (Sarstedt, 
Leicester, UK).  They were instructed to remove the cotton roll from inner tubing, place it 
in their mouth, and chew on it for approximately 2 minutes to ensure a sufficient amount 
of saliva was absorbed for analysis. The cotton roll was then placed back into the inner 
tube, and after replacing the lid, the sample tube was placed in the fridge. The same 
procedure was repeated for each time point of sampling. Participants were required not to 
have breakfast and not to brush their teeth, or eat or drink for the first hour of awakening, 
and also in the 30 minutes before 2 pm and bedtime sampling. This was asked in order to 
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avoid bleeding in oral cavity or food-stimulated cortisol rises that could result in false 
increase in cortisol levels (Mondelli et al., 2010). In addition, participants were instructed 
to specify the exact time of each sampling and to provide information with regards to 
whether they accidentally had anything to eat or drink, and any difficult or tense situation, 
unpleasant thoughts or any kind of pain before taking the sample (see appendix-H). 
Individuals who described problems during sample collection in the self-recorded 
questionnaire provided, or who did not respect the time-intervals required, were taken out 
of the analysis (3 participants were excluded due to protocol deviation). Furthermore, 
participants were asked to fill up BDI questionnaire (see appendix-E) on the day of 
sampling.  
        
Upon completion of collecting six saliva samples in a single day and keeping them 
refrigerated overnight, patients were asked to return all sample tubes on the following 
morning together with the completed information sheet and BDI questionnaire in a pre-
paid padded envelope provided. Once received, the samples were stored in -20 ºC freezer 
until assayed.  
 
The methods used for various measurements are described in the subsequent sections.  
The numbers of patients varied between the studies due to lack of availability or 
insufficient samples when performing different experiments. It should be also noted that 
not all the patients who provided blood samples also agreed to provide saliva sample. In 
the other hand, some patients were only interested to donate saliva samples and not blood.  
In addition, for the GR function assessment, PBMC were not available for all the patients 
who were investigated for their gene expression analysis. Therefore, each experiment was 
performed on a subset of the study population based on the availability of the sample for 
that specific experiment. 
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2.2 Peripheral Cortisol and CRP Measurements  
The blood samples collected in sodium-heparin and clot activator containing tubes were 
centrifuged to separate plasma and serum, respectively. The samples were stored in -80 
ºC freezer until assayed. For analysis, the plasma and serum samples were sent to 
biochemistry laboratory, KingsPath, at King’s College Hospital where the measurements 
of the levels of CRP in serum and cortisol in plasma took place using commercially 
available ELISA kits and following the recommended procedure. The report of the 
method used was sent to me as described in the following paragraphs with a very few 
editing changes.  
 
The levels of peripheral CRP were determined performing the Cormay high sensitivity 
CRP (HsCRP) assay (P.Z. Cormay, Lublin, Poland) (Peters et al., 2012). Briefly, the 
assay employed an anti-CRP antibody which had been sensitized to latex particles. 
Coating the surface of latex particles by antibody resulted in the formation of milky 
appearing sensitized latex. CRP within the serum samples then reacted with this antibody, 
forming visible agglutination. The purpose of using latex particles was magnifying the 
antigen-antibody complex. The amount of CRP within the samples was proportional to 
the degree of agglutination detected as a reduction in the intensity of transmitted light at 
572 nm. The assay was analysed on the Siemens Advia 2400. The minimum detectable 
concentration of hsCRP was 0.01 mg/dL. Inter and intra-assay co-efficient of variations 
were <10%.   
 
Cortisol reagents were supplied by Siemens Healthcare Diagnostics Ltd, Camberley, 
Surrey, UK (Burrage et al., 2009). The plasma cortisol measurements, samples were first 
incubated with a ‘Lite reagent’ which was cortisol labelled with acridinium ester; and a 
‘solid-phase reagent’ which was an anti-cortisol antibody bound to paramagnetic particles 
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(PMP). The incubation facilitates competing labelled cortisol with cortisol in the plasma 
samples for the PMP-bound antibody binding sites. Next, a magnetic field was applied to 
the reaction mixture causing the solid-phase PMP containing the bound labelled cortisol 
to be held at the side of the reaction cuvette while the liquid phase was aspirated. The 
cuvette contents were washed with deionised water which was then aspirated, again with 
the magnetic field applied. Acid reagent containing hydrogen peroxide was then added to 
the cuvette to begin the light-emission reaction with the acridinium ester. The cuvette was 
then moved to the luminometer at which point base reagent was added to enhance the 
light reaction. The light intensity was measured immediately and converted to 'relative 
light units' (RLU). The RLU value indicated an inverse relationship with cortisol 
concentration. Therefore, the more labelled cortisol was bound, the less patient cortisol 
would be bound. The RLU value was compared with those of the analyte master curve to 
obtain the analyte concentration via the relevant curve-fit algorithm. The minimum 
detectable concentration was 30 nmol/L. Inter and intra-assay co-efficient of variations 











2.3 Measurement of Salivary Cortisol 
Salivary cortisol levels were measured using commercially available high sensitivity 
salivary cortisol enzyme immunoassay kit (Product code: 1-3002, Salimetrics) (Mondelli 
et al., 2010). The recommended procedure was followed. Salivettes containing saliva 
samples were taken out of the freezer and left in room temperature 1 hour before the 
assay. After thawing the samples completely, they were centrifuged at 3000 rpm for 15 
minutes at room temperature. Centrifuging was performed to obtain a clear supernatant of 
low viscosity in order to avoid falsely elevated results due to mucin and other particulate 
matter which might interfere with the antibody binding. The procedure was carried out by 
adding 25 µl of standards, controls and saliva samples into appropriate wells of a 
microtitre plate coated with anti-cortisol monoclonal antibodies. All the samples were 
assayed in duplicate. 200 µl of diluted enzyme conjugate solution (1:1600) was then 
added to each well. Therefore, cortisol linked to horseradish peroxidase (HRP) competed 
with cortisol in the standards and unknowns for the antibody binding sites. After 2 hours 
incubation, the plate was washed 4 times using a plate washer to wash away unbound 
components. 200 µl tetramethylbenzidine (TMB) solution was then added to each well 
followed by mixing on a plate rotor for 5 minutes and incubating the plate in the dark at 
room temperature for an additional 25 minutes. Therefore, bound cortisol peroxidase was 
measured by the reaction of the peroxidase enzyme on the substrate TMB. The reaction 
which produced a blue colour was then stopped by adding 50 µl stop solution of sulfuric 
acid turning the colour to yellow. Optical density was read on Beckman Coulter DTX 880 
plate reader, with Multimode Detection Software 2.0.012, at 450nm with correction at 
620nm. By measuring the intensity of colour, the amount of cortisol peroxidase was 
detected that was inversely proportional to the amount of cortisol present in the samples; 
so the darker the colour, the lower concentration of cortisol. SoftMax Pro 4.8 software 
was used to calculate the cortisol values, following a 4-parameter fit. The analytical 
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sensitivity was set to 0.33 nmol/l. Inter and intra-assay co-efficients of variations ranged 
from 8% to 11% and 6% to 10%, respectively. Salivary cortisol measurements were 
conducted by Dr Patricia Zunszain, senior laboratory coordinator, at Stress, Psychiatry 
and Immunology laboratory (SPI-Lab), KCL. 
 
To investigate the responsiveness of the HPA axis, the repeated measures of salivary 
cortisol was used to calculate the area under the curve (AUC) of the cortisol awakening 
response (CAR) and diurnal cortisol with respect to the increase (AUCI) as well as with 
respect to the ground (AUCG). The formulas for the calculations of the AUC were derived 
from the trapezoidal formula introduced by Pruessner and colleagues (Pruessner et al., 
2003).  
 
Repeated measures with variable time between measurements: 
 
AUC for CAR: 
AUCG= (A+B)/2×t1 + (B+C)/2×t2 + (C+D)/2×t3 
AUCI= [(A+B)/2×t1 + (B+C)/2×t2 + (C+D)/2×t3)] – [A × (t1+ t2+ t3)] 
AUCI= AUCG – [A × (t1+ t2+ t3)] 
 
AUC for diurnal cortisol: 
AUCG= (A+E)/2×t4 + (E+F)/2×t5 
AUCI= [(A+E)/2×t4 + (E+F)/2×t5] – [A × (t4+ t5)] 
AUCI= AUCG – [A × (t4+ t5)] 
 
A: cortisol measure at awakening 
B: cortisol measure at 15 minutes 
C: cortisol measure at 30 minutes 
D: cortisol measure at 60 minutes 
E: cortisol measure at 2 pm 




t1: time between A & B 15 minutes 
t2: time between B & C 15 minutes 
t3: time between C & D 30 minutes 
t4: time between A & E 
t5: time between E & F 
 
 
Prior to performing the calculations, the data for each measure has been double checked 
against the specific time point required for collecting the saliva samples. There were also 
missing data due to unavailability of sample, insufficient saliva sample, or not collecting 
sample in the specific time required. Individuals who had missing data at awakening point 
were excluded (2 patients). For those who had missing data at 15 min or 30 min, the 
average of the two points before and after the missing value was used. For missing data 
for 15 min, the average of awakening and 30 min was used, and for 30 min, the average 
of 15 min and 60 min (see appendix-I). 14 patients (7 in each group), with missing data at 







2.4 Gene Expression Analysis 
Gene expression experiment was conducted by Dr Izabela Barbosa at SPI-Lab, KCL. The 
following sections describe the method used. 
 
2.4.1 RNA Isolation from PAXgene and cDNA Synthesis   
Blood samples for gene expression of IL6, NFkB, TNF-α, IL1β, and GR Total were 
collected using PAXgene Tubes (Qiagen). After blood samples were withdrawn, 
PAXgene tubes were inverted few times and then kept for 3 hours at room temperature in 
order to achieve complete lysis of blood cells.  The tubes were placed first at -20ºC for 48 
hours and then stored at -80ºC until they were processed.  
 
Isolation of RNA was performed using the PAXgene Blood RNA Kit (Qiagen) according 
to manufacturer´s instructions. In brief, samples were defrosted by incubating them for 
the minimum of 3 hours prior to processing. The blood was pelleted, washed, and then re-
suspended with a lysis buffer and proteinase K to digest cellular proteins. Samples were 
then passed through PAXgene Shredder spin columns to homogenise the lysate and filter 
out cell debris. The supernatant of the flow-through was then passed through the 
PAXgene RNA spin column where the silica membrane selectively binds to the RNA. 
After several wash steps the RNA is eluted and heat-denatured (see appendix-M). The 
RNA quality and quantity were assessed by evaluation of the A260/280 and A260/230 
ratios using a Nanodrop spectrometer (NanoDrop Technologies, USA). Samples were 
kept frozen at -80 ºC until further use. One microgram of total RNA was used for cDNA 




2.4.2 Quantitative Real Time PCR (qPCR) 
Gene expression analysis of candidate genes involved in GR function (GR total) and 
inflammatory responses (IL-6, NFkB, TNF-α, and IL1β) was conducted via qPCR. qPCR 
was performed using HOT FIREPol EvaGreen qPCR (Solis BioDyne, Tartu, Estonia) 
according to the SYBR Green method. For each target primer set a validation experiment 
was performed to demonstrate that PCR efficiencies were within the range of 90-100% 
and approximately equal to the efficiencies of the reference genes; glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), beta-actin (ACTB), and beta-2-microglobulin 
(B2M). Briefly, after an initial heating step at 95 ºC for 15 min to activate the polymerase, 
45 PCR cycles were performed. Each cycle consisted of a denaturation step at 95 ºC for 
30 sec, an annealing step at 60 ºC for 30 sec and an elongation step at 72 ºC for 30 sec. 
Each sample was assayed in duplicate and each target gene (IL6, NFkB, TNF-α, IL1β, 
and GR Total) was normalized to the geometric mean of the expression of the three 
housekeeping genes as reference. Pfaffl method (Pfaffl, 2001) was used to quantify the 
relative expression levels of each target gene according to the following equation: 





R = ----------------------------------------------- 





As it is shown in the equation the result is expressed as Relative Expression Ratio (R) 
representing the ratio of a target gene which is expressed in a sample of interest versus a 
control (in this study CHD depressed versus CHD non-depressed) in comparison to a 
reference gene. In the equation, E represents the real time PCR efficiency of 
target/reference gene transcript, and ΔCP is the CP (or Ct) values of the sample and 
control.  
This method has been previously used (Anacker et al., 2011b, Cattaneo et al., 2013). The 
primer sequences are listed in the Table 2.1. 
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Table 2.1 Primer sequences of the primers used for gene expression experiment. 
Primer name Primer sequence 
Glucocorticoid receptor (GR) forward 5’-AACTCTGCCTGGTGTGCTCT-3’ 
Glucocorticoid receptor (GR) reverse 5’-GCTGTCCTTCCACTGCTCTT-3 
Tumor necrosis factor-alpha (TNF-α) 
forward 
5’-CTGCTGCACTTTGGAGTGAT-3’ 
Tumor necrosis factor-alpha (TNF-α) reverse 5’-CAGCTTGAGGGTTTGCTACA-3’ 
Nuclear Factor-kappaBeta (NF-kB) forward 5’-GTGAGGTGGGATCTGCACT-3’ 
Nuclear Factor-kappaBeta (NF-kB) reverse 5’-CTCTGTCATTCGTGCTTCCA-3’ 
Interleukin-6 (IL-6) forward 5’-AAGCCTGACCACGCTTTCTA-3’ 
Interleukin-6 (IL-6) reverse 5’-GCTCCCTGGTTTCTCTTCCT-3’ 
Interleukin1-β (IL-1β) forward 5’-ACGATGCACCTGTACGATCA-3’ 
Interleukin1-β (IL-1β) reverse 5’-GAACACCACTTGTTGCTCCA-3’ 
glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) forward 
5’-CAATGACCCCTTCATTGACC-3’ 
glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) reverse 
5’-TGGAAGATGGTGATGGGATT-3’ 
beta-actin (ACTB) forward 5’-CTCTTCCAGCCTTCCTTCCT-3’ 
beta-actin (ACTB) reverse 5’-AGCACTGTGTTGGCGTACAG-3’ 
beta-2-microglobulin (B2M) forward 5’-ACTGAATTCACCCCCACTGA-3’ 








2.5 GR Function Evaluation 
GR function was measured directly on previously isolated and stored peripheral blood 
mononuclear cells (PBMC) by thawing and culturing them using “glucocorticoid 
inhibition of lipopolysaccharide (LPS)-stimulated IL-6 levels” technique. In this method, 
the cells were first stimulated by LPS which is highly immunogenic causing the cells to 
produce IL-6. Next, dexamethasone (DEX), synthetic glucocorticoid, was used at 
different concentrations to inhibit the production of IL-6 facilitated by GR. Therefore, as 
the higher DEX concentration, the less IL-6 is expected to be produced. However, in case 
of GR impairment, there would not be a decrease in the production of IL-6. IL-6 levels 
were measured using IL-6 ELISA assay, and so GC mediated-GR function could be 
evaluated.  
 
2.5.1 Isolation and Cryopreservation of Human Peripheral Blood 
Mononuclear Cells (PBMC) 
Sodium-heparinized blood was diluted 1:1 with phosphate buffered saline (PBS). PBMC 
were isolated by Ficoll-Paque density gradient centrifugation, as per previous 
publications (Knijff et al., 2007, Sarkar et al., 2003). The procedure was carried out by 
layering diluted blood on top of Ficoll (2:1 e.g. 30 ml diluted blood on 15 ml of Ficoll) in 
a 50 ml polypropylene tube. The tube was then centrifuged at 1000g for 15 min at room 
temperature, without the break. Using a sterile pastures pipette the buffy coat layer 
containing PBMC was collected into a new 50 ml polypropylene conical tube. PBMC re-
suspended in PBS to the total volume of 50 ml, and centrifuged at 800 g for 10 min at 
room temperature. The supernatant was discarded and PBMC rich pellet was re-
suspended in a cryovial in 1 ml cold cell culture fluid 1 (CF1) medium consisted of 10% 
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FCS (fetal calf serum), and 1% PEN-STREP (Penicillin-Streptomycin), and 90% RPMI 
1640 with 25 mM Hepes and Ultraglutamin-1 medium. After labeling, the cryovials 
containing cell suspension were kept on ice. PBMC were counted using hemacytometer 
and trypan blue exclusion method (please see the next section 2.5.2 for detailed 
explanation). 
  
Freshly prepared cell culture fluid 2 (CF2) containing 80% CF1 and 20% DMSO 
(dimethylsulfoxide, Me2SO) were then added 1:1 slowly in droplets to the cell 
suspension. The cells were distributed in 1 ml aliquots in precooled cryovials ready for 
storage using slow temperature-lowering method by incubating them in an isopropyl 
alcohol bath in Cryo 1ºC freezing container (Mr. Frosty polyethylene vial holder). The 
cryovials in the freezing container were placed into the -80 ºC freezer overnight and then 
transferred into liquid nitrogen for long term storage until future use (see the appendix-J 
for the protocol and step by step procedure). 
 
2.5.2 Thawing of Cryopreserved Cells 
The cryovials containing PBMC were taken out from liquid nitrogen.  The cryovials were 
thawed immediately in a 37 ºC water bath. No more than 2 cryovials were thawed at the 
same time. To dilute the PBMC and wash out the DMSO, while still a few crystals of ice 
were visible, the cells were transferred to a 15 mL corning tube with 10 mL of warmed 
CF1 inside. The tubes were centrifuged at 800 g for 5 min at room temperature. The 
supernatants were discarded and the cells were re-suspended in 1 ml of CF1. 
   
Recovery and viability of PBMC were examined by trypan blue exclusion technique. 
Cryopreserved and thawed cells contained greater than 95% viable recovered cells. 
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PBMC were counted using hemacytometer. A cover glass was placed in the center of the 
hemacytometer. Re-suspended cells were stained using 0.4% trypan blue solution. One 
hemacytometer chamber was filled with 10 µl of the cell and dye solution. Under the 
microscope cells were counted in the four corners of 4x4 areas. To determine PBMC 
count the mean was used multiplied by dilution factor (e.g. 10 µl PBMC solution + 40 µl 
PBS + 50 µl 0.4% trypan blue solution; dilution factor = 10).  The cell count were 
recorded as number of cells in million per ml. The amount of 100K cells required for each 
well in a total volume of 200 µl was then calculated.  
x × 0.2 (ml) = 100.000 (cells/well)     
x= 500.000 = 50 × 10
4
 (cells/ml)  
C1×V1= C2×V2 
Number of cells counted (cells/ml) × x (ml) = 50 × 10
4
 (cells/ml) × 0.2 (ml)  
x (ml) = [50 × 10
4
 (cells/ml) × 0.2 (ml)] / [Number of cells counted (cells/ml)] 
 
2.5.3 Cell Culture 
PBMC were cultured in a 96-well round-bottomed tissue culture plate (Falcon, 3077) at a 
concentration of 50 × 10
4
 cells/ml in CF1. The following factors were either present or 
not in the culture according to the template below representing the culture plate designed 
for each PBMC sample: LPS of Escherichia Coli (E.coli) in a concentration of 1 ng/ml to 










 M to 
inhibit the production of LPS-induced IL-6; and clomipramine (CMI), citalopram (CIT), 
and omega-3 fatty acid, eicosapentaenoic acid (EPA), in a concentration of  10
-5
 M to 
investigate the effect of these drugs on GR function. Drug concentrations were used based 
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on previously published studies such as (Carvalho et al., 2010, Carvalho et al., 2008) for 
antidepressants and (Lu et al., 2010) for EPA. Ethanol (ETOH) also was added to the 
control wells at a concentration of 10
-5
 M, since DEX, CIT, and EPA were diluted in 
ETOH.  Each condition was assayed in duplicate. 
 
The cells culture template is presented below (Table 2.2 on page 76). The template 
illustrates the conditions in which the cells were treated. The columns 1 and 8 contained 
the PBMC cultured in CF1 and without stimulation. In all the other wells the same 
amounts of LPS were also added, so the cultured PBMC were induced for the production 
of IL-6. As shown in the template, in the columns 4  to 7 and 10  to 12, DEX was added 










M) to obtain the dose 
response curve. The rows represent the conditions in which the drugs were also added 
(CMI in C & D; CIT in E & F; and EPA in G & H rows). 
 
PBMC were then incubated for 24 h at 37 ºC, under 5% CO and humidified air. After 24 
hrs, the plate was centrifuged at 1000 g for 10 min at 4 ºC. The supernatant from each 
well were harvested and transferred to a labelled Eppendorf. The culture supernatants 
were then stored at -20 ºC until they were assayed for measurements of IL-6 levels in the 
following day. The samples were then transferred to -80 ºC for long term storage. 
 
Drugs and reagents: LPS, DEX, CMI, CIT, and EPA were purchased from Sigma. LPS 
was dissolved in PBS (1 mg/ml) and aliquots stored at -20 ºC. DEX was dissolved in 
ETOH freshly prepared before use. CMI was dissolved in PBS freshly prepared before 
use. CIT and EPA were dissolved in ETOH (10 mg/ml) and aliquots stored at -20 ºC. All 
the subsequent dilutions for the required concentrations were made in CF1 fresh before 
use (see the appendix-K for the protocol and step by step procedure). 
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Table 2.2 Cell culture template 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
 





















































































































































































































































     
Unst, unstimulated; LPS, lipopolysaccharide; DEX, Dexamethasone; CMI, clomipramine; CIT, citalopram; EPA, eicosapentaenoic acid; ETOH, ethanol
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2.5.4 Cytokine Assay 
The levels of pro-inflammatory cytokine IL-6 in supernatants of the PBMC cultures were 
measured via IL-6 specific enzyme-linked immunosorbant assay (ELISA) as per 
previously published work with slight modifications (Knijff et al., 2007). A 96-well 
ELISA  plate (Costar 3590) was coated overnight at 4 ºC adding 100 µl diluted (1:1000) 
IL-6 specific capture antibody (Invitrogen: Ms mAb Anti-Hu IL-6) to each well. After 
overnight incubation, the wells were then emptied and tapped on a paper filter. Next, 300 
µl block buffer, PBS containing 0.5% BSA (bovine serum albumin, Sigma) solution, was 
added to each well, and the plate was incubated for 2 h in room temperature. After 
blocking step, the plate was washed 4 times using the plate washer machine and freshly 
prepared wash buffer (MilliQ water containing 0.9% Nacl and 0.05% Tween20 solution). 
The supernatant samples were diluted to a measurable solution (1:2, 1:100, and 1:50 for 
Unst, LPS, and DEX, respectively) in working buffer (PBS containing 0.5% BSA). The 
standard solutions of IL-6 (R&D: recombinant human IL-6) were prepared in serial 
dilution (500, 250, 125, 62.5, 31.25, 15.63, 7.8, 3.9, 1.95, 0 ng/ml) for the standard curve. 
100 µl of diluted samples and standard solutions were aliquoted in duplicate in the 
appropriate wells. 50 µl diluted (1:500) IL-6 detection antibody (Invitrogen: Ms mAb 
Anti-Hu IL-6 Biotin) were thereafter added to each well followed by incubation for 2 h 
on a plate shaker at room temperature. After another washing step, 100 µl diluted 
(1:15000) streptavidine poly HRP (Thermo scientific) was added to enhance the reaction, 
and the plate was incubated for 30 min under continuous shaking at room temperature.  
The plate was then washed 5 times. The reaction was developed in dark after adding 100 
µl of TMB substrate (Thermo Scientific). The reaction was then stopped by adding 100 µl 
1 M H2SO4 when the colour of Blank and the standard solution in the lowest 
concentration started to turn slightly blue (approximately after 3-5 min). The absorbance 
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at 450/620 nm was measured using ELISA reader (MULTISKANEX, Thermo Electron 
Corporation) (see the appendix-L for protocol and step by step procedure).  
 
The standard curve was used to calculate concentrations of IL-6 in samples of 
supernatants using GraphPad Prism Software version 4.03 for windows, Inc., San Diego, 
California, USA. Inter- and intra-assay variations were <10%. The analytical sensitivity 
was set to 2 ng/mL. The values obtained from the levels of IL-6 of the unstimulated cells 
were deducted from the LPS-stimulated IL-6 levels for each condition. The calculation of 
percentage inhibition for each concentration of dexamethasone was as follows: 
 
                                               Mean IL-6 levels (LPS-stimulated with DEX) 
IL-6 levels % (DEX only) = -------------------------------------------------------------- x 100 
                                             Mean IL-6 levels (LPS-stimulated without DEX) 
 
Glucocorticoid suppression was calculated by normalizing the data to LPS-stimulated IL-
6 levels in the absence of dexamethasone expressed by 100% (Carvalho et al., 2010).  
IC50-DEX [M] representing the DEX concentration that would give 50% inhibition effect 












The procedure of in vitro evaluation of GR function directly on PBMC is summarized and 
illustrated in the figure below. 
 
Figure 2.2 In Vitro GR Function Evaluation on PBMC (DEX-inhibition of LPS-
stimulated IL-6 Production). Photographs of the author reproduced with kind permisson of 
Martha Villegas-Montes.  
 
All the experiments in relation to GR function were performed at the University of 
Roehampton. Cell culture experiments were conducted in the microbiology laboratory 
containment level 2, and ELISA in the clinical laboratory, strictly observing the Health 





2.6 Tryptophan and Kynurenine Pathway Analysis 
Tryptophan and kynurenine pathways were assessed by measuring the serum 
concentrations of tryptophan, kynurenine, and their metabolites. Serum samples were sent 
to Dr Aye Mu Myint and her colleagues in Germany (Laboratory for 
Psychoneuroimmunology, Ludwig-Maximilians University, Munich) to determine the 
levels of TRP, KYN, KYNA, 3-HK, and 3-HAA metabolites, using High performance 
liquid chromatography (HPLC) method. Based on their report, the measurements were 
performed according to the method of Herve et al. with some modifications (Herve et al., 
1996). However, the recently published method using HPLC (Oades et al., 2010) was 
used to measure 3-HK. The following is a brief description of the method used: KYN was 
detected spectrophotometrically at 365 nm. KYNA was detected fluorimetrically at an 
excitation wavelength of 334 nm and an emission wavelength of 388 nm. KYNA was 
analyzed in plasma that was deproteinised using perchloric acid. 3-HK was measured at a 
wavelength of 365 nm by UV detection. All of the analyses were conducted using HPLC 
with a reversed phase C-18 column. The 3-HK analysis method has been validated 
showing an absolute recovery of 85.8%, intra-day precision of 3.9%, and inter-day 
precision of 7.5%. A time series demonstrated total stability of the analyte 3-HK during 
the extraction and analysis steps for up to 3x repeated freezing/thawing cycles, which 
ensured the validity of the analysis in samples that had already been thawed and frozen 
again. The intra- and inter-assay coefficients of variation ranged from 5% to 7% for all of 
the metabolites. The kynurenine to tryptophan (KYN/TRP) ratio was calculated by 





2.7 Vascular Endothelial Growth Factor (VEGF) Measurement in 
Plasma 
The quantitative determination of vascular endothelial growth factor (VEGF) 
concentrations in plasma samples was measured by commercially available ELISA kit 
(R&D systems, Minneapolis, MN, USA) (Rosti et al., 2007). The recommended 
procedure was followed. Briefly, the plasma samples were taken out of the freezer and 
thawed leaving them in room temperature. After adding 50 µl of Assay Diluent, 100 µl of 
standards, plasma samples, and controls (all assayed in duplicate) were pipetted into the 
appropriate wells of a microplate pre-coated by monoclonal antibody specific for VEGF. 
The plate was covered with the adhesive strip provided and was incubated for 2 hours in 
room temperature. The procedure allowed VEGF presented in samples to be bounded by 
the immobilized antibody. The plate were then washed using a plate washer to remove 
any unbound substances. After blotting the plate against clean paper towel to make sure 
removal of possible remaining wash buffer, 200 µl of VEGF conjugate (an enzyme-linked 
polyclonal antibody against VEGF conjugated to horseradish peroxidase) was added to 
each well, and the plate was incubated for 2 hours. After washing the plate to wash away 
any unbound antibody-enzyme reagent, 200 µl TMB solution was added to the wells and 
the plate was incubated for 25 minutes at room temperature and protected from light. The 
procedure allowed developing colour (from colourless to blue) in proportion to the 
amount of VEGF bound initially. The reaction was then stopped by adding 50 µl stop 
solution of sulfuric acid turning the colour from blue to yellow. The intensity of the 
colour was measured. Microplate reader (Beckman Coulter DTX 880) was used to 
determine optical density at 450 nm with correction at 570 nm. SoftMax Pro 4.8 software 
was used to calculate the VEGF values. Inter- and intra-assay variations were <10%. 
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2.8 Data Analysis 
All statistical analyses were performed using SPSS software version 20.0 for Windows. 
The data were reported as the mean ± SEM. All data were tested for suitability for 
parametric or non-parametric analysis. In some cases such as CRP, the data with skewed 
distribution were log-transformed to correct the distribution for subsequent analysis. For 
comparing all the biological factors assessed in this study between the two groups of 
CHD patients without depression and CHD patients with depression, independent t-test 
was used (or Mann-Whitney U-test, as the non-parametric counterpart of the t-test, where 
specified). Dichotomous variables were compared using Chi-squared test for variables 
such as gender, marital and educational status, ethnicity, smoking statues, and also 
cardiac factors and concomitant medications. Correlations were assessed using Pearson’s 
product moment correlation (or Spearman’s correlation coefficient where the data 
violated parametric assumptions). For comparison of more than two groups, One-way 
ANOVA analysis (or its non-parametric counterpart Kruskal-Walis test) was carried out. 
A two-way ANOVA was used to determine how a response was affected by the two 
relevant factors. The analysis was performed on salivary cortisol repeated measurements 
as well as dexamethasone inhibition of LPS stimulated IL-6 levels. General linear model 
(GLM) was performed for taking into account the effect of covariates (ANCOVA) such 
as gender, age, and antidepressant usage on the findings. The p-values of <0.05 were 







2.9 A Summary of Personal Contribution 
I have optimized the cell culture protocol for measuring the sensitivity of GR. I recruited 
healthy controls, processed their blood, and isolated PBMC for the protocol optimization. 
I then conducted all the in vitro experiments in relation to GR sensitivity and the effects 
of drugs on the GR function in the patients. I also completed all ELISA assays to measure 
IL-6 levels in supernatant of the cultured cells. 
 
For measuring cortisol and CRP levels, plasma and serum samples were sent to 
biochemistry laboratory, KingsPath, at King’s College Hospital. I have then run all the 
data analysis in relation to these parameters. 
 
I have contributed to the saliva samples collection by helping and supervising Jennie 
Parker who was a master student working in the INFLAME-BEAT study. Salivary 
cortisol measurements were conducted by Dr Patricia Zunszain at SPI-Lab, KCL. I, then, 
performed all the calculations of the CAR and AUC using formulas introduced by 
Pruessner and colleagues, followed by subsequent analyses. 
 
Gene expression experiment was conducted by Dr. Izabela Barbosa at SPI-Lab, KCL. 
However, I performed all the subsequent calculations using Pfaffl method following by 
analyses to determine the Relative Expression Ratio of the candidate genes, and 
subsequent statistical analysis with the data. 
 
The kynurenine and tryptophan pathway metabolites were measured by Dr Aye Mu 
Myint and her colleagues in Germany (Laboratory for Psychoneuroimmunology, Ludwig-
Maximilians University, Munich). I have organized the transfer of samples from SPI-Lab 
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to Germany, and performed all required calculations and the subsequent statistical 
analyses after receiving the raw data.   
 
I have run ELISA experiment for measuring VEGF levels followed by analyzing the data. 
And finally, I have organized the database of the biological data, ensuring data-quality 















































3.1 Characteristics of CHD Patients with and without Depression 
The Characteristics of the CHD patients with depression (n=28) and without (n=55) are 
shown in the following tables.  
 
Table 3.1 Socio-demographic characteristics of CHD patients with and without 
depression 
 CHD (n=55) CHD-D (n=28) Test  and significance 
Age (years) (mean ± SEM) 70 ± 1  69 ± 2  t (81)=0.72, p=0.48 
Gender (% of males) 89 54 χ2 =13.26, p=0.001** 
Ethnicity (% of white) 91 82 χ2 =1.35, p=0.25 
Marital Status [n (%)] 
Married/civil partnership 
Separated/divorced  

































































Table 3.1 represents the socio-demographic characteristics of the patients. Except for 
gender, the two groups of CHD patients, with and without depression, did not differ in 
any demographic characteristics in terms of age, ethnicity, marital status, educational 
levels, employment, and smoking status. Due to the gender difference (χ2 =13.26, 
**p<0.01), and specifically the fact that there were more female in depressed group than 
non-depressed (46% vs 11% respectively), the effect of gender has been analysed and 























Table 3.2 Psychometric characteristics of CHD patients with and without depression 
 CHD (n=55) CHD-D (n=28) 
CIS-R (%) 0.0 100.0 
BDI score (mean ± SEM) 
At the time of blood collection 
At the time of saliva collection 
 
4.2 ± 0.4 
4.3 ± 0.4 
 
19.0 ± 1.3 
18.2 ± 1.7 
History of Depression (%) 0 54 
Family history of Depression (%) 13 36 
CIS-R, Clinical Interview Schedule-Revised; BDI, Beck Depression Inventory 
 
The Table 3.2 demonstrates the psychometric characteristics of the study population. The 
two main characteristics: CIS-R and BDI score, were used to define depression in CHD 
patients. As described previously, clinical diagnosis of depression was assessed based on 
the CIS-R. As shown in the table, all the CHD depressed patients (CHD-D) were 
clinically diagnosed with depression according to the CIS-R. In addition, all CHD-D 
subjects show depressive symptoms at the time of the sample collection that was 
quantified using the BDI (≥10). The information in regards to the history of depression 
and family history of depression were recorded by participant self-report at the baseline 
interview. 54% of CHD-D had a history of depression in the past, and 36% had a family 
history of depression. The control group, CHD without depression, were selected based 








Table 3.3  Cardiac factors and diagnosis of CHD patients with and without 
depression 
 CHD (n=55) CHD-D (n=28) Test  and significance 
Myocardial Infarction (%) 47 36 χ2 =1.01, p=0.32 
Hypertension (%) 69 79 χ2 =0.92, p=0.34 
Heart Rate (mean ± SEM) 58 ± 1 67 ± 4 t (52)=-2.09, p=0.047* 
Body Mass Index (BMI) 
(kg/m2) (mean ± SEM) 
29.17 ± 0.77 30.15 ± 1.54 U= 733.0, z= -0.23, p=0.82 
High Cholesterol (%) 66 56 χ2 =0.84, p=0.36 
Family History of  




Diabetic CHD (%) 18 29 χ2 =1.18, p=0.28 
The Table 3.3 demonstrates cardiac related factors and diagnosis of the study participants. 
As presented, the two groups of CHD patients, with and without depression, had the same 
population with a history of myocardial infarction (p>0.05), the factor associated with 
increased risk of development of depression and cardiovascular mortality (Lichtman et 
al., 2008, Vasan et al., 2003). Some other cardiac factors, which have an unfavourable 
impact on inflammation and cardiovascular related events, have been also analysed with 
no difference being found between the two groups. These included hypertension defined 
as elevated systolic blood pressure ≥140 mmHg and/or diastolic blood pressure 
≥90 mmHg (p>0.05); BMI defined as weight (kg) divided by the square of height (m) 
(p>0.05); high cholesterol defined as elevated levels of total circulatory cholesterol ≥240 
mg/dL (high density lipoprotein + low density lipoprotein + 20% triglyceride) (p>0.05); 
family history of heart problems defined as whether one or two of the patents and/or 
siblings developed heart problems (p>0.05) (Roger et al., 2011); as well as diabetes as 
diagnosed and recorded by their general practitioners (p>0.05).  
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As shown in the table, depressed group had significantly higher heart rate as compared to 
non-depressed CHD patients (*p<0.05). Although no significant difference was found 
between the two CHD groups regarding being on beta blocker therapy as presented in 
Table 3.4, there were more non-depressed (60%) than depressed (52%) taking beta 
blocker medications. Therefore, the findings in regards to heart rate were controlled for 


















Table 3.4 Concomitant medications of CHD patients with and without depression 
 CHD (n=55) CHD-D (n=28) Test  and significance 
Antidepressants (%) 0 39  
Statin (%) 89 80 χ2 =0.99, p=0.32 
ASA (%) 71 80 χ2 =0.69, p=0.41 



























ACE, angiotensin-converting-enzyme inhibitor; ASA, acetylsalicylic acid 
The concomitant medications of the study population are presented in the Table 3.4. As 
demonstrated in the table, CHD control group were free from antidepressant usage. 
However, 39.3% of CHD depressed group were taking antidepressants including SSRIs: 
fluoxetine, citalopram, sertraline, and TCAs: amitriptyline, nortriptyline, dosulepin. The 
effect of antidepressant have been analysed in biological system investigated in this PhD 
thesis by comparing depressed patients who are drug free and those who are on 
antidepressants. In both groups, almost all the patients were taking medications related to 
their cardiac condition, the most common of which are indicated in the table above. The 
cholesterol lowering statins included atorvastatin, simvastatin, rosuvastatin, and 
pravastatin. They were used in more than 80% of patients with no differences between the 
two CHD groups (p>0.05). The use of anti-inflammatory drug, acetylsalicylic acid 
(ASA), most commonly known as aspirin, also did not differ between CHD depressed 
and non-depressed (p>0.05). No differences were found in taking warfarin and 
clopidogrel which were two anticoagulant medications in the two study groups (p>0.05). 
More than 90% of the subjects in each group were taking antihypertensive medications 
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including β-blockers (atenolol, bisoprolol, carvedilol, metoprolol, propranolol, nebivolol), 
angiotensin-converting-enzyme (ACE)-inhibitors (ramipril, lisinopril, enalapril, 
perindopril), and Ca
2+
-channel inhibitors (amlodipine, nifedipine, felodipine, diltiazem). 
There were no significant differences between groups in taking antihypertensive 
























3.2 Inflammation in CHD Patients with and without Depression 
 
3.2.1 Inflammatory Biomarker: C - Reactive Protein (CRP)  
In order to investigate the degree of inflammation in the study population, the present 
study firstly focused on the CRP levels in both CHD patients with and without 
depression, and compared the circulatory levels of CRP in serum between the two groups.  
 
CRP is the most sensitive acute phase reactant and a marker of on-going inflammation 
(Willerson and Ridker, 2004). CRP as a clinical biomarker of inflammation has been 
found to be a robust predictor of future cardiac events, even stronger than LDL 
cholesterol (Ridker, 2003). In addition, elevation of CRP which is implicated in the 
pathogenesis of CHD (Huffman et al., 2013), has been also shown to be associated with 
presence of the depressive symptoms in otherwise healthy individuals (Miller et al., 
2002).  
 
According to the American Heart Association, the CRP levels <1, 1-3, and, >3 mg/L are, 
respectively, low, intermediate, and high risk factors for cardiovascular events. Measuring 
the circulating serum levels of CRP in the present study population, as shown in Figure 
3.1, demonstrated that both CHD groups exhibited CRP levels more than 3 mg/L, and so 
being in high risk group (CHD 3.34 ± 0.75 mg/L and CHD-D 5.21 ± 0.99 mg/L). 
However, inflammation was found to be even higher (>5 mg/L) in CHD patients with 
depression.  
 
The CRP values were tested for normality, and since the data were not normally 
distributed, they were log transformed (log10) to improve suitability for parametric 
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statistics. CRP concentrations were significantly higher in CHD-D when compared with 
CHD control group: Log CRP (mean ± SEM); CHD 0.096 ± 0.12, CHD-D 0.509 ± 0.12, t 
(52) = -2.361, p=0.016. However, for the presentation purposes, the raw values were used 
to illustrate the actual levels of CRP as shown in Figure 3.1.  
 
CRP was found to be positively correlated with the BDI scores (rs=.342, p=.012, n=53) 
indicating the association of inflammation with the severity of depressive symptoms in 
CHD patients with and without depression (Figure 3.2). In addition, CRP was found to be 






























Figure 3.1 Circulating CRP concentrations (mg/L) in CHD patients with and 
without depression. Data expressed as mean ± SEM, (CHD, n=33; CHD-D, n=21).  
CHD patients with and without depression had high levels of CRP (>3 mg/L) and both 
are at high risk group for cardiovascular events. Compared to non-depressed group (CHD, 
n=33), CHD patients with depression (CHD-D, n=21) showed a statistically significant 











Figure 3.2 Association of CRP concentrations with BDI scores in CHD patients with 
and without depression (rs=.342, *p<.05, n=53). 
Serum CRP levels (mg/L) were significantly associated with the BDI scores in CHD 
patients with and without depression (rs=.342, *p<.05, n=53). The positive correlation 
indicates that higher inflammation was associated with more severe depressive symptoms 










3.2.2 Gene Expression and Inflammation 
Gene expression profile is suggested to be a useful tool developed for identifying 
molecular biomarkers associated with diseases (Sunde, 2010). Whole blood is considered 
as an ideal tissue for measuring the expression levels of genes due to its feasible 
obtainability. This is especially relevant in advancing neuropsychiatric research where the 
CNS tissue is rather inaccessible (Sullivan et al., 2006). Since there is a constant 
interaction between blood cells and the entire body, alteration in gene expression at the 
peripheral level may reflect the changes of the particular tissue associated with the 
disorder (Liew et al., 2006). Studies show expression of a large proportion of the genes, 
approximately 80%, by peripheral blood cells which in turn share over 80% similar gene 
expression profiles when compared with a range of different major tissues including the 
brain (Liew et al., 2006, Sullivan et al., 2006, Sunde, 2010). Indeed, peripheral blood 
cells are being used to peruse transcriptomic research in major depression (Mehta et al., 
2010). Pro-inflammatory changes in relation to depression have been also studied through 
genome expression analysis at the peripheral level (Savitz et al., 2013).  
 
For the purpose of this PhD thesis, in addition to measuring circulatory levels of CRP in 
the study population, inflammation has been also investigated through gene expression 
analysis of candidate genes involved in inflammatory response that included: IL-6, IL-1β, 
NF-kβ, and TNF-α.  
 
As described before in section 1.2.8 antidepressants exert beneficial effect in modulation 
of  inflammation and specifically studies suggest their role in inhibition of production and 
release of pro-inflammatory cytokines including IL-1, IL-6, and TNF-α (Tousoulis et al., 
2009, Xia et al., 1996). Therefore, considering the fact that almost 40% of CHD-D 
patients were on antidepressant treatment, it was interesting to investigate the in vivo 
98 
 
effects of antidepressants on the expression of the candidate genes by comparing 

























3.2.2.1 Gene Expression of Interleukin-6 (IL-6)  
In order to evaluate further the inflammatory response, gene expression levels of IL-6 
were analysed. IL-6 encoded by IL-6 gene is a circulating pro-inflammatory cytokine and 
a potent inducer of acute phase responses that regulates hepatic synthesis and release of 
CRP (Heinrich et al., 1990, Yudkin et al., 2000). Although hepatic acute phase reactions 
are regulated also by other pro-inflammatory cytokines, IL-6 plays a primary role in this 
regard. Indeed, as evidenced by animal studies, compared to IL-1 and TNF-α deficient 
models, IL-6 knockout animals are the ones exhibiting acute phase response impairment 
(Maes et al., 2011, Sherwood et al., 2007).  
 
IL-6 is known as a powerful predictor of chronic and low-grade inflammatory state 
(Rohleder et al., 2012). This pro-inflammatory cytokine and its signalling events 
contribute to prognosis of atherosclerosis (Schuett et al., 2009). In addition, IL-6 in the 
context of inflammation is a major mediator of CNS-immune interaction and its elevation 
has been shown to be closely linked in chronic stress as well as fatigue and sleep 
disturbances (Rohleder et al., 2012). Furthermore, increased IL-6 and its direct effect on 
the brain are implicated in the pathophysiology of depression (Glassman et al., 1993).    
 
Therefore, in the present thesis, IL-6 gene expression was considered as an important 
candidate gene to be investigated in the study population. As illustrated in Figure 3.3, IL-
6 mRNA expression was shown to be significantly increased in CHD depressed patients 






The effects of antidepressant treatment on IL-6 gene expression are presented in Figure 
3.4. Both groups of CHD depressed patients either on antidepressant treatment or drug-
free, showed significantly higher levels of IL-6 gene expression as compared to CHD 
patients without depression (One-way ANOVA, F(2,36)=8.083, p=0.0013). 
Antidepressant use had no significant effect on the gene expression of IL-6 in CHD 
patients with depression compared to antidepressant-free CHD depressed individuals 
(t=0.8170, df=14, p=0.428).  
 
Gender and age were found to have a significant effect on IL-6 expression; 
F(1,36)=4.226, p=0.047 and F(1,36)=6.167, p=0.018, respectively. However, the result 
held true after controlling for the effect of these covariates (F(3,35)=4.538, p=0.04).  
 
As presented in Figure 3.5, the result on the association between the pro-inflammatory 
cytokine IL-6 and severity of depression showed a positive correlation between IL-6 gene 
expression and depressive symptomatology quantified by BDI scores (r =.356, p=.026, 














Figure 3.3  IL-6 mRNA expression in CHD patients with and without depression. 
Data expressed as mean ± SEM, (CHD, n=23; CHD-D, n=16).  
CHD patients with depression (CHD-D, n= 16) exhibited significantly increased in IL-6 
































Figure 3.4 The effect of antidepressants on IL-6 gene expression. Data expressed as 
mean ± SEM, (CHD, n=23; CHD-D-noAD, n=9; CHD-D-AD, n=7).  
CHD depressed patients with (CHD-D-AD, n=7) and without (CHD-D-noAD, n=9) 
antidepressant treatment showed significantly higher levels of IL-6 gene expression as 
compared to CHD patients without depression (CHD, n=23) (***p<0.001). 
Antidepressant use had no significant effect on the gene expression of IL-6 in CHD 
patients with depression compared to antidepressant-free CHD depressed individuals 
(CHD-D-AD vs CHD-D-noAD, p>0.05).  
   
 
   













































Figure 3.5 Association of IL-6 expression with BDI scores in CHD patients with and 
without depression (r =.356, *p<.05, n=39). 
IL-6 gene expression was significantly associated with the BDI scores in CHD patients 
with and without depression (r =.356, *p<.05, n=39). The positive correlation indicates 
that increase in expression of inflammatory cytokine IL-6 were associated with more 











3.2.2.2 Gene Expression of Interleukin-1beta (IL-1β)            
IL-1β was another inflammatory cytokine whose expression was assessed in this PhD. IL-
1β encoded by IL-1β gene is a member of IL-1 family and classified as type 1 cytokines 
involved in enhancing cellular immune responses. This potent inducer of innate immune 
response stimulates the expression and release of secondary inflammatory mediators. IL-
1β is the main circulating IL-1 involved in systemic inflammatory response.  
 
An increased level of this cytokine has been reported in inflammatory disorders and CHD 
(Hansson, 2005a, Stegger et al., 2012). Indeed, IL-1β has been suggested to be involved 
in development of atherosclerotic arteries (Olofsson et al., 2009) and incidence of 
myocardial infarction (Iacoviello et al., 2005). On the other hand, elevation of IL-1β is 
observed in MDD, late-life depression, and treatment resistant depression (Maes et al., 
1993, Maes et al., 1997, Thomas et al., 2005).   
 
Therefore, IL-1β gene expression was assessed as another candidate gene. As illustrated 
in Figure 3.6, there was no difference in IL-1β mRNA expression in CHD patients with 
and without depression (t=0.277, df=38, p=0.784).  
 
The effect of antidepressants treatment on IL-1β gene expression is presented in Figure 
3.7. The graph shows that antidepressants appeared to decrease the gene expression of IL-
1β in CHD patients with depression compared to antidepressant-free CHD depressed 
individuals, but the effect was not found significant (One-way ANOVA: F(2,37)=2.147, 






























Figure 3.6 IL-1β mRNA expression in CHD patients with and without depression. 
Data expressed as mean ± SEM, (CHD, n=24; CHD-D, n=16). 
There was no difference in the levels of IL-1β gene expression when CHD patients with 
depression (CHD-D, n=16) were compared with CHD patients without depression (CHD, 

















































Figure 3.7 The effect of antidepressants on IL-1β gene expression. Data expressed as 
mean ± SEM, (CHD, n=24; CHD-D-noAD, n=9; CHD-D-AD, n=7).  
Antidepressants appeared to decrease the gene expression of IL-1β in CHD patients with 
depression (CHD-D-AD, n=7) compared to antidepressant-free CHD depressed 









3.2.2.3   Gene Expression of Tumour Necrosis Factor-alpha (TNF-α) 
Gene expression of TNF-α was assessed in this PhD thesis, because this cytokine also is 
known to be involved in systemic inflammation and triggering acute phase reactants 
(Popa et al., 2007). As the name suggests, the cytokine was first recognized as an 
endotoxin induced serum factor triggering the necrosis of tumours (Carswell et al., 1975). 
TNF-α is encoded by TNF gene, and its expression, synthesis, and release into the 
circulation are induced in response to inflammatory stimuli (Kriegler et al., 1988). This 
pro-inflammatory cytokine plays a role in regulating the expression of IL-6 and its 
elevation has been observed in chronic inflammatory conditions (Bradley, 2008, Suarez-
Cuervo et al., 2003).  
 
The studies on TNF-α in relation to heart disease suggest the implication of increased 
circulatory levels of the cytokine in pathophysiology of cardiac related conditions 
specifically in the development of atherosclerosis and the progression of chronic heart 
failure  (Feldman et al., 2000, Sack, 2002). In relation to depression, a recent meta-
analysis of 24 published studies reported significantly higher concentration of this pro-
inflammatory cytokine along with IL-6 in MDD patients as compared to healthy controls 
(Dowlati et al., 2010).        
 
Therefore, TNF-α gene expression was assessed as another candidate gene. As illustrated 
in Figure 3.8, there was no difference in TNF-α mRNA expression in CHD patients with 
and without depression (t=0.449, df=38, p=0.656). The effect of antidepressants treatment 
on TNF-α gene expression is presented in Figure 3.9. Antidepressants had no significant 
effect on gene expression of TNF-α in CHD patients with depression compared to 
antidepressant-free CHD depressed individuals (One-way ANOVA: F(2,37)=0.191, 
p=0.827); CHD-D-noAD vs CHD-D-AD t=0.506, df=14, p= 0.621). 
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Figure 3.8 TNF-α mRNA expression in CHD patients with and without depression. 
Data expressed as mean ± SEM, (CHD, n=24; CHD-D, n=16). 
CHD patients with depression (CHD-D, n=16) showed no difference in the levels of 
TMF-α gene expression when compared with CHD patients without depression (CHD, 
n=24) (p>0.05).  
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Figure 3.9 The effect of antidepressants on TNF-α gene expression. Data expressed 
as mean ± SEM, (CHD, n=24; CHD-D-noAD, n=9; CHD-D-AD, n=7).  
Antidepressants treatment had no significant effect on gene expression of TNF-α in CHD 
patients with depression (CHD-D-AD, n=7) when compared with antidepressant-free 










3.2.2.4    Gene Expression of Nuclear Factor-kappaB (NF-kB) 
NF-kB is one of the most important transcription factors involved in regulation of 
immune and inflammatory responses. While activated in response to inflammatory 
cytokines IL-1 and TNF-α,  NF-kB is one of the main regulators and mediators of gene 
expression and synthesis of pro-inflammatory cytokine including IL-1, IL-6, and TNF-α 
(Baldwin, 1996). Inappropriate activation of NF-kB plays a key role in pathogenesis of 
inflammatory diseases (Tak and Firestein, 2001).  
 
NF-kB has been identified to be implicated in cardiac related conditions including its 
involvement in initiation and progression of atherosclerotic plaque, development of 
unstable angina, and heart failure (Valen et al., 2001). In regards to depression, animal 
studies reveal the association between activation of NF-kB (and also increased IL-1β, 
TNF-α, IL-6) and onset of stress-induced depressive like behaviour (Kubera et al., 2011).   
 
Therefore, NF-kB gene expression was assessed as another candidate gene. As illustrated 
in Figure 3.10, there was no difference in NF-kB mRNA expression in CHD patients with 
and without depression (t=0.591, df=38, p=0.559). The effect of antidepressants treatment 
on NF-kB gene expression is presented in Figure 3.11. As shown, antidepressants had no 
significant effect on gene expression of NF-kB in CHD patients with depression 
compared to antidepressant-free CHD depressed individuals (One-way ANOVA, 







Figure 3.10 NF-kB mRNA expression in CHD patients with and without depression. 
Data expressed as mean ± SEM, (CHD, n=24; CHD-D, n=16). 
CHD patients with depression (CHD-D, n=16) showed no difference in the levels of NF-
kB gene expression when compared with CHD patients without depression (CHD, n=24) 
(p>0.05).  
 




































































Figure 3.11 The effect of antidepressants on NF-kB gene expression.  Data expressed 
as mean ± SEM, (CHD, n=24; CHD-D-noAD, n=9; CHD-D-AD, n=7).  
Antidepressants treatment had no significant effect on gene expression of NF-kB in CHD 
patients with depression (CHD-D-AD, n=7) when compared with antidepressant-free 










3.3 Cortisol in CHD Patients with and without Depression 
Having investigated the inflammatory response and the findings in regards to high levels 
of circulatory CRP and increased IL-6 gene expression in this PhD project, the next step 
was assessing the HPA axis as the main physiological circuit involved in regulation of 
stress induced inflammatory responses, through measuring the levels of endogenous 
glucocorticoid cortisol as an end product of the system. HPA axis, its function and 
regulation were described in details in section 1.2.2.               
There is extensive evidence indicating the involvement of the HPA system in the 
pathophysiology of stress-related disorders including MDD that was discussed in section 
1.2.4. In the other hand, HPA axis dysregulation and its implication in cardiovascular 
diseases has been also reported by various studies (Kumari et al., 2011, Reynolds et al., 
2010, Yamaji et al., 2009).    
 
Therefore, in order to elucidate possible disturbances in the HPA axis activity in the 
present population the circulatory concentrations of cortisol in plasma as well as free 










3.3.1 Plasma Cortisol  
Circulatory cortisol levels in plasma were measured and compared in CHD patients with 
and without depression. As demonstrated in Figure 3.12, CHD patients with depression 
had lower plasma cortisol than non-depressed group; cortisol (mean ± SEM); CHD 354.7 
± 19.28 nmol/L, CHD-D 280.6 ± 26.66 nmol/L, t (55) = 2.285, p=0.026. The effect of 
antidepressants treatment on plasma cortisol has been also investigated and is presented in 
Figure 3.13. As shown, antidepressants had no significant effect on plasma cortisol 
concentration in CHD patients with depression compared to antidepressant-free CHD 
depressed individuals (One-way ANOVA, F (2,54)= 2.652, p= 0.080); CHD-D-noAD vs 















                     
Figure 3.12 Plasma Cortisol levels (nmol/L) in CHD patients with and without 
depression. Data expressed as mean ± SEM, (CHD, n=36; CHD-D, n=21). 
Compared to CHD patients without depression (CHD, n=36), depressed CHD individuals 
(CHD-D, n=21) showed significantly lower circulatory levels of cortisol (nmol/L) as 



























Figure 3.13 The effect of AD on the plasma cortisol levels. Data expressed as mean ± 
SEM, (CHD, n=36; CHD-D-noAD, n=12; CHD-D-AD, n=9).  
Antidepressants treatment had no effect on the levels of plasma cortisol (nmol/L) in CHD 
patients with depression (CHD-D-AD, n=9) when compared with antidepressant-free 











3.3.2 Salivary Cortisol   
In a healthy response, secretion of cortisol follows pronounced circadian rhythms which 
is characterized by marked increased in the morning shortly after awakening over the first 
hour with the peak at around 30 minutes (up to 50 to 60%), and then steadily decrease 
over the day within which short-term increases can be observed in response to normal 
daily stimuli such as meal, exercise, and other stressors (Tsigos and Chrousos, 2002, 
Wust et al., 2000).  The very distinctive post awakening pattern of cortisol is known as 
cortisol awakening response (CAR) which is studied also together with the pattern of 
cortisol secretion over the day as indicators of adrenocortical functioning. Modification of 
diurnal cortisol profile is thought to be associated with pathophysiological changes in 
stress related disorders and immune response activity, and serves as an index to identify 
HPA axis disturbances (Pruessner et al., 1997, Wilhelm et al., 2007).   
     
Cortisol circadian rhythm can be examined by measuring the free adrenal hormone in 
both blood and saliva samples showing the same diurnal pattern (Aardal and Holm, 
1995). However, salivary cortisol sampling has been the preferred method over blood 
sampling in clinical studies and research settings as being an easy to employ, inexpensive, 
non-invasive, laboratory independence and stress-free way to collect samples especially 
from home-based patients and widely dispersed populations (Clow et al., 2004, 
Kirschbaum and Hellhammer, 1999). Therefore, in the present thesis, apart from a single 
assessment of cortisol in blood sample to determine the circulatory plasma concentration 
and compare the levels in the two groups of CHD patients with and without depression, 
salivary cortisol samples were also obtained over the day to assess the HPA axis activity 




Obtaining repeated measurements of salivary cortisol and then calculating the area under 
the curve of the measures or AUC (section 2.3) provided two types of information 
embodied in the multivariate data by transforming them into univariate form. AUCG, 
being calculated with reference to the ground, revealed information in regards to the total 
cortisol output by measuring the total area under the curve considering the distance of the 
measures from the ground and therefore providing information regarding intensity and 
magnitude of the cortisol response. Whereas, AUCI, being calculated with reference to 
the increase from the baseline measurement revealed information in regards to sensitivity 
of the response by measuring the cortisol changes over time taking into account the 
distance of each measure from its neighbour (Pruessner et al., 2003).   
 
The response of cortisol to the awakening is presented in Figure 3.14. Results showed that 
CHD patients with depression exhibited significantly decreased cortisol levels in the first 
hour after awakening compared to CHD non-depressed (Two-way ANOVA, F(1,3)= 
19.45, n=51, p<0.0001). The lower cortisol concentrations were observed for each 
measure taken at 0, 15, 30, 60 min post awakening specially with the significant findings 
at 30 min (t=2.732, p<0.05) and 60 min (t=3.149, p<0.01) obtained by performing 
Bonferroni post-tests. The results from calculating the area under the curve for the 
cortisol awakening response in respect to the ground (distance from zero) also revealed 
significantly lower cortisol output during the first hour post awakening: CAR AUCG, 
(mean ± SEM); CHD 724.3 ± 60.80, CHD-D 452.1 ± 65.54, t (51) = 2.663 , p=0.010).  
 
In addition, CHD depressed showed a blunted HPA axis reactivity as indicated by the 
blunted cortisol response to the awakening compared to CHD without depression. The 
response was calculated first as a difference between the cortisol levels at 30 minutes 
after awakening when the peak is expected, and those at the awakening (delta cortisol 
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levels at 30 minutes). The depressed patients had lower delta cortisol levels at 30 minutes 
post awakening compared with non-depressed group: Δ30min (mean ± SEM); CHD 5.26 
± 0.63, CHD-D 3.15 ± 0.68, t (51) = 2.029, p=0.048). Indeed, calculating the area under 
the curve taking into account the measurements of the first hour post awakening in 
respect to the increase from the baseline measurement (awakening) showed decreased 
cortisol response and so diminished responsiveness of HPA axis to the stress of 
awakening in CHD depressed compared to non-depressed group: CAR AUCI (mean ± 
SEM); CHD 228.3 ± 27.67, CHD-D 132.9 ± 30.58, U (51) = 2.076, p=0.043).  
 
Having found high levels of inflammation as indicated by CRP levels (section 3.2.1), and 
blunted HPA axis activity as indicated by blunted cortisol response, CRP was found to be 
negatively associated with CAR AUCI (r=-0.429, p=0.029). The result is illustrated in 
Figure 3.15 showing that lower HPA axis responsiveness is associated with higher 




































Figure 3.14 Mean salivary cortisol levels for the first hour after awaking at four 
sampling points on awakening and 15, 30, and 60 mins later in CHD patients with 
and without depression. Data expressed as mean ± SEM, (CHD, n=37; CHD-D, 
n=16). 
Compared to CHD patients without depression (CHD, n=37) as indicated by solid line, 
depressed CHD individuals (CHD-D, n=16) as indicated by dotted line, showed 
significantly lower levels of free cortisol (nmol/l) in the first hour after awakening as 
measured in four time points (0, 15, 30, and 60 min) in saliva (p<0.0001). Overall cortisol 
output in the first hour post awakening was decreased in CHD depressed compared to 
non-depressed group calculated by area under the curve: CAR AUCG (p<0.05). In 
addition, CHD depressed patients exhibited blunted cortisol response when compared 








Figure 3.15 Negative association of CAR with CRP in CHD patients with and 
without depression (r=-0.429, *p<.05, n=26). 
Cortisol awakening response (CARI) was negatively associated with CRP (r=-0.429, 
*p<.05, n=26). The negative correlation indicates that lower in HPA responsiveness were 










Diurnal cortisol was also assessed (Figure 3.16). Although as illustrated in the figure, 
cortisol levels showed a decline at each time point (awakening, 2 pm, and bedtime) of 
sampling in CHD patients with depression compared to CHD without depression, the 
result did not reach the statistical significance, and it only showed a trend of decreased 
cortisol concentration in CHD depressed individuals (Two-way ANOVA, F=3.390, 
p=0.068). The area under the curve for the diurnal cortisol was also calculated with the 
result showing no significant difference in the overall cortisol output during the day when 
calculated with the reference to the ground: Diurnal AUCG: U (51) = 225.0, p= 0.172. 
Calculating the area under the curve with respect to the increase also revealed no 
significant difference when comparing CHD patient with and without depression: Diurnal 
AUCI: U (51) = 275.0, p= 0.691. No difference in awakening time was found between the 







































             
Figure 3.16 Mean salivary cortisol levels over the day presented at three sampling 
points on awakening, 2 pm, and Bedtime in CHD patients with and without 
depression.  Data expressed as mean ± SEM, (CHD, n=37; CHD-D, n=16). 
Compared to CHD patients without depression (CHD, n=37) as indicated by solid line, 
depressed CHD individuals (CHD-D, n=16) as indicated by dotted line, showed a trend 
but not significantly decrease the levels of diurnal cortisol (nmol/l) as measured in three 
time points during the day (awakening, 2 pm, and bedtime) in saliva (p=0.068). Overall 
diurnal cortisol did not differ in CHD patients with and without depression as calculated 








3.4 Glucocorticoid Receptor (GR) in CHD Patients with and without 
Depression 
GR and its involvement in inflammation and depression were discussed in details in 
sections 1.2.3 and 1.2.4. As mentioned before, the crucial immunosuppressive and anti-
inflammatory role of GC is in fact through GR mediated transrepression activity targeting 
the genes associated with inflammatory cytokines (De Bosscher and Haegeman, 2009). 
Indeed, GR sensitivity to GC is crucial in order to produce an appropriate response that is 
determined by the number, affinity, and function of the receptor. Therefore, any alteration 
in GR number, its binding affinity, and/or functional capacity results in alteration of GR 
mediated GC response (Marques et al., 2009). Indeed, inflammatory response regulated 
by the effect of GC, cannot be terminated in case of GR resistance and diminished 
sensitivity of immune cells to the hormones (Stark et al., 2001). GR resistance has been 
observed in patients with MDD (Anacker et al., 2011a, Pariante, 2006). On the other 
hand, it has been suggested that prolonged inflammation can have a direct effect in 
reducing GR sensitivity and disrupting its functional properties (Miller et al., 1999). 
 
Taking all together, and having investigated inflammatory response and HPA axis 
activity, it was of interest to assess the GR to identify any possible alteration in its 
expression and/or function in CHD patients with and without depression and in order to 
understand whether or not GR has an involvement in inflammatory activation and HPA 





3.4.1 Gene Expression of GR   
Along with the expression of genes related to inflammatory cytokines that was 
demonstrated in section 3.2.2, another candidate gene to investigate was GR gene. As 
illustrated in Figure 3.17, CHD-D individuals exhibited significantly reduced expression 
of GR as compared to CHD patients (t=2.105, df=38, p= 0.042). Assessing the effect of 
antidepressants treatment on GR expression did not show any significant result: One way 
ANOVA, F=2.386, p=0.106; CHD-D-noAD vs CHD-D-AD t=0.685 df=14, p=0.505. 
Covariates gender and age also did not have any effect on GR expression outcome; F 


































         
Figure 3.17 GR mRNA expression in CHD patients with and without depression. 
Data expressed as mean ± SEM, (CHD, n=24; CHD-D, n=16). 
CHD depressed patients (n=16) displayed significantly lower GR expression as compared 
to CHD non-depressed (n=24) (*p<0.05). 
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Figure 3.18 The effect of antidepressants on GR total gene expression. Data 
expressed as mean ± SEM, (CHD, n=24; CHD-D-noAD, n=9; CHD-D-AD, n=7).   
Antidepressants treatment had no significant effect on gene expression of GR in CHD 
patients with depression (CHD-D-AD, n=7) when compared with antidepressant-free 








3.4.2 GR Sensitivity 
3.4.2.1 Protocol Optimization 
As mentioned previously in details (section 2.5), GR function was measured in vitro 
directly on PBMC by culturing them using DEX inhibition of LPS-stimulated IL-6 levels 
method. The present study optimised and tested the protocol on healthy control before 
carrying out the experiment on the patients.   
Primarily, the cell culture media included CF1 and human serum. However, high levels of 
IL-6 produced were observed in unstimulated cells. Therefore, additional experiments 
were designed to understand if any component of the media was triggering the production 
of IL-6 in unstimulated cells.  
 
As illustrated in Figure 3.19, PBMC were cultured with and without adding human serum 
in the culture. As well as LPS-simulated cells, unstimulated cells in the presence of 
human serum produced IL-6. In contrast, cultured PBMC without added human serum in 
the culture media showed only very low levels of IL-6 when unstimulated, and IL-6 is 
produced considerably when stimulated by LPS. Therefore, removing human serum from 
the culture resulted in the expected response and desired outcome. 
 
Another approach was deciding on the number of PBMC sufficient to run the in vitro 
experiment.  The initial protocol was using 200K PBMC in each well. It was of interest to 
investigate the effect of three different drugs on GR sensitivity at the same time of 
evaluating GR function for each patient. Since there were limited amount of isolated and 
cryopreserved PBMC available for each patient, the whole experiments would have been 
only possible if less number of cells could be used.  Therefore, the protocol tested four 
different number of cells; 200, 150, 100, and 50 K.  
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As demonstrated in Figure 3.20, for all conditions, IL-6 produced by cells shows 
considerably low levels before stimulation of cells by LPS and remarkably higher 
production of the cytokine for LPS- simulated cells. In addition, as illustrated in Figure 
3.21, for the four different numbers of PBMC, glucocorticoid inhibition of LPS-
stimulated IL-6 levels using three different concentration of dexamethasone; 1, 0.03, and 
0.001 µM, show the expected dose response curve and similar results for each 
dexamethasone concentration. Therefore, the decision was made to use 100K PBMC per 
well in order to investigate GR sensitivity in vitro as well as the effect of antidepressants 
clomipramine and citalopram, and omega-3 on GR function at the same time.  
 
Finally, the protocol was examined on 5 healthy control samples. As presented in Figure 
3.22, PBMC showed remarkably increased in IL-6 levels after being stimulated by LPS. 
In addition, dexamethasone inhibition of LPS-stimulated IL-6 production is illustrated in 
Figure 3.23 testing five different concentration of dexamethasone; 1, 0.1, 0.03, 0.01, and 
0.001 µM. The figure represents the expected dose dependent response to the effect of the 
glucocorticoid mediated by GR that shows the higher dexamethasone concentration the 






























Figure 3.19 IL-6 levels (ng/ml) of PBMC before and after in vitro LPS stimulation 
culturing the cells with and without human serum.  
In vitro stimulation of PBMC by LPS (1 ng/ml) with and without human serum (HS) 
showed that adding HS in the culture (+HS) triggered unstimulated cells (white column) 
to produce IL-6. When PBMC were stimulated by LPS and without adding HS (-HS) in 
the culture, unstimulated cells produced very low levels of IL-6, while the levels 



























Figure 3.20  IL-6 levels (ng/ml) of PBMC before and after in vitro LPS stimulation 
culturing different number of cells: 200, 150, 100, and 50 K. 
The graph demonstrates four different PBMC cultures each containing specific number of 
cells, 200, 150, 100, and 50 K. For all conditions, IL-6 produced (ng/ml) by cells showed 
considerably low levels before stimulation of cells by LPS (white columns) and 










































Figure 3.21 Dexamethasone inhibition of LPS stimulated IL-6 production in PBMC 
culturing different number of cells: 200, 150, 100, and 50 K. 
Dexamethasone (1, 0.03, and 0.001 µM) inhibition of LPS-stimulated IL-6 levels showed 
similar results when culturing four different numbers of cells: 200, 150, 100, and 50 K. 
Results are expressed by the percent dexamethasone inhibition (LPS-stimulated IL-6 
levels with dexamethasone divided by LPS-stimulated IL-6 levels without 



























Figure 3.22 IL-6 levels (ng/ml) of PBMC before and after in vitro LPS stimulation 
with and without clomipramine in healthy individuals. Data expressed as mean ± 
SEM, (n=5). 
The graph represents IL-6 production (ng/mL) before and after stimulation of PBMC by 
LPS with (hashed columns) and without (white columns) clomipramine (10 µM) in 








































Figure 3.23 Dexamethasone inhibition of LPS stimulated IL-6 production in PBMC 
of healthy individuals with and without clomipramine. Data expressed as mean ± 
SEM, (n=5). 
Dexamethasone (1, 0.1, 0.03, 0.01, and 0.001 µM) inhibition of LPS-stimulated IL-6 
levels in PBMC of healthy controls (n=5) showed expected dose dependent response to 
the effect of the glucocorticoids. Results are expressed by mean ± SEM of the percent 
dexamethasone inhibition (LPS-stimulated IL-6 levels with dexamethasone divided by 







3.4.2.2 In Vitro Stimulation of PBMC in CHD Patients with and without 
Depression 
In this study an in vitro evaluation of GR function was performed on previously 
cryopreserved PBMC stored in liquid nitrogen. Utilization of cryopreserved PBMC for 
immunologic assays in clinical trials and studies has been recently widely employed to 
allow collecting required samples from all patients particularly when large numbers of 
samples are required, and to perform the assays together in a specific period of time and 
in a single laboratory. These reasons would allow us to eliminate or at least minimize 
inter-assay variation and inter-laboratory variability that have been reported by studies as 
confounders (Chen et al., 2010, Shearer et al., 2003). The advantage of using frozen 
PBMC in this PhD study was that GR function could be performed in parallel for 
depressed and non-depressed patients.  
 
As described in details before in section 2.5.2, the recovery and viability of PBMC 
following thawing were examined (>95%) to ensure reliable results in performing GR 
functional assay. Monitoring the quality of the cryopreserved PBMC and obtaining a 
viability of >80% has been suggested as an important requirement in immunological 
assays (Dyer et al., 2007), since changes in cells viability have been reported as a 
potential challenge posing from cryopreservation of PBMC (Jeurink et al., 2008, Koch et 
al., 1991). 
 
Using bacterial LPS to stimulate PBMC for the production of cytokines has been 
extensively used in in vitro studies mimicking the inflammatory condition. As illustrated 
in Figure 3.24, in the absence of LPS, PBMC display considerably low levels of IL-6 
detected. Following stimulation of PBMC by LPS, IL-6 is produced significantly as 
shown by remarkably high levels of the cytokine in both CHD patients with and without 
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depression. The IL-6 released following LPS stimulation did not differ between the two 









































     
Figure 3.24 IL-6 levels (ng/mL) of PBMC before and after in vitro LPS stimulation 
in CHD patients with and without depression.  Data expressed as mean ± SEM, 
(CHD, n=16; CHD-D, n=12). 
In vitro stimulation of PBMC (100K) by LPS (1 ng/mL) induced production of IL-6 
(ng/mL) in CHD patients with (hashed columns, n=12) and without (white columns, 
n=16) depression. The levels of IL-6 were low in the absence of LPS in both groups 









3.4.2.3 Dexamethasone Inhibition of LPS-induced IL-6 Production of PBMC 
Performing in vitro method of synthetic glucocorticoid dexamethasone inhibition of LPS-
stimulated IL-6 production in PBMC, GC mediated GR function was assessed in CHD 
patients with and without depression. In this method, the higher concentration of 
glucocorticoid should induce the greater inhibition of LPS-stimulated IL-6 levels.  
 
As illustrated in Figure 3.25, both CHD patients with and without depression showed 
dose response curve and suppression of LPS-stimulated IL-6 levels in a concentration 
dependent manner. However, compared to non-depressed group, CHD depressed 
individuals exhibited higher levels of IL-6 for each concentration of dexamethasone that 
indicated lower ability of GR to respond to the inhibition effect of the glucocorticoid on 







































        
Figure 3.25 Dexamethasone inhibition of LPS stimulated IL-6 production in PBMC 
of CHD patients with and without depression.  Data expressed as mean ± SEM, 
(CHD, n=16; CHD-D, n=12). 
As compared to CHD non-depressed individuals (n=16) represented by solid line, CHD 
depressed patients (n=12) indicated by dotted lines have lower GR sensitivity (p<0.001). 





is found less production of IL-6, and CHD depressed showing higher levels of IL-6 
produced for each concentration of the glucocorticoid suggesting less GR sensitivity to 
the inhibition effect of dexamethasone. Results are expressed by mean ± SEM of the 
percent glucocorticoid inhibition (LPS-stimulated IL-6 levels with dexamethasone 





3.4.2.4 Half Maximal Inhibitory Concentration of Dexamethasone (IC50-DEX) 
Effectiveness of dexamethasone to inhibit production of in vitro LPS-stimulated IL-6 that 
is mediated by GR was measured by calculating half maximal inhibitory concentration 
(50% IC or IC50). IC50 values derived from DEX dose response curve using GraphPad 
Prism software. 
 
As illustrated in Figure 3.26, CHD depressed patients exhibited significantly higher IC50 
as compared to CHD non-depressed individuals; IC50-DEX [M] (mean ± SEM); CHD 
7.6 ± 0.1, CHD-D 8.1 ± 0.2, t=3.267, df=26, p=0.0031. The results showed that depressed 
group required a higher concentration of dexamethasone at which 50% of IL-6 synthesis 
is inhibited which confirmed a reduced ability of GR to respond to glucocorticoids. 
 
In addition, as demonstrated in Figure 3.27, IC50-DEX was found to be significantly 
associated with the BDI scores in CHD patients with and without depression (r=.505, 
p=.006, n=28) indicating the relation between GR resistance and the severity of 


























            
Figure 3.26 IC50-DEX [M] for LPS stimulated IL-6 production in PBMC of 
individual CHD patients with and without depression. (CHD, n=16; CHD-D, n=12). 
Calculating IC50-DEX [M] of individual subjects showed CHD depressed patients 
(CHD-D, n=12) required significantly higher concentration of dexamethasone for the half 
inhibitory effect on LPS-stimulated IL-6 production as compared to CHD non-depressed 
(CHD, n=16) (p<0.01). The dots represent the IC50, and the solid lines demonstrate the 













Figure 3.27 Association of IC50-DEX [M] with BDI scores in CHD patients with and 
without depression (r=.505, **p<.01, n=28). 
IC50-DEX [M] was significantly associated with the BDI scores in CHD patients with 
and without depression (r=.505, **p<.01, n=28). The positive correlation indicates that 










3.4.3 Effect of Drugs on GR Sensitivity 
Assessing GR function in vitro, the effect of two antidepressants clomipramine (TCA) 
and citalopram (SSRI) as well as omega-3 PUFA as an agent with anti-inflammatory and 
antidepressive properties was also investigated on GR sensitivity in this PhD thesis, in 
order to understand whether these medications exert any effect on reversing the GR 
resistance in these patients.  
 
3.4.3.1 Effect of Clomipramine on GR Sensitivity 
The tricyclic antidepressants are suggested to have the ability to modulate GR function 
(McQuade and Young, 2000). This class of antidepressants has been shown to enhance 
GR function (Pariante et al., 1997) and contribute in regulation of intracellular cortisol 
concentration and GR expression (Pariante et al., 2003). Most of the studies on the effect 
of these antidepressants has been done in cell line and animal models, and very few in a 
clinical population including the study by Carvalho that will be discussed later (Carvalho 
et al., 2008). Therefore, it was of interest to investigate the effect of clomipramine in this 
class on GR function in vitro in this clinical setting. 
 
As demonstrated in Figure 3.28, clomipramine improved the sensitivity of GR in CHD 
depressed patients as shown by the reduction in the levels of LPS stimulated IL-6 
production for each concentration of dexamethasone (F=8.835, p= 0.0036). However, the 
significant effect was not observed in GR sensitivity in CHD patients without depression 
















































































Figure 3.28 Effect of clomipramine (10 µM) in vitro on GR mediated dexamethasone 
inhibition of LPS stimulated IL-6 production in PBMC of CHD patients with (b) 
and without (a) depression. Data expressed as mean ± SEM, (CHD, n=15; CHD-D, 
n=10). 
In CHD patients b) with depression (n=10), in the presence of clomipramine (10 µM) 
(dotted lines); LPS stimulated IL-6 levels were decreased for each concentration of 
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dexamethasone. Therefore, clomipramine increased GR sensitivity in CHD depressed 
patients (p<0.01). However, clomipramine in vitro did not have an effect on GR 
sensitivity in CHD non-depressed individuals (n=15) (p>0.05). Results are expressed by 
mean ± SEM of the percent glucocorticoid inhibition (LPS-stimulated IL-6 levels with 























3.4.3.2 Effect of Citalopram on GR Sensitivity 
The choice of antidepressants for CHD patients requires special attention since 
epidemiological studies reveal the use of antidepressants could be associated with both 
decreased and increased cardiac risk (Sherwood et al., 2007). For example TCAs and 
MAOIs are known to have cardiotoxic side effects, and therefore, not a preferable choice 
for treatment of depression in heart disease patients. The SSRI antidepressants and 
specially citalopram and sertraline are recognised to be safe and effective, thus the first-
line antidepressants for CHD patients who suffer from moderate to severe as well as 
recurrent depression (Glassman et al., 1993, Glassman et al., 2002, Lespérance et al., 
2007).  
 
As part of this PhD thesis, it was of relevance to investigate whether or not citalopram has 
any effect on GR function in vitro. The result presented in Figure 3.29, revealed no 
significant effect of citalopram in GR sensitivity in CHD patients without depression 
(CHD F= 0.4726, p=0.4927). However, in CHD depressed patients who already exhibited 
decreased GR sensitivity (Figure 3.25 and Figure 3.26), citalopram appeared to 






















































































Figure 3.29 Effect of citalopram (10 µM) in vitro on GR mediated dexamethasone 
inhibition of LPS stimulated IL-6 production in PBMC of CHD patients with (b) 
and without (a) depression. Data expressed as mean ± SEM, (CHD, n=15; CHD-D, 
n=10). 
In CHD patients b) with depression (n=10), in the presence of citalopram (10 µM) (dotted 
lines); LPS stimulated IL-6 levels were decreased for each concentration of 
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dexamethasone. Therefore, citalopram increased GR sensitivity in CHD depressed 
patients (p<0.001). However, citalopram in vitro did not have any effect on GR 
sensitivity in CHD non-depressed individuals (n=15) (p>0.05). Results are expressed by 
mean ± SEM of the percent glucocorticoid inhibition (LPS-stimulated IL-6 levels with 























3.4.3.3 Effect of EPA on GR Sensitivity 
Omega-3 fatty acids have been suggested as a therapeutic option in patients with heart 
disease (Christensen et al., 1996). Dietary omega-3 has a protective effect on adverse 
cardiac events specially heart attack according to the epidemiological studies (Breslow, 
2006, Harris et al., 2007, Lee et al., 2008). On the other hand, the association of this 
medication with depression has been described in section 1.2.9. However, the mechanism 
of their action has not been completely understood.  
 
Eicosapentaenoic acid (EPA) derived from fish oil is the biologically potent omega-3 
PUFA that is widely used in animal and clinical studies (Simopoulos, 2002) . Thus this 
PhD thesis also investigated the effect of omega-3 specifically on GR function as this 
might throw more light on their specific mode of action as anti-inflammatory and 
antidepressant medication.     
 
As illustrated in Figure 3.30, GR function in CHD patients with and without depression 
was assessed in vitro in the presence of EPA. The result showed EPA increased GR 
sensitivity in CHD patients with depression (F= 27.98, p<0.0001) as well as in CHD non-
depressed individuals (F=18.71, p<0.0001) as presented by decreased production of LPS 




















































































Figure 3.30 Effect of EPA (10 µM) in vitro on GR mediated dexamethasone 
inhibition of LPS stimulated IL-6 production in PBMC of CHD patients with (b) 
and without (a) depression. Data expressed as mean ± SEM, (CHD, n=15; CHD-D, 
n=10). 
For both CHD patients b) with (n=10) and a) without (n=15) depression, in the presence 
of EPA (10 µM) (dotted lines), LPS stimulated IL-6 levels were decreased for each 
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concentration of dexamethasone. Therefore, EPA increased GR sensitivity in CHD 
patients with and without depression (p<0.0001). Results are expressed by mean ± SEM 
of the percent glucocorticoid inhibition (LPS-stimulated IL-6 levels with glucocorticoid 






















3.5 Kynurenine Pathway of Tryptophan Metabolism in CHD Patients 
with and without Depression 
The kynurenine pathway of the tryptophan metabolism and its relation to inflammation 
and depression has been described in details in 1.2.7. Considering CHD as an 
inflammatory condition, it was justified to investigate this system in the present 
population of CHD patients with and without comorbid depression. Therefore, tryptophan 
metabolism pathway was assessed with a focus on the kynurenine diversion of the 
system, and measuring the circulatory levels of the metabolites produced. 
 
As presented in the Table 3.5, CHD patients with depression showed lower serum levels 
of tryptophan when compared with CHD non-depressed individuals: (mean ± SEM); 
CHD 12.64 ± 0.64 µg/ml, CHD-D 10.42 ± 0.58 µg/ml, t=2.247, df=43, p=0.030. 
Kynurenine/tryptophan (KYN/TRP) ratio, indicator of activated IDO, were found 
significantly higher in depressed CHD compered to non-depressed group  (mean ± SEM); 
CHD 62.21 ± 3.10, CHD-D 74.43 ± 5.26, t=-2.144, df=43, p=0.038. The serum levels of 
kynurenic acid, 3-HK and 3-HAA did not differ in CHD patients with and without 
depression (p>0.05). As illustrated in Figure 3.31, KYN/TRP ratio were found to be 
associated with the levels of the neurotoxic metabolite of the kynurenine pathway 3-HK 
in CHD patients with and without depression (rs =.405, p=.006, n=45), coincided with no 
association between KYN/TRP ratio and the levels of the neuroprotective metabolite 
kynurenic acid in these patients (r =.096, p=.53, n=45). 
 
Having investigated the inflammatory response (section 3.2.1), the kynurenine pathway 
was also assessed in relation to inflammation. As presented before in Figure 3.1, CHD 
patients with and without depression showed high levels of inflammation as measured by 
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circulatory CRP levels. CRP as an inflammatory biomarker were found to be associated 
with KYN/TRP ratio (r=.322, p=.040, n=41) as well as with the neurotoxic metabolite 3-


























Table 3.5 Serum levels of kynurenine pathway metabolites in CHD patients with and 
without depression. 
 CHD (n=29) 
(mean ± SEM) 
CHD-D (n=16) 
(mean ± SEM) 
Test  and significance 
TRP (µg/ml) 12.64 ± 0.64 10.42 ± 0.58 t=2.25, p=0.030* 
KYN (ng/ml) 843.50 ± 54.37 763.85  ± 43.18 U=209.0, z= -0.55, p=0.59 
KYN/TRP  62.21 ± 3.10 74.43 ± 5.26 t=-2.14, p=0.038* 
KYNA (ng/ml) 15.57 ± 1.18 13.21 ± 1.79 t= 1.14, p=0.259 
3-HK (ng/ml) 18.85 ± 1.77 18.73 ± 1.43 U=199.5, z= -0.77, p=0.44 
3-HAA (ng/ml) 34.31 ± 3.35 33.50 ± 5.13 U=219.0, z= -0.31, p=0.76 
TRP, tryptophan; KYN, Kynurenine; KYNA, Kynurenic acid; 3-HK, 3-hydroxykynurenin; 3-
HAA, 3-hydroxyanthranilic acid 
 
As compared to CHD non-depressed individuals (n=29), CHD depressed patients (n=16) 
exhibited significantly decreased in serum TRP levels (µg/ml) lower GR (*p<0.05). 
KYN/TRP ratio was significantly higher in depressed individuals when compared with 
non-depressed group (p<0.05). The serum levels of KYN, KYNA, 3-HK and 3-HAA did 










Figure 3.31 Positive correlation of KYN/TRP ratio with 3-HK in CHD patients with 
and without depression (rs=.405, **p<.01, n=45). 
Kynurenine/Tryptophan (KYN/TRP) ratio was significantly associated with the levels of 
3-HK in CHD patients with and without depression (rs=.405, **p<.01, n=45). The 
positive correlation indicates that greater rates of IDO enzyme activity (as measured by 
the KYN/TRP ratio) were associated with higher production of 3-HK, the neurotoxic 














Figure 3.32 Association between circulatory CRP and KYN/TRP ratio in CHD 
patients with and without depression (r=.322, *p<.05, n=41). 
CRP was significantly associated with KYN/TRY ratio in CHD patients with and without 
depression (r=.322, *p<.05, n=41). The positive correlation indicated that higher 
inflammation in these patients was associated with greater rate of IDO activity as 













Figure 3.33 Association between circulatory CRP and 3-HK in CHD patients with 
and without depression (rs=.420, **p<.01, n=41). 
CRP was significantly associated with 3-HK in CHD patients with and without 
depression (rs=.420, **p<.01, n=41). The positive correlation indicated that higher 
inflammation in these patients was associated with higher production of 3-HK, the 








3.6 Plasma VEGF in CHD Patients with and without Depression 
Originally identified for its ability to promote vascular permeability (Senger et al., 1986), 
vascular endothelial growth factor (VEGF) is known as a secreted angiogenic mitogen 
(Leung et al., 1989). It is the most potent growth factor for endothelial cells and a main 
regulator of angiogenesis and vasculogenesis (Byrne et al., 2005, Keck et al., 1989) as 
well as one of the key factors involved in BBB stability (Lee et al., 2003). Apart from its 
involvement in endothelial processes, VEGF exhibit a neurologic role involved in 
neurogenesis and exerts neuroprotective effect (Jin et al., 2002, Storkebaum et al., 2004). 
  
Due to the crucial involvement in vascular system as well as neurological processes, 
VEGF was found to be an interesting biological candidate to be investigated in CHD 
patients with and without depression.  
 
Following measuring the VEGF levels, the obtained values did not meet the parametric 
assumptions being not normally distributed, thus the data were log transformed to 
improve suitability for parametric statistics. Comparing the groups showed that CHD 
depressed patients exhibited significantly higher plasma VEGF levels than CHD non-
depressed: Log VEGF (mean ± SEM); CHD 1.816 ± 0.07, CHD-D 2.06 ± 0.09, t(48)=-
2.251, p=0.029. However, for presentation purposes, the raw values were used as 
illustrated in Figure 3.34. 
 
An increased in VEGF levels in CHD depressed patients appeared to be affected by 
antidepressant treatment. Although, the result were not found statistically significant, they 
showed a strong trend for elevation in VEGF levels in CHD depressed who were on 
antidepressants compared to antidepressant-free CHD depressed and CHD non-depressed 
groups; One-way ANOVA: Log VEGF F(2,47)= 3.121, p=0.0534; CHD vs CHD-D-
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noAD t(40)=1.48, p= 0.147; CHD vs CHD-D-AD t(35)=2.24, p=0.031; CHD-D-noAD vs 
CHD-D-AD t(19)=1.048, p=0.308. 
 
Gender and age were analysed as covariates and no significant effect was found on the 


































Figure 3.34 Plasma VEGF levels (pg/mL) in CHD patients with and without 
depression Data expressed as mean ± SEM, (CHD, n=29; CHD-D, n=21). 
Compared to CHD patients without depression (CHD, n=29), depressed CHD individuals 
(CHD-D, n=21) showed significantly higher levels of circulatory VEGF (pg/mL) as 








































Figure 3.35 The effect of antidepressants on VEGF levels (pg/mL) in plasma. Data 
expressed as mean ± SEM, (CHD, n=29; CHD-D-noAD, n=13; CHD-D-AD, n=8).   
Antidepressants treatment appeared to have an effect in elevated levels of VEGF in CHD 
depressed patients who were on antidepressants medications (CHD-D-AD, n=8) when 
compared with antidepressant-free CHD depressed (CHD-D-noAD, n=13) and CHD non-
depressed individuals (CHD, n=29). The result was not statistically significant but 









Table 3.6 Analysis of covariates age, gender, and antidepressant usage in relation to 
the outcome of the biological factors assessed in CHD patients with and without 
depression 
 gender age antidepressants 
CRP F(1,51)=0.01, p=0.92 F(1,51)=1.30, p=0.17 F(1,51)=0.73, p=0.40 
GR IC50-DEX F(1,25)=1.32, p=0.26 
 
F(1,25)=0.09, p=0.77 F(1,25)=1.87, p=0.18 
Plasma Cortisol  F(1,54)=1.26, p=0.27 
 











F(1,50)=0.34, p=0.07 F(1,50)=0.37, p=0.55 
TRP  F(1,42)=0.14, p=0.72 
 
F(1,42)=3.02, p=0.09 F(1,42)=0.31, p=0.58 
Heart rate F(1,51)=0.01, p=0.92 
 
F(1,51)=0.83, p=0.37 F(1,51)=2.83, p=0.10 
KYN F(1,42)=2.15, p=0.15 
 
F(1,42)=0.27, p=0.61 F(1,42)=0.002, p=0.99 
KYNA F(1,42)=1.01, p=0.32 
 
F(1,42)=1.52, p=0.23 F(1,42)=0.62, p=0.44 
3-HK F(1,42)=2.11, p=0.15 
 
F(1,42)=0.05, p=0.82 F(1,42)=1.80, p=0.19 
3-HAA F(1,42)=0.08, p=0.78 
 
F(1,42)=0.44, p=0.51 F(1,42)=2.53, p=0.12 
 
The table above demonstrates the analysis (GLM) of the effect of age, gender, and 
antidepressants treatment on serum CRP levels, plasma cortisol levels, peripheral GR 
resistance, cortisol awakening response, diurnal salivary cortisol levels, heart rate, and 
circulatory tryptophan, kynurenine, kynurenic acid, 3-HK, and 3-HAA metabolites. There 






























4.1 Summary of the Findings 
The present results show that in CHD patients, depression is accompanied by elevated 
levels of inflammation in the context of low cortisol output, GR resistance, and increased 
activation of the kynurenine pathway of tryptophan metabolism. 
 
Although, CHD patients without depression also exhibit high inflammation as measured 
by circulatory levels of CRP in the serum, the level of inflammation is even higher in 
cases of comorbidity with depression (Figure 3.1). Consistent with high CRP in CHD 
depressed, candidate gene expression analysis also reveals significantly increased in IL-6 
gene expression (Figure 3.3), the pro-inflammatory cytokine which stimulates the release 
of CRP. Both peripheral CRP (Figure 3.2) and IL-6 gene expression (Figure 3.5) are 
associated with the severity of depression. 
 
Association between CHD and depression in relation to inflammation has been reported 
extensively, and as a focus of this PhD project, the possible underlying mechanisms 
leading to the higher inflammation in CHD patients with depression were investigated. In 
fact, the present study extends the findings by assessing in various aspects the 
glucocorticoid signalling as a potential contributor factor in this specific population. The 
results reveal that the depressed group exhibit insufficient glucocorticoid signalling 
possibly due to the decreased hormone bioavailability as well as attenuated glucocorticoid 
responsiveness. Indeed, CHD depressed patients display significantly lower levels of 
cortisol both in plasma (Figure 3.12) and saliva (Figure 3.14). In addition, the negative 
correlation between cortisol awakening response and CRP demonstrates that depression is 
associated with inflammation in the presence of blunted HPA axis responsiveness (Figure 
3.15). In addition to a reduced availability of the hormone, CHD patients with depression 
represent diminished responsiveness to the effect of cortisol not only as a result of a 
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decrease in the number of GR as represented by significantly lower expression levels of 
GR mRNA (Figure 3.17), but also due to alteration in GR sensitivity as shown by less 
functional ability of the receptor to respond to glucocorticoids (Figure 3.26). GR 
resistance is also found to be associated with the severity of depression (Figure 3.27). 
 
The result of the in vitro effect of medications on the GR functional properties reveals 
that antidepressants clomipramine (Figure 3.28) and citalopram (Figure 3.29) increase the 
GR sensitivity in depressed CHD patients. However, omega-3 fatty acids increase the GR 
sensitivity in both CHD patients with and without depression (Figure 3.30).  
 
The present results also confirm that elevated inflammation is associated with effects on 
the serotonergic system through activation of the kynurenine pathway of tryptophan 
metabolism. The data reveal that CHD patients with depression exhibit lower levels of 
tryptophan together with higher IDO activity, as measured by KYN/TRP ratio (Table 
3.5), which in turn is associated with an increased 3-HK level (Figure 3.31). In addition, 
elevated inflammation is found to be associated with increased activity of IDO enzyme 
(Figure 3.32) and high levels of neurotoxic 3-HK (Figure 3.33). Therefore, the results 
suggest that activated inflammatory response may lead to increased rate of tryptophan 
degradation and diversion of the kynurenine pathway towards the neurotoxic branch in 
CHD patients with depression. 
 
Finally, for all of these biological factors assessed in this study, antidepressants were 
investigated as cofactors (Table 3.6) to understand whether or not antidepressant 
treatment had any effect to the outcome, and based on the results no effect was found on 
any of these biological factors. However, it is important to note that only 39.3% of the 
depressed CHD patients were under antidepressants treatment (Table 3.4), that brings into 
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attention the importance of screening, monitoring, and managing depression in this group 
of patients. In fact, more than half of the CHD patients with depression are not taking any 
antidepressants which not only would improve their depressive status, but would also 























4.2 Elevation of Inflammation in CHD Patients with Depression: 
Inflammation has been assessed as a first approach in this PhD thesis hypothesising that 
CHD depressed individuals have higher circulating levels of CRP as compared to CHD 
patients without depression.  
 
As mentioned before, CRP is clinically used as a biomarker of inflammation and indeed 
is the best biological marker for detection of inflammatory response (Willerson and 
Ridker, 2004). In addition, CRP is known as a mediator and marker of atherosclerosis and 
has been consistently reported to be a potent predictor of future vascular serious events 
including myocardial infarction, ischemic stroke, and sudden cardiac death. This 
predictive value has been shown to be independent of sex, age, blood pressure, 
cholesterol, smoking, and diabetes (Ridker, 2003, Ridker, 2007). Furthermore, elevation 
of inflammation and increased CRP concentration has been implicated in pathogenesis of 
depression and has been described in more details in section 1.2.5.     
 
The present result indicates that indeed CHD patients with depression show considerably 
higher levels of CRP in serum as compared with non-depressed indicating elevation of 
inflammation in this group. As illustrated in Figure 3.1, the level of circulatory CRP is 
more than 3 mg/L in CHD patients without depression which is considered as a high risk 
factor for cardiovascular events as defined by the American Heart Association (see 
section 3.2.1), and even significantly higher in CHD depressed more than 5 mg/L 
exhibiting the higher levels of inflammation. This is a significant cause of concern since 
even a small elevation in CRP levels greatly increases the risk of heart attack, angina, and 




In fact, the high CRP levels in CHD patients without depression itself represent the 
inflammatory activation in these patients. The endothelial damage of the cerebral 
vasculature as a result of high inflammation has been postulated as one of the major 
contributing factor for development of depressive disorder (Halaris, 2013). The cytokine 
and inflammatory hypothesis of depression has been described before in support to the 
critical role of inflammation in development and prognosis of depression (sections 1.2.1 
&1.2.5). Recently, attention has been paid to the BBB hypothesis as one of the potential 
mechanisms underlying pathogenesis of psychiatric conditions including depression in 
relation to inflammation. The hypothesis suggests breakdown of BBB and its abnormal 
communication leading to breaching the gate and permitting penetration of inflammatory 
molecules into the brain (Shalev et al., 2009). CRP has been shown to be associated with 
increased BBB permeability (Hsuchou et al., 2012). The possible routes by which 
inflammatory cytokines are able to passively penetrate into the CNS have been described 
before in section 1.2.5. In accordance with findings of this PhD thesis, a very recent 
systematic review and meta-analysis of longitudinal studies concluded a significant 
association between elevation of the two inflammatory markers CRP and IL-6 with 
subsequent development of depressive symptoms (Valkanova et al., 2013). Indeed, the 
present results also suggest an association of both CRP and IL-6 with the severity of 
depressive symptoms in this study population of CHD patients (Figure 3.2 & Figure 3.5, 
respectively). 
 
Significantly increased in IL-6 gene expression in CHD patients with depression in this 
study, as demonstrated in Figure 3.3, is consistent with higher CRP levels in this group. 
As mentioned before, IL-6 is the most potent inflammatory marker that induces the 
release of CRP and other pro-inflammatory cytokines. Pro-inflammatory cytokines are 
directly involved in prognosis of atherosclerosis and pathogenesis of CHD. In fact, the 
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release of these cytokines as a consequence of endothelial damage leads to 
thrombogenesis (Koenig, 2001, Mulvihill and Foley, 2002). IL-6 is believed to be a 
contributing factor in the stimulation of the processes leading to the formation and 
propagation of coronary plaque including release of adhesion molecules from 
endothelium and platelet aggregation (Barton, 1996). Indeed, studies have shown the 
expression of IL-6 gene transcripts and presence of IL-6 protein in human atherosclerotic 
lesions (Rus et al., 1996, Seino et al., 1994). In addition, expression and plasma 
concentration of IL-6 and CRP as its by product have been reported to be indicator of the 
intensity of inflammatory induced coronary plaque and are associated with instability of 
the plaque and vulnerability to rupture (Ikeda et al., 2001).      
 
Therefore, it appears that elevated inflammation in depressed CHD patients can 
potentially contribute to worsening their cardiac condition. Indeed, the directionality of 
the depression-inflammation has been evaluated prospectively in relation to elevation of 
both CRP and IL-6 and their association with depressive symptoms, and the study 
suggests augmented inflammation preceded by depression as one of the mechanisms 
through which depression adversely affects cardiac health (Stewart et al., 2009).   
     
Overexpression of IL-6 is also shown to be associated with aging. Age-associated 
elevation in IL-6 has been argued to account for clinically important late-life phenotypic 
changes and frailty as well as development of chronic inflammatory conditions in relation 
to advanced age (Ershler and Keller, 2000). The association between cardiovascular 
disease and inflammation and in particular increased in IL-6 levels as a key mediator of 
CRP production is the cause of concern due to increased risk of myocardial infarction and 
severe cardiac complications in this population. In addition, inappropriate elevations in 
IL-6 and CRP among the elderly have been linked to onset of disabilities including 
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muscle atrophy, arthritis, and osteoporosis (Ferrucci et al., 1999). Furthermore, joint 
elevation in the levels of IL-6 and CRP has been shown to be associated with remarkably 
increased mortality in a population of old people (Harris et al., 1999). These findings are 
important to be discussed considering the age of the present participants (Table 3.2) 
indicating the greater risk of disability, cardiovascular events, and mortality in this CHD 
depressed group who are showing elevated levels of both IL-6 expression and CRP 
concentrations. 
 
Having discussed the findings in regards to IL-6 gene expression, the other results of 
testing the second hypothesis of this PhD, that CHD depressed have greater gene 
expression of cytokines than non-depressed, show that gene expression of IL-1β (Figure 
3.6), TNF-α (Figure 3.8), and NF-kB (Figure 3.10) did not differ in CHD patients with 
and without depression. Despite the studies reporting increased level of these 
inflammatory biomarkers in MDD, the finding has not been confirmed by all studies 
(Haack et al., 1999, Kagaya et al., 2001). In addition, the protein levels of these cytokines 
have not been measured in this study, and since CHD is also associated with elevation of 
inflammatory cytokines, the circulatory levels might be already elevated in both groups 
with no difference between the two. It is also relevant to note that although mediated by 
other pro-inflammatory cytokines as well, IL-6 preserves a primary role in regulation of 
acute phase responses (Maes et al., 2011, Sherwood et al., 2007).  
 
Taken altogether, CHD patients present on-going and chronic inflammation which 
potentially contributes to development of depression with the consequence of further 
activation in inflammatory processes which in turn can lead to further endothelial damage 
and serious cardiac complications. These findings confirm inflammation as a common 
link between heart disease and depression.  
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4.3 Insufficient Glucocorticoid Signalling in CHD Patients with 
Depression 
 
4.3.1 HPA Axis Disturbance and Reduced Glucocorticoid Bioavailability 
Assessing the HPA axis activity as a main regulatory system in the control of stress 
response and inflammation revealed very interesting findings. In this PhD, it was 
hypothesised that CHD patients with depression would show HPA axis abnormalities by 
demonstrating higher levels of cortisol both in plasma and saliva. The idea of the 
hypothesis came from the evidence in regards to the hyperactivity of the HPA axis, which 
is observed in patients with MDD in the presence of GR resistance (section 1.2.4).  
 
Surprisingly, the present data show that compared to CHD non-depressed, depressed 
patients have actually lower levels of cortisol as elucidated by a single measurement in 
plasma (Figure 3.12) as well as repeated measures in saliva (Figure 3.14). HPA axis 
responsiveness was addressed by assessing its activation followed by waking up and 
measuring the cortisol response within the first hour of awakening that is considered as a 
reliable biological marker for the HPA axis activity (Pruessner et al., 1997). Indeed, a 
very high correlation between plasma and salivary cortisol has been reported in more 
recent studies investigating HPA axis function and recommending salivary cortisol 
measurements as reliable marker of HPA axis assessment (Petrowski et al., 2013). The 
result reveals significantly lower total cortisol output during the first hour post awakening 
as well as blunted response to the stress of awakening in CHD depressed patients (Figure 
3.14). In fact, the cortisol awakening response is found to be significantly lower in CHD 
depressed individuals with no peak observed at 30 min which is expected in a healthy 
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response. Indeed, depressed patients have lower delta cortisol levels at 30 minutes post 
awakening compared with non-depressed group (section 3.3.2).  
 
Despite the popularity of studies showing higher levels of cortisol in MDD as a result of 
hyperactivity of the HPA axis and presence of GR resistance, not all the studies have 
found the same results. Indeed, decreased morning cortisol in both serum and saliva 
samples were reported in depressed as well as vulnerable individuals in the community 
(Strickland et al., 2002). While some studies report findings in regards to hyperactivity of 
the HPA axis and elevation in cortisol levels observed in old depressed patients 
(Gotthardt et al., 1995, O'Brien et al., 1996), other studies explore the opposite findings 
suggesting hypoactivity of the HPA axis and hypocortisolism associated with late-life 
depression (Morrison et al., 2000, Oldehinkel et al., 2001). Indeed, a more recent study 
suggested the association of late-life depressive symptoms with both hyper and 
hypoactivity of the HPA axis and proposing the possible distinct mechanisms involved 
(Penninx et al., 2007). As mentioned in section 1.2.4, decreased levels of cortisol have 
been consistently shown in stress related conditions including atypical depression, PTSD, 
chronic fatigue syndrome and fibromyalgia. Some studies suggest physical frailty and 
exhaustion as underlying mechanism associated with HPA axis insufficiency among 
elderly with depression (Fries et al., 2005, Morrison et al., 2001, Oldehinkel et al., 2001). 
 
Inconsistent findings have also been reported in regards to the association of cortisol with 
depression in patients with cardiovascular diseases. In the Heart and Soul Study, Otte and 
colleagues have found an association between depression and elevated urinary cortisol in 
CHD patients. However, increased cortisol has not been found to be related to the 
worsening of cardiac function in these patients (Otte et al., 2004). In another study in 
CHD patients, the results have shown an association of depression with flatter diurnal 
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cortisol rhythms which in turn contributed to prognosis of coronary atherosclerosis 
(Bhattacharyya et al., 2008). Lack of association between depressive symptoms and 
diurnal cortisol profile has been also reported in patients following hospitalization with an 
acute coronary syndrome (Molloy et al., 2008).     
 
In general, chronic inflammatory exposure in CHD is one of the stressful challenges that 
these patients face, and adaptation to such condition require involvement of neural-
endocrine-immune mechanisms (Chrousos and Gold, 1992, McEwen, 1998). The impact 
of exposure to chronic or extreme stress on the neurobiology of the HPA axis is well 
documented. Indeed, prolonged activation of the HPA axis has an adverse effect on health 
outcomes both physically and emotionally (Sapolsky et al., 2000). Some studies have 
shown an association of hypocortisolemia with physical complains and chronic fatigue 
after long term HPA axis overstimulation under chronic physical stress (Fries et al., 2005, 
Hellhammer et al., 2004). The activity of the HPA axis in the concept of cortisol 
awakening response provides the individual with energetic boost needed for the diurnal 
activity, and it has been suggested that lower awakening cortisol can predict greater 
degree of physical symptoms and fatigue during the day (Adam et al., 2006).  
 
Therefore, considering all the findings described above, the present lower cortisol levels 
in the CHD depressed patients could be explained by exhaustion of the HPA axis which 
no longer respond sufficiently to the stress with secretion of the endocrine glucocorticoid. 
In fact, it can be postulated that these patients had already been under a prolonged period 
of HPA axis hyperactivity as a result of their chronic inflammatory condition and now the 




There are also other possibilities that can be suggested in relation to the HPA axis 
hypoactivity observed in CHD patients in the present study. The study by Pickering and 
colleagues proposed an association between obesity and MDD episodes with atypical 
features (Pickering et al., 2007). In addition, another study by Bryan and colleagues found 
that MDD patients with diabetes experience more physical symptoms of MDD with more 
atypical features (Bryan et al., 2008). Considering the well-known association of obesity 
and diabetes with cardiovascular disease, it can be expected that atypical subtype of 
depression could be strongly associated with heart disease. On the other hand, patients 
with atypical depression have been suggested to display a hypoactive state of the HPA 
axis mainly associated with decline in upstream secretagogues and specially CRH 
deficiency (Gold and Chrousos, 2002). The present demographic characteristic of the 
patients in relation to their cardiac conditions (Table 3.3) show that patients have BMI 
around 30 kg/m
2
 being borderline overweight and obese according to National Heart, 
Lung, and Blood Institute definition (BMI kg/m
2
: 18.5-24.9 healthy weight, 25-29.9 
overweight, 30-39.9 obese, >40 extreme obese). Therefore, it would be possible that CHD 
depressed patients in this study are displaying atypical features of depression and thus 
hypoactivity of the HPA axis. However, the information in regards to the classification of 
depression is not available in this PhD to reach this conclusion.  
 
The investigation in regards to the relationship between HPA activity and elevated 
inflammation in this study population also reveals that cortisol awakening response is 
negatively associated with CRP, so the lower cortisol awakening response is followed by 
higher inflammation as indicated by the levels of CRP (Figure 3.15). Therefore, this 
finding elucidates that in CHD patients, depression is associated with inflammation in the 
presence of blunted cortisol response to the awakening and in the other words attenuated 
HPA axis reactivity.  
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Taken altogether, it can be postulated that endogenous cortisol secretion due to 
hypoactivity of the HPA axis is insufficient to limit inflammation in CHD patients with 
depression leading to higher inflammatory response in these population. 
 
 
4.3.2 Attenuated Glucocorticoid Responsiveness 
Assessing GR was one of the main interests of this study due to the crucial role of this 
receptor in the negative feedback regulation of the HPA axis and also its 
immunosuppressive and anti-inflammatory effect through transrepression activity. 
Considering the evidence in regards to the impact of prolonged inflammation in GR 
alteration (section 1.2.5) and also observations of GR resistance in patients with MDD 
(section 1.2.4), this PhD hypothesised that CHD patient with depression exhibit GR 
resistance displaying lower number and sensitivity of GR. The present data indeed 
demonstrated that compared to CHD patients without depression, depressed CHD patients 
show attenuated glucocorticoid responsiveness as assessed by both expression and 
function of GR.  
 
4.3.2.1 Decreased GR Number 
Peripheral GR levels have been investigated through measuring total GR gene expression. 
Although animal studies have shown a similar pattern of upregulation and 
downregulation of GR both in the immune system and the CNS (Spencer et al., 1991), the 
findings in clinical studies in regards to decreased in GR levels (either measuring directly 
GR number or assessing GR gene expression) in depressed patients rely on evaluation of 
the peripheral levels due to limited access to the brain tissue (Pariante and Miller, 2001).       
176 
 
Based on the result in regards to GR gene expression presented in Figure 3.17, CHD 
patients with depression showed lower levels of total GR mRNA expression than CHD 
patients without depression indicating a decrease in the levels of these receptors in 
depressed group. It can be therefore suggested that these patients would have less GR 
available for responding to the glucocorticoids. 
 
4.3.2.2 Alteration in GR Sensitivity 
In vitro evaluation of GR function in PBMC revealed that GR sensitivity was reduced in 
CHD depressed patients who show less inhibition of LPS stimulated IL-6 in response to 
GR mediated dexamethasone effect (Figure 3.25). Decreased ability of GR indicates 
higher level of glucocorticoids is required to obtain 50% inhibitory effect in CHD patients 
with depression compared to non-depressed individuals (Figure 3.26). 
 
The present reduction in GR sensitivity together with a decrease in gene expression of the 
receptor found in CHD depressed patients is consistent with the observation of higher 
inflammation in this group. Since glucocorticoids exert anti-inflammatory effects and 
inhibit the expression and production of IL-6 in the body, an impairment in GC signalling 
in terms of availability and function on depressed CHD patients leads to elevation of IL-6 
levels, and thus CRP as its hepatic by-product. Indeed, an attenuated inhibitory response 
of the immune cells to the well-established immunosuppressive effect of GCs has been 
shown by in vitro studies in patients with MDD; this is while healthy subjects normally 
exhibit marked inhibition of cytokine production and suppression of immune activation in 




As earlier described, the present CHD non-depressed patients have shown high levels of 
inflammation as measured by CRP levels. It is suggested that long-term inflammation can 
lead to GR alteration as mentioned before. Therefore, it can suggested that on-going and 
chronic inflammation in CHD patients could affect GR function, and the consequence of 
inflammatory induced GR impairment would lead to even higher inflammation that was 
shown in depressed CHD patients. These findings can further confirm the evidence for 
bidirectional association between inflammation and glucocorticoid receptors.  
 
In addition, the findings of this study also reveal the association between GR resistance 
and the severity of depressive symptomatology (Figure 3.27) that is in line also with the 
association of inflammatory markers IL-6 and CRP with the severity of depression as 
discussed in section 4.2. These results suggest that more severe depression is associated 
with less GR functioning in combination with higher inflammation in this CHD 
population.   
 
Although the present results could explain the elevation of inflammation in relation to 
diminished glucocorticoid responsiveness in CHD depressed patients, how is it possible 
that these patients are showing hypoactivity of the HPA axis in the presence of GR 
resistance, whereas previous published studies on MDD patients have reported 
hyperactivity of the HPA axis in the presence of GR resistance due to alteration in 
negative feedback inhibition of cortisol secretion mediated by GR? To address this 
question it would be first needed to explain the methodological approaches in regards to 
GR assessment. 
 
As the result of this PhD showed, CHD depressed patients exhibited decreased sensitivity 
of GR to dexamethasone as measured in vitro directly on PBMC, and so the GR 
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sensitivity was assessed at the peripheral level. However, another standard method which 
is designed to evaluate GR function in relation to the HPA axis activity and assessing the 
integrity of GR-mediated negative feedback is the in vivo dexamethasone suppression test 
(DST) in which HPA axis response is measured following dexamethasone administration. 
Although the test has been used extensively for verification of HPA axis dysregulation, 
due to its modest sensitivity (40-50%) and lack of specificity to depression, it has been 
refined by combining the DST and CRH challenge. In this test, which is known as 
DEX/CRH test, following pre-treatment by dexamethasone, ACTH response to CRH is 
suppressed. Thus, GR-mediated feedback inhibition can be challenged via DST and 
DEX/CRH tests at the level of pituitary, and are used to quantify indirectly HPA axis 
dysregulation (De Kloet et al., 1998).  
 
Performing the in vivo tests described above, would provide further support for 
confirming the GR resistance found in this population of study. However, since the in 
vivo assessment has not been carried out in this project, there is no evidence whether 
alteration in GR sensitivity may directly affect the HPA axis that might be intact 
otherwise.  It could be possible that GR present in HPA tissue display different mode of 
action from the peripheral once found in PBMC. Some studies reveal different GR 
functioning in different tissue. For instance, animal studies have shown the alteration in 
both expression and function of GR in the pituitary contributing to HPA axis 
hyperactivity and still functional GR in the hippocampus (Schmidt et al., 2009).  
 
It should be also considered that impairment within the HPA axis that can affect the 
production and/or release of cortisol contributes to hypoactivity of the HPA axis and 
insufficient levels of glucocorticoids. While not performed in this study, measurements of 
ACTH and CRH as higher-level regulatory factors controlling cortisol release could 
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provide some insight into the possible mechanisms underlying the dysregulation of the 
HPA axis. Indeed, attenuated synthesis and release of upstream signalling molecules and 
their blunted response potentially lead to insufficient GC signalling implicated in 
neuropsychiatric conditions including chronic fatigue syndrome (Scott et al., 1998), 
fibromyalgia (Torpy et al., 2000), and atypical depression (Geracioti et al., 1997).  In 
addition, understanding HPA axis activity requires consideration of confounding factors 
which can potentially affect the neuroendocrine function and cortisol levels (Cleare, 
2003). Although not assessed in this PhD, measurements of activity levels and sleep 
disturbance implicated in hypocortisolaemic conditions (Cleare, 2003) could help with 
better interpretation of HPA axis alteration in this study population.    
 
Taken altogether, the evidence from the investigation of the HPA axis and GR in this PhD 
thesis suggests that depression is associated with insufficient glucocorticoid signalling in 
CHD patients. The inadequate signalling capacity of glucocorticoids appears to be due to 
reduced cortisol bioavailability as well as lack of sufficient GR-mediated glucocorticoid 
response due to reduced numbers and sensitivity of the receptor. Blunted cortisol 
response and HPA reactivity as well as GR resistance at peripheral level are in turn 












4.4 Diversion of the Kynurenine Pathway towards the Neurotoxic 
Branch in CHD Patients with Depression 
Having discussed insufficient glucocorticoid responsiveness which partly explained the 
elevated inflammation in CHD patients with depression, kynurenine pathway of 
tryptophan metabolism as a psychoneuroimmunologic bridge known to be implicated in 
inflammatory induced MDD, appeared to be an interesting and important system to 
investigate in this CHD population. Therefore, this thesis hypothesized that CHD patients 
with depression would demonstrate disturbances in tryptophan metabolism pathway 
through showing activation of IDO enzyme and production of neurotoxic metabolites of 
the kynurenine pathway. 
 
As described in section 1.2.7, following an increased inflammatory response and IDO 
activation, the peripheral availability of tryptophan is reduced that in turn putatively leads 
to reduced serotonin synthesis in the brain. A shift towards the kynurenine pathway and 
the production of neurotoxic metabolites are considered to be essential steps in the 
pathophysiological processes. In fact, it is believed that the imbalance between the 
neuroprotective and neurotoxic metabolites of the system potentially contributes to 
depression with 3-hydroxykynurenine and quinolinic acid overcoming the kynurenic acid 
production. 
 
The findings in regards to investigation of kynurenine pathway in this study are presented 
in Table 3.5. The results show that CHD patients with depression exhibited lower 
peripheral levels of tryptophan as compared to CHD non-depressed. The depressed group 
also display an increased in IDO activation as reflected by the KYN/TRP ratio which is in 
turn associated with higher levels of the neurotoxic metabolite 3-hydrokynurenine (Figure 
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3.31). However, such an association was not found between KYN/TRP ratio and the 
levels of neuroprotective metabolite kynurenic acid. The results therefore indicate that the 
kynurenine pathway is more likely going through the neurotoxic branch in CHD 
depressed persons.   
 
As mentioned before, activated inflammatory responses have been suggested to induce 
depressive symptoms not only by directly affecting the brain but also modulating the 
serotonergic system suggesting a causal relationship between altered inflammation and 
the disturbances in the serotonergic system (Dantzer et al., 2011, Wichers and Maes, 
2004). Inflammatory induced IDO overstimulation has been shown to be associated with 
depressive symptoms as a result of peripheral tryptophan depletion which in turn results 
in serotonin deficiency (Wichers and Maes, 2002). The animal study by Zalcman showed 
that following intraperitoneal injection of IL-6, neurotoxic metabolites, as measured by 
levels of 5-HIAA, were elevated in the prefrontal cortex and hippocampus (Zalcman et 
al., 1994).  
 
In regards to cardiovascular diseases, previous studies have shown decreased tryptophan 
concentration and higher KYN/TRP ratio coincided with increased neopterin 
concentration (marker of monocyte/macrophage activation) in CHD patients compared to 
healthy control (Wirleitner et al., 2003b). In a line with the findings of this PhD thesis a 
very recently published study also revealed an association between KYN/TRP ratio and 
CRP as well as neopterin in CHD patients suggesting IDO activity to be related with 
immune and inflammatory activation (OZKAN et al., 2014). IDO activity is believed to 
be associated with risk factors for atherosclerosis and prognosis of cardiovascular 
disorders (Niinisalo et al., 2008, Pedersen et al., 2011, Pertovaara et al., 2007). One study 
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also suggested an association between depressive symptoms and carotid atherosclerosis in 
relation to the effect of IDO activation (Elovainio et al., 2011).  
 
Although kynurenine pathway has been studied in relation to inflammation induced 
depression, and also IDO activity in relation to inflammation and atherosclerosis, to my 
knowledge, no studies to date have been investigated IDO activity and the kynurenine 
pathway in CHD patients in relation to inflammation and with comorbid depression. This 
study indeed has taken into consideration the levels of CRP and IL-6 confirming 
inflammatory activation in the present population.  
 
Considering CHD as an inflammatory condition, inflammation appears to be associated 
with the activation of the kynurenine pathway in CHD patients with and without 
depression as indicated by the correlation between KYN/TRY ratio and CRP in this study 
population (Figure 3.32). The result is in line with the findings in relation to the 
association between inflammation and IDO activity. In addition, the correlation between 
CRP and 3-HK (Figure 3.33) might indicate the effect of inflammation in triggering 
kynurenine pathway activation and production of neurotoxic metabolites. 
 
Taking into account the previous results in relation to insufficient glucocorticoid 
signalling and consequently elevated inflammation in CHD patients with depression, it 
appears that high inflammation in these patients activates the kynurenine pathway of 
tryptophan metabolism via increased IDO activity. An increased rate of tryptophan 
degradation results in measurable decline in tryptophan levels in CHD depressed patients. 
The consequence of the increased inflammatory response in turn may lead to a diversion 
of the kynurenine pathway towards the neurotoxic branch in CHD patients with 
depression. The schematic diagram of these findings is illustrated in Figure 4.1.  
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Measuring quinolinic acid level in plasma in patients would confirm further the diversion 
of kynurenine pathway towards the neurotoxic branch. In addition, the kynurenine 
metabolites were measured in the periphery, and it would have been ideal to measure the 
associated metabolites in the cerebrospinal fluid (CSF) as well. However, this could not 
be possible since quinolinic acid is notoriously very difficult to measure, and the CSF 












Figure 4.1 Diversion of the kynurenine pathway towards the neurotoxic branch in 












4.5 Increased VEGF in CHD Patients with Depression 
Overexpression of VEGF is implicated in the pathophysiology of diseases such as 
malignancies and promotes vascular permeability in involved tissues (Grothey and 
Galanis, 2009, Thurston, 2002). In addition, VEGF circulatory levels are associated with 
disease progression in autoimmune conditions (Carvalho et al., 2007). VEGF has been 
studied extensively in relation to tumour angiogenesis and has been indeed suggested as a 
target for anticancer therapy (Albini and Sporn, 2007, Carmeliet, 2005).  
 
VEGF has been also studied in CHD patients. Some studies have shown increased VEGF 
levels in patients with coronary atherosclerosis (Blann et al., 2002) and thus indeed 
suggesting an association between prognosis of coronary atherosclerosis and elevated 
VEGF (Fleisch et al., 1999), and also beneficial effect of statin therapy (atorvastatin) in 
lowering VEGF circulatory levels (Alber et al., 2002). However, no correlation between 
VEGF plasma concentration and severity of coronary artery disease has been also 
reported (Alber et al., 2005). 
 
Since VEGF is widely expressed throughout the body, attention has been recently paid to 
the role and implications of this vascular permeability factor beyond the vasculature and 
specifically in the brain. Known as a neurotrophic factor, VEGF is thought to exert 
neuroprotection (Storkebaum et al., 2004) and neurogenesis (Jin et al., 2002) effect in 
addition to vasculogenesis. The direct neurotrophic activity of VEGF in the brain has 
been shown to be exerted through stimulating axonal outgrowth and enhancing cell 
survival (Sondell et al., 1999), protecting hippocampal neurons against glutamate 
mediated toxicity (Matsuzaki et al., 2001), and influencing synaptic plasticity (Licht et 




Since VEGF plays a critical role in both the brain and vascular system, and considering 
the relationship between CHD and depression, VEGF has been suggested to be one of the 
molecular links underlying the comorbidity of these two disorders (Warner-Schmidt and 
Duman, 2008). Therefore, this PhD thesis hypothesised that CHD depressed patients 
would display higher plasma levels of VEGF as compared to CHD individuals without 
depression.  
 
There are considerable discrepancies among studies investigating VEGF in depression. 
While some studies have reported increased VEGF mRNA (Iga et al., 2007), serum (Kahl 
et al., 2009) or plasma (Lee and Kim, 2012, Takebayashi et al., 2010) levels in patients 
with MDD, others have found significant decreases in VEGF peripheral levels (Dome et 
al., 2009, Isung et al., 2012, Katsuura et al., 2011) associated with depression. In contrast 
to all these studies, VEGF protein levels have also been reported to show no difference 
between patients with MDD and healthy control (Kotan et al., 2012, Ventriglia et al., 
2009). A very recent review assessing clinical studies on VEGF and depression 
speculated that elevation in VEGF levels in patients with MDD appears to be due to the 
response to the perceived stress associated with depression resulting in an attempted 
neuroprotective effect. Whereas, decreased levels of VEGF seem to be observed in 
treatment-resistant depressed patients whose brains are  less able to undergo neurogenesis 
processes (Clark-Raymond and Halaris, 2013). 
 
The present data suggested significant elevation in circulatory VEGF in CHD patients 
with comorbid depression (Figure 3.34). However, having investigated the effect of 
antidepressants, it appeared that the increase in VEGF levels in CHD depressed patients is 
mainly affected by antidepressant treatment (Figure 3.35). VEGF has been studied in 
relation to antidepressants. An increased VEGF expression in the hippocampus has been 
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achieved in response to different classes of antidepressants including SSRIs. In addition, 
VEGF signalling via its corresponding receptor (tyrosine kinase fetal liver kinase; Flk-1 
or VEGFR2) has been suggested as an essential inducer of the antidepressants-mediated 
neurogenesis activity (Warner-Schmidt and Duman, 2007). This neurotrophic factor has 
been proposed to be a putative biomarker for treatment plan in depression and predictor 
of treatment response (Clark-Raymond and Halaris, 2013), therefore, a potential 
candidate for therapeutic interventions (Warner-Schmidt and Duman, 2008). 
 
It should be noted that in the present study, VEGF was measured in the plasma. 
Interestingly, decreased in VEGF levels in some brain regions including hippocampus 
and frontal cortex, but no change in serum levels have been observed in a genetic rat 
model of depression (Elfving et al., 2010). Whether or not VEGF peripheral levels 
correlate with those in the human brain remains a future hypothesis to be investigated in 










4.6 Increased Heart Rate in CHD Patients with Depression 
The metabolic demand of the body is controlled by heart activity through its rate. The 
association between an increase in the basal heart rate and the progression of 
atherosclerosis and sudden CHD death is documented. Indeed, the heart rate is known as 
an independent prognostic risk factor for morbidity and mortality related to 
cardiovascular disease (Dyer et al., 1980).  Clinical studies have shown prognostic benefit 
of a reduction in the heart rate following beta-blockers treatment and improvement in 
cardiac outcome and decreased in mortality (Ferrari et al., 2003).  Elevation in the heart 
rate has been observed in patients with comorbid CHD and depression (Carney et al., 
1988, Carney et al., 1993).  
 
In the present study, CHD patients with depression also show a higher heart rate than 
those non-depressed (Table 3.3). The finding is found to be independent of beta-blocker 
therapy considering the fact that more than half of the patients in each group were on this 
medication (Table 3.4). Therefore, higher heart rate in CHD depressed patients may be an 
indication of adverse consequence of comorbidity of depression in this population leaving 
the patients at higher risk of severe cardiac events and death.   
 
Alteration in heart rate in major depression is thought to be as a result of alteration in 
neural control of cardiac function. Epinephrine and norepinephrine effects on cardiac β-
adrenergic receptors or an increased sensitivity of the receptor have been suggested as the 
underlying mechanisms. Indeed, elevation in the levels of catecholamine in CSF as well 
as plasma has been observed in patients with MDD (Gold et al., 2005, Grippo and 
Johnson, 2009). The present results showed an association between the CRP levels and 
heart rate (section 3.2.1) indicating that high degree inflammation could raise the heart 
rate in CHD patients. 
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4.7 Inflammation as a Target in Treatment of Depression in CHD 
Patients: Evidence from the In Vitro Study  
Having investigated inflammation in CHD patients with and without depression in this 
PhD thesis, and considering inflammation as a potential mechanism contributing to the 
development of depression in patients with CHD, and also the negative impact of 
comorbid depression on the cardiac outcome in CHD depression, it appears that targeting 
inflammation could be considered as one of the potential therapeutic strategies in 
increasing the treatment rates for the depression in CHD patients.  
 
Statins are the most commonly used medications in heart disease due to their lipid 
lowering properties, and they are also known to exert anti-inflammatory effect 
(Schonbeck and Libby, 2004). There is evidence of pleiotropic functions of statins in 
diminishing levels of the inflammatory marker CRP that appears to be independent of its 
lipid lowering effect (Musial et al., 2001, Ridker et al., 1999, Ridker et al., 2001). In this 
study, although, more than 80% of the patients have been on statin treatment (Table 3.4), 
the results showed that CRP levels were higher in both CHD depressed and non-
depressed and even significantly higher in the depressed group. This reveals that statin 
therapy alone might not have sufficient anti-inflammatory effect in CHD patients with 
comorbid depression. While once it was thought that a statin could be beneficial in the 
treatment of depression due to its effect in reducing inflammation, studies have emerged 
proposing the contribution of this medication to the development of depression through 
the lowering of cholesterol levels, which are essential for the serotonin system (Pasco et 




On the other hand, considering the relation of inflammation in the pathophysiology of 
depression, treatment with anti-inflammatory agents such as cyclooxygenase-2 inhibitor 
has been shown to be beneficial in patients with MDD (Muller et al., 2006). In addition, 
as mentioned before in section 1.2.8, studies on therapeutic strategies using 
antidepressants report that some antidepressants appear to exhibit beneficial effect 
through reducing levels of inflammatory biomarkers and modulating inflammation-
induced depression (Tousoulis et al., 2009) as well as attenuating neuro-inflammatory 
activation in depression (Lu et al., 2010, O'Sullivan et al., 2009). However, the 
mechanisms of actions of antidepressants as anti-inflammatory agents are still under 
investigations.  
 
For the treatment strategies in reducing inflammation in CHD patients with depression, 
the goal would be targeting the specific mechanisms underlying the inflammatory 
activation in these patients. Due to major role of adequate glucocorticoid signalling in the 
regulation of inflammation and metabolism, studies on potential therapeutic intervention 
in CHD, have paid attention to the involvement of GR in the pathophysiology of 
atherosclerosis.  
 
GR genes have been studied in relation to heart disease. Studies suggest variation 
between individuals in relation to glucocorticoid functionality. Four common 
glucocorticoid receptor gene polymorphisms; BclI C/G, GR-9β A/G, N363S, and 
ER22/23EK, have been associated with glucocorticoid sensitivity (Huizenga et al., 1998, 
Van Rossum and Lamberts, 2004). GR gene haplotype 3 (GR-9β A/G) related to reduced 
GR sensitivity and more pro-inflammatory response has been shown to be associated with 
risk of cardiovascular disease (van den Akker et al., 2008). In addition, the investigation 
in regards to the association of these genes with depression in a population of CHD 
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patients has revealed that this common genetic variant of GR is also associated with 
depression and has been suggested as a vulnerability factor for depression in CHD (Otte 
et al., 2009). Moreover, in CHD patients the therapeutic effect of beta-blockers and 
calcium blocker has been investigated on GR suggesting the mechanisms for their anti-
inflammatory activity through increasing GR levels (Ji et al., 2010). Therefore, GR 
appears to be a strong link between CHD and MDD, and a potential candidate to be 
targeted in treatment of depression in heart disease.  
 
As the result of this study showed and discussed in detailed (section 4.3.2), CHD 
depressed patients exhibited lower sensitivity of GR (Figure 3.26) as one of the potential 
mechanisms leading to elevated inflammatory response (Figure 3.3 & Figure 3.1) in these 
patients. Evaluating GR function, It was also hypothesised that antidepressant and omega-
3 treatment in vitro would improve GR-mediated glucocorticoid response in CHD 
depressed patients who showed decreased GR sensitivity. Indeed, testing the hypothesis 
in this population revealed that the GR functional responsiveness appeared to be 
improved by the in vitro effect of antidepressants clomipramine (Figure 3.28) and 
citalopram (Figure 3.29) as well as EPA (Figure 3.30); that potentially may lead to more 
effective response to the anti-inflammatory and immunosuppressive activity of 
glucocorticoids.      
 
The effects of antidepressants in regulation of GR function have been suggested by 
various studies (Carvalho and Pariante, 2008, Pariante and Miller, 2001). Tricyclic 
antidepressant desipramine has been shown to enhance GR function by facilitating GR 
translocation from cytoplasm into the nucleus in vitro (Pariante et al., 1997). 
Clomipramine has been observed to reduce GR function in vitro in healthy individuals, 
and the absence of the effect was reported in treatment resistance depressed patients 
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(Carvalho et al., 2008). Although clomipramine was found to increase GR sensitivity in 
CHD depressed patients in the present study, it would not be considered clinically as the 
treatment choice in pharmacotherapy of depression in this population due to cardiotoxic 
effects of tricyclic antidepressants and the risk of overdose death liability associated with 
this class of antidepressants (Alvarez and Pickworth, 2003, Roose and Glassman, 1994). 
However, it can be argued that the finding might be relevant in general in comorbidity of 
depression in medically-ill patients experiencing chronic inflammatory conditions.     
 
The SSRI antidepressants and specially citalopram and sertraline are recognised to be safe 
and effective, thus the first-line antidepressants for CHD patients who suffer from 
moderate to severe as well as recurrent depression (Glassman et al., 1993, Glassman et 
al., 2002, Lespérance et al., 2007). Studies on the effects of citalopram in relation to heart 
disease and depression, have been shown the beneficial actions of this antidepressant in 
patients with comorbid cardiovascular disease and depression through improvement in 
endothelial function (van Zyl et al., 2009). Based on the result of in vitro assessment of 
citalopram on GR function (Figure 3.29), the present study also reveals that this SSRI 
antidepressant may also improves GR sensitivity in CHD depressed patients who exhibit 
GR resistance. Although, this finding does not explain the exact mechanism through 
which citalopram increases GR responsiveness, it might indicate the potential mechanism 
of anti-inflammatory action of this antidepressant that seems to be through modulation of 
GR function.   
 
The present data in regards to the effect of EPA on GR functionality in vitro show an 
increase in the sensitivity of GR in both CHD patients without depression and those with 
depression when EPA was co-incubated with dexamethasone. This finding may also 
reveal the potential mechanism of anti-inflammatory effects of omega-3 PUFAs through 
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increasing GR function thus a better response to the cortisol. Indeed, clinical studies have 
shown the inverse association of omega-3 and the two inflammatory biomarkers CRP and 
IL-6 in a population of CHD patients (Farzaneh-Far et al., 2009). The authors have 
suggested omega-3 fatty acids may prevent adverse cardiac events possibly through 
mechanisms that lead to the inhibition of inflammation. Omega-3 PUFAs are found to 
influence capacity of monocytes for the synthesis of cytokines such as IL-1 and TNF. 
Indeed, they are found to promote the cytokine suppression at the levels of transcription 
and regulation of their gene expression (Simopoulos, 2002). Omega-3 PUFAs synthesise 
classes of lipid mediators such as resolvins, lipoxins, maresins, and protectins that are 
known to resolve inflammation (Lee, 2012). Decreased leucocyte chemotaxis, inhibiting 
adhesion molecule expression, and diminishing interaction between leukocyte and 
endothelium are other anti-inflammatory activities of these fatty acids (Calder, 2013). 
 
Based on the result of this PhD thesis, it has been shown that CHD patients with and 
without depression exhibited high levels of inflammation, and that CHD depressed 
individuals showed even higher inflammation and in the presence of GR resistance when 
compared with CHD non-depressed. In addition, it was observed that there was an 
association between CRP, IL-6, and GR resistance with the severity of depressive 
symptoms. Furthermore, the in vitro findings revealed that EPA might lower the 
inflammatory status through increasing GR sensitivity in both CHD patients with and 
without depression. Therefore, it can be postulated that omega-3 would be potentially an 
effective therapeutic medication in CHD patients with or without comorbid depression.  
 
The significant of this finding relies on the fact that omega-3 can be favourable choice of 
medication due to their lack of side effects. Indeed, this agent is known as a safe 
therapeutic component with potentially no known side effect for CHD patients. In 
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addition, omega-3 is believed to be both protective and therapeutic agent for depression 
(Su et al., 2000). Furthermore, the effect of omega-3 has been already investigated in 
clinical trials and has been suggested to be an effective mediation in reducing depressive 
symptoms in MDD patients (Nemets et al., 2002) as well as TRD individuals (Puri et al., 
2002). Moreover, epidemiological studies reveal the protective effect of dietary omega-3 
on adverse cardiac events (Breslow, 2006, Harris et al., 2007, Lee et al., 2008).  
 
Although not measured in this study, low levels of omega-3 PUFAs have been reported in 
patients with MDD. The brain contains high concentration of PUFAs which are essential 
for the proper functioning of the CNS (Bourre et al., 1991). Since they are the major 
component of neuronal cell membranes, their alterations cause disturbances in membrane 
microstructure leading to alteration in signal transduction and increasing the risk of 
depression (Horrobin and Bennett, 1999, Logan, 2003).  
 
Deficiency of omega-3 fatty acids has been considered as a crucial factor contributing to 
the pathophysiology of heart disease and depression and is a potential link between the 
two (Severus et al., 1999). Omega-3 deficiency in platelet membrane is associated with a 
decreased heart rate variability which is the risk for sudden cardiac death (Christensen et 
al., 1997) and has been reported to be remarkably lower in depressed patients with CHD 
(Carney et al., 1995).     
 
It must be noted that the effects of the antidepressants clomipramine and citalopram, and 
EPA on GR function were assessed in vitro, thus with no involvement of 
pharmacodynamic and pharmacokinetic parameters which influence in vivo studies. This 
study assessed the in vitro effect of EPA on improving GR sensitivity in CHD patients 
with or without depression that in turn could result in reducing inflammation in these 
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patients. However, the effect is suggested to be investigated further through in vivo 
observations. 
CHD patients remain under the conditions of chronic inflammation, and the present 
results showed the deleterious effect of comorbidity with depression on GR and HPA axis 
leading to a further augmentation of inflammation. Therefore, managing inflammation- 
induced depression and preventing further elevation of inflammation appear to be the 
vital approach to treatment of these patients. This would be only possible by targeting the 
specific mechanisms underlying inflammatory activation in these patients one of which 
could be GR alteration. It can be postulated that co-administration of suitable anti-
inflammatory medications with effective antidepressants might have strongest effect and 



















4.8 Strengths, Limitations, and Future Work of the Study 
This project is the first to investigate detailed mechanisms associated with inflammatory 
activation in CHD patients with and without depression by assessing inflammatory 
response, HPA axis activity, GR sensitivity and kynurenine pathway in the same 
population. Indeed, compared to other studies, this study is the only one looking at the 
potential cause and consequences of inflammation associated with depression in CHD at 
the same time. Although other published studies have assessed HPA axis activity in CHD 
patients with depression, this study has revealed the HPA axis disturbances together with 
blunted cortisol awakening response in relation to elevated CRP levels and in the 
presence of GR resistance at the periphery. In addition, kynurenine and tryptophan levels 
have been previously assessed by other studies and more recently in relation to elevated 
inflammation, however, the kynurenine pathway has never been investigated before in 
this specific population. 
 
It should be noted that investigating glucocorticoid signalling through measurements of 
GR expression and function which directly assesses the responsiveness status is more 
accurate and stable indicator than only measuring cortisol levels due to such a circadian 
fluctuation during a single day. However, the present study assessed both direct and 
indirect functional measurements of GR by investigating GR expression and function, as 
well as circulating cortisol levels both with a single measure in plasma and repeated 
measures in saliva. 
 
This study also benefits from the fact that patients did not differ in terms of using 
concomitant medication (besides antidepressant) which can be a complication in such 
198 
 
complex conditions. Also, gender did not have an effect in all the findings that is also a 
common complication in stress related conditions. 
This PhD study mainly concentrated on the role of inflammation involved in the 
pathophysiology of depression investigated in a specific population of CHD patients. 
However, major scientific theories proposed in relation to the potential causes and 
possible mechanisms involved in the development of depression have been mentioned in 
section 1.2.1 and cannot be ignored. Rather conflicting results yielded by different 
published studies in relation to depression appear to be mainly due to the heterogeneity of 
this disease and specifically when it is comorbid with other physical illnesses; and it 
seems to be even more diverse in elderly population.  
 
The cross-sectional nature of this PhD thesis offered some valuable findings for better 
understanding of the role of inflammation in CHD patients with and without depression 
by investigating the mechanisms underlying the pathophysiology of inflammation- 
induced depression and the biologically related consequences of comorbidity of 
depression in CHD patients. However, further prospective investigation would enable 
examining the longitudinal association between heart disease and depression in relation to 
inflammation. 
 
All the patients have been followed up by UP-BEAT study for four years every six 
months recording the information in regards to their depression and cardiac status, and 
these data could be used for future studies in order to investigate the development of 
depression and cardiovascular related complications including MI and death. In addition, 
DNA samples were collected from 400 CHD patients with and without depression that 
will be genotyped for detecting polymorphisms associated with inflammation, GR, and 
serotonin. The genetic approaches would advance our understanding of the underlying 
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common mechanisms involved in the co-morbidity of these two devastating disorders. 
The ultimate goal will be identifying the genetic and/or biological markers that can be 
used for prediction or early detection of depression in CHD patients.  
 
Detecting inflammatory-induced depression will have important translational significance 
as it will identify biomarkers that predict future development of depression and thus 
identify subjects that may benefit from targeted therapeutic prophylactic intervention. 
Moreover, it will confirm inflammation as a pharmacological target to develop new 
antidepressants, and will detect biomarkers that could be used to monitor changes in 
vulnerability. 
 
One of the limitations of this study is the sample size of the group with depression, and 
specifically the very small sample size when the groups were divided for the 
antidepressants usage; this may have contributed to the non-significant findings in these 
analyses. In addition, in some experiments only a subtype of the patients was analysed 
due to the lack of availability of the samples. For example, for saliva samples there were 
cases that the amount of samples collected were not sufficient to measure; in addition, not 
all the patients who provided blood samples also provided saliva sample. This also 
happened in the GR function assessment that PBMC were not available for all the patients 
that were investigated for their gene expression levels. Furthermore, it should be noted 
that the study participants were elderly and that the old age is also associated with 
inflammation, higher prevalence of depression, and increased risk of cardiovascular 
complications. However, the findings of this study were controlled for age. Moreover, 
assessments of confounding variables such as activity levels and sleep disturbance that 





This PhD thesis provides valuable finding in regards to the well-established association 
between CHD and depression with an insight into the role of inflammation. Based on the 
results of this study, it can be concluded that chronic inflammation in patients with CHD 
potentially contributes to the development of depression which in turn leads to further 
activation of inflammatory processes as reflected in joint elevation in IL-6 expression and 
CRP levels both with a significant association with the severity of depressive 
symptomatology in this population. CHD depressed patients display hypoactivity of the 
HPA axis possibly due to the exhaustion of the system because of long-term 
inflammation. The elevated inflammation in CHD patients with depression is concomitant 
with insufficient glucocorticoid signalling as a result of decreased hormone 
bioavailability, as observed through lower levels of plasma and salivary cortisol as well as 
attenuated glucocorticoid responsiveness due to the decreased expression and function of 
GR. Inadequate glucocorticoid signalling associated with inflammation may make CHD 
patients with depression less equipped to respond to stress. Blunted cortisol response and 
HPA reactivity as well as GR resistance at peripheral level are indeed associated with 
high inflammation in these patients showing dysfunction of the regulatory mechanisms to 
limit the inflammation. The consequence of increased inflammation associated with 
depression adversely affects the patients with CHD. Indeed, CHD individuals with 
depression show the involvement of the serotonergic system through the activation of the 
kynurenine pathway of tryptophan metabolism as evidenced by an increase in IDO 
activity. An increased rate of tryptophan degradation results in measurable decline in 
tryptophan levels in CHD depressed patients. The consequence of the increased 
inflammatory response in turn may lead to diversion of the kynurenine pathway towards 
the neurotoxic branch in CHD patients with depression. In addition, having higher heart 
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rate in CHD patients with comorbid depression may leave the patients at higher risk of 
severe cardiac events and death.  
  
These findings may provide a better understanding of the role of inflammation in the 
pathogenesis of depression in coronary heart disease and an ample support of the 
observations in regards to inflammation as a remarkable link between these two 
devastating disorders. Therefore, enhancing the knowledge of the relationship between 
heart disease and depression, and uncovering in details the specific mechanisms involved, 
would open the possibility for promising therapeutic strategies. The strategies that would 
target directly those affected mechanisms, and avoid trying unnecessary conventional 
therapies. Indeed, the management of inflammation-associated depression through anti-
inflammatory approaches remains as a novel strategy for the treatment of depression in 
patients with CHD and other chronic inflammatory disorders. Therefore, this study 
provides evidence in regards to improvement of GR function in vitro in response to the 
effect of antidepressants and anti-inflammatory agents which may lead to a more effective 
response to the anti-inflammatory and immunosuppressive activity of glucocorticoids.  
Specifically, omega-3 PUFAs would potentially increase GR sensitivity in both CHD 
patients with and without depression. Upon validation of their remarkable effect on GR 
function by in vivo studies, this study recommends that omega-3 may be potentially an 
effective therapeutic medication in CHD patients with or without comorbid depression.    
 
Recognition and management of depression in CHD patients remain essential to avoid its 
deleterious effect associated with the negative cardiac prognostic impact.  The ultimate 
goal is to attenuate the adverse cardiac outcome in depressed heart disease patients, to 
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Appendix-A Patient Information and Invitation letter 
                                                                                                                                      
Patient Information Sheet  
REC REF 09/H1103/19 
 
Inflame-BEAT: Understanding the role of inflammation in predicting depression in patients 
with heart disease 
 




We would like to invite you to participate in this research study. Before you decide it is important 
that you understand why the research is being done and what it will involve. Please take time to 
read through this information carefully and discuss it with others if you wish. Please ask us if 
there is anything that is not clear or if you would like more information. Thank you for reading 
this. 
 
What is the purpose of the study? 
 
Depression and heart disease are common health problems. Patients who suffer from heart 
problems may have an increased risk of becoming depressed.  Unfortunately, depression in 
patients with heart disease increases the risk of having future cardiac problems and death. It is 
unclear why depression affects people with heart disease.  
 
In our research study we are interested in identifying what the main risk factors that predispose to 
depression are. In particular, we want to know whether there are any genes or molecules that 
increase the risk of developing depression, either alone or by interacting with environmental 
factors such as stress, and infections. Part of the reason why some people become ill may lay in 
genetic differences between people, in the same way that we are different in the colour of our 
eyes, hair etc. These genetic differences also correspond to differences in certain molecules in our 
blood and saliva. To achieve this, we will compare the blood, saliva and genetic make-up of 
people with heart disease with and without current diagnosis of depression with the make-up of 
people with similar characteristics but no history of heart disease or mental health problems. 
 
By understanding the role of molecules in the blood that make some people more susceptible than 
others to becoming ill; and by understanding how environmental factors work together with 
molecules and genes in causing depression in the future will allow us to predict and treat better 
these devastating disorders. 
 
In conclusion, the type of genetic analysis that we carry out is only for research purposes and does 
not at present produce clinically relevant results.  
 
Why have I been invited? 
 
We are interested in patients who have been diagnosed with heart disease. Your GP thinks you 
have (or have had) heart disease and would like you to discuss participating in the study with a  
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member of the study team. We want about 800 with heart disease to help us with the study. 
However, no information will be passed to the study team without your consent. 
 
Do I have to take part? 
 
No. It is entirely up to you whether or not you decide to participate in this study and a member of 
the research team will discuss this with you. They will describe the study and go through this 
information sheet, which we will then give to you. If you decide you would like to take part you 
will be asked to sign a consent form but will still be free to withdraw at any time without giving a 
reason. If you decide not to take part, or withdraw at any time, this will not affect the care you 
receive from your GP or any other health professional involved in your care. 
 
What will happen to me if I take part? 
 
We would like to follow people for 1 year. Initially a researcher will contact you to arrange a 
convenient time to meet, either at your home, at King’s College London or at your GP’s surgery. 
At this meeting the researcher will tell you more about the research and answer any questions you 
may have. The researcher will then contact you again 2 days later to discuss whether you wish to 
participate in the study. They will ask you to sign a consent form and then complete a 
questionnaire. The questionnaire will ask you questions about symptoms of heart disease and 
depression, your treatment, and your social circumstances. In this occasion we will ask from you a 
small sample of blood and a cheek swab sample.  The cheek swab is a simple procedure (we can 
show you the kit and illustrate the technique) that collects some of the cells from the inside of 
your cheek. This part will take about an hour. After this we will contact you every 6 months, 
during one year and arrange a convenient time either personally or by phone and ask you to 
complete a shorter questionnaire again asking questions about your symptoms and mood. This 
will take about half an hour. In total you will meet with the researcher 3 times. All information 
you give us will be treated in the strictest confidence. You will be given a study number so that no 
information you give us has your name on it.  We will not interfere with your normal treatment in 
any way.  
 
A medically trained researcher will take the blood sample using disposable sterile equipment. It 
will only take few minutes as for any routine blood sample. If you are unable or unwilling to give 
a blood sample it is also possible to perform genetic analysis from cheek swab samples, a simple 
procedure that (we can show you the kit and illustrate the procedure) collects dead cells present in 
your saliva and in your mouth. From the cheek swab sample we cannot measure level of 
medication or look at expression of genes, we can only extract a small amount of DNA. Therefore 
we prefer to ask for a blood sample to guarantee a better quality of our results and make the most 
out of your generous help.  
 
A researcher will demonstrate how to collect saliva sample and will provide you with the tubes 
required. The level of some proteins contained in the saliva can give us an indication of 
differences in the level of stress experienced by healthy volunteers and people suffering from 
mental illnesses. 
 
We will also ask you for some of your time to collect clinical and social demographic information 
using standardised research instruments: diagnostic interview, symptoms rating scale, socio 
demographic interview and neuropsychological tests. Depression and life events questionnaires 
can be potentially embarrassing or upsetting, as could disclosure of symptoms during face to face 




                                                                                                                                                                              
What is being tested?  
We may use your blood and the cheek swab sample to: 1) Measure the level of hormones and 
proteins contained in the blood serum and in the blood cells; 2) Look at the variation in some 
genes of interest in the cheek cells. 
A medically trained researcher will take the blood sample and conduct the cheek swab, using 
disposable sterile equipment. It will only take few minutes.  
 
You will continue to receive your care as usual through your GP or other health professionals. We 
will not interfere with any care you receive. 
 
What will I have to do? 
 
We would ask you to meet with the researcher at 6 monthly intervals at a time and place 
convenient to you. The researcher will contact you to arrange these meetings. At the meetings we 
would also ask you to answer the questions asked by the researcher.  
 
What will happen to my sample and medical information? 
 
Your DNA sample and medical information will be assigned a number and will be bar coded with 
this.  This number will be how researchers keep track of samples and information. Of the 
collected blood, serum and lymphocyte/monocyte cell fractions (PBMC) will be prepared, 
thereafter stored at -180C, until molecular and functional tests will take place. Genomic DNA 
will be collected at certain points in the study from the PBMC, but strictly used for polymorphism 
studies only and as indicated. After completion of the studies left over genomic DNA will be 
destroyed. All information will be anonymised. 
 
Expenses and payments 
 
You will be reimbursed any travel costs associated with participating in this study.  
As a gesture of gratitude for your participation you will be reimbursed for your time. 
 
Will personal information about me be kept confidential? 
 
Your confidentiality is of the up most importance to us, therefore we have put together a number 
of steps to safeguard your information.  We will follow ethical and legal practice and all 
information about you will be handled in confidence. Your research record will be kept in a 
separate secure file at the Institute of Psychiatry (IoP) and your medical records will not hold any 
of your results from this research.  Your blood or cheek swab cannot be linked back to you as 
your sample will be coded with your participant number (not your name).  Under no 
circumstances will any of your personal details be passed to anyone outside the IoP. Your 
participation is strictly confidential.  Your medical information and any results will be put on a 
computer and stored (in coded form) in an electronic database.  It is likely that the results of this 




                                                                                 
What are the possible risks of taking part? 
 
The risks involved are those of ordinary blood tests such as small pain and occasionally a small 
bruise around the area from where the sample has been taken. There is no risk involved in the 
collection of cheek swab. Since your care is not being affected in any way, there are no other risks 
to participating in the study. 
 
What are the possible benefits of taking part in the study? 
Although we cannot promise that this study will be of immediate benefit to you, by taking part 
you will help to increase the knowledge of what causes people to be more susceptible to 
depression and heart disease.  
We hope that in the future this knowledge may lead to the development of better treatments and 
improve prevention of these illnesses. You may benefit from this. 
 
Will I be contacted again? 
If you agree, we may contact you in the future to invite you to participate in other studies. 
If you would prefer not to be contacted this will not affect your participation in this study. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm you 




What will happen if I don’t want to carry on with the study? 
You are free to withdraw from the study at any time without giving reason, and your care will not 
be affected. If you withdraw from the study information already collected may still be used. 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to Dr Livia 
Carvalho who will do his best to answer your questions (Contact number: 0207 848 0352). If you 
remain unhappy and wish to complain formally, you can do this through the Institute of 
Psychiatry Complaints Procedure. Details can be obtained from the Institute of Psychiatry. 
Confidentiality 
All information which is collected about you during the course of the research will be kept strictly 
confidential.  Any information about you which leaves the practice will have your name and 




                                                                                         
What will happen to the results of the study? 
The results should be published in a medical journal within 18 months of the end of the study. 
They will also be fed back to you doctor, and to appropriate non-statutory agencies. We will send 
you a newsletter reporting the findings of this study. You will not be identified in any report or 
publication arising from the study. 
 
Who is organising and funding the study? 
The study is funded by the Department of Health and is sponsored by King’s College, London. 
Your doctor is not being paid anything extra for including you in the study. 
 
Who has reviewed the study? 
 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee to protect your safety, rights, wellbeing and dignity. This study has been reviewed and 
given a favourable opinion by the Research Ethics Committee. 
 
You will be given a copy of this Patient Information Sheet and a signed consent form to keep. 
 
Where can I get further information about the study? 
If you would like further information please contact: 
 
 
Dr Livia Carvalho  
 
Stress, Psychiatry and Immunology Laboratory 
Institute of Psychiatry, King’s College London 
















Appendix-B Appointment Confirmation 
 
 









Dear        
 
Thank you for agreeing to participate in our research project.  
I confirm our appointment on the .................... at .......... AM.  
 








I will be waiting for you at the main reception.  
 
You will be reimbursed for your travel expenses (provided you leave the receipt 
with us). 
 
In the unlikely event that you are not able to come on the agreed day, please 
contact me asap on 0772 500 0710. 
 




Dr. Livia Carvalho 
CCBB, The James Black Centre 
Institute of Psychiatry, King’s College London 
125 Coldharbour Lane 






    
Dr. Livia A Carvalho 
 
Department of Psychological Medicine 
Centre for the Cellular Basis of 
Behaviour, The James Black Centre  
Institute of Psychiatry, Kings College 
London  
125 Coldharbour Lane  
London SE5 9NU  
 
Tel    + 44 (0) 207 848 0352 






      
  
       
 
  
      
    Stress, Psychiatry 
    and Immunology 
    









Appendix-C Participant Consent Form                                                    
                                                                                         
Participant Consent Form                                                   REC REF 09/H1103/19 
 
A copy of this consent form (signed and dated) will be given to you. 
 
Inflame-BEAT: Understanding the role of inflammation in predicting depression in patients 
with heart disease  
 
Reference number:     Participant number:  
 
My signature below indicates that: 
 
 I have read this form and the research has been explained to me. 
 I have been able to discuss the research and ask questions.  I am satisfied with the 
answers I have received. 
 I have been given the time to consider whether or not to take part in this study. 
 My participation in this research is completely voluntary. 
 It has been explained to me that I am free to withdraw from the study at any time 
without giving reason, and without my medical care or legal rights being affected.  
 I am willing for researchers to seek information from doctors that have treated me 
for mood disorder and to review my medical records.  
 
The following consent elements are optional.  Please initial each box to indicate your consent: 
 
Participant’s Name: _______________________________________________________    
(Please print) 
 
Participant’s Signature: ______________________________________   
Date:____/_____/_____ 
         
 (Day/Month/Year) 
 
Individual obtaining the Participant’s Consent:  I verify that I have explained the nature of 
this study to the participant and to the best of my knowledge addressed any questions the 
participant has asked. 
 
Name: ___________________________________________________________________  
(Please Print) 




 I agree to provide blood sample  YES NO 
 I agree to provide a sample of my DNA using a cheek swab. YES NO 
 I am willing to be contacted in the future regarding participation in other 
studies. YES NO 
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Appendix-D Participant Questionnaire 
 







Telephone number: __________________Email:_______________________________ 
 
Age _______________ ___________   Date of Birth_____________________________ 
 




















5) Did you have breakfast today? At what time? 
 
 

























1 0 I do not feel sad 12 0 I have not lost interest in other people
1 I feel sad 1 I am less interested in other people than I used to be
2 I am sad all the time and I can't snap out of it 2 I have lost most of my interest in other people
3 I am so sad or unhappy I can't stand it 3 I have lost all of my interest in other people
2 0 I am not particularly discouraged about the future 13 0 I make decisions about as well as I ever could
1 I feel discouraged about the future 1 I put off making decisions more than I used to
2 I have nothing to look forward to 2 I have greater difficulty in making decisions than before
3 I feel that the future is hopeless and that things 3 I can't make decisions at all anymore
cannot improve
14 0 I don't feel I look any worse than I used to
3 0 I do not feel like a failure 1 I am worried that I am looking old or unattractive
1 I feel I have failed more than the average person 2 I feel there are permanent changes in my appearance
2 As I look back on my life, all I can see is a lot of that make me look unattractive
failures 3 I believe that I look ugly
3 I feel I am a complete failure as a person
15 0 I can work about as well as before
4 0 I get as much satisfaction out of things as I used to 1 It takes extra effort to get started at doing something
1 I don't enjoy things the way I used to 2 I have to push myself hard to do anything
2 I don't get real satisfaction out of things anymore 3 I can't do any work at all
3 I am dissatisfied or bored with everything
16 0 I can sleep as well as usual
5 0 I don't feel particularly guilty 1 I don't sleep as well as I used to
2 I feel guilty a good part of the time 2 I wake up 1-2 hours earlier than usual and find it hard
3 I feel quite guilty most of the time to get back to sleep
4 I feel guilty about everything 3 I wake up several hours earlier than I used to and 
cannot get back to sleep
6 0 I don't feel I am being punished
1 I feel I may be punished 17 0 I don't get more tired than usual
2 I expect to be punished 1 I get tired more easily than I used to
3 I feel I am being punished 2 I get tired from doing almost anything
3 I am too tired to do anything
7 0 I don't feel disappointed in myself
1 I am disappointed in myself 18 0 My appetite is no worse than usual
2 I am disgusted with myself 1 My appetite is not as good as it used to be
3 I hate myself 2 My appetitie is much worse now
3 I have no appetite at all anymore
8 0 I don't feel I am any worse than anybody else
1 I am critical of myself for my weaknesses and 19 0 I haven't lost much weight, if any, lately
my mistakes 1 I have lost more than 5 pounds; I am purposely
2 I blame myself all the time for my faults trying to lose weight
3 I blame myself for everything bad that happens 2 I have lost more than 10 pounds in weight by 
eating less
9 0 I don't have any thoughts of killing myself 3 I have lost more than 15 pounds: Y__ N__
1 I have thoughts of killing myself, but I would not
carry them out 20 0 I am no more worried about my health than usual
2 I would like to kill myself 1 I am worried about physical problems such as aches
3 I would kill myself if I had the chance and pains, upset stomach, or constipation
2 I am very worried about physical problems and it is
10 0 I don't cry anymore than usual hard to think of much else
1 I cry more now than I used to 3 I am so worried about my physical problems that I 
2 I cry all the time now cannot think about anything else
3 I used to be able to cry, but now I can't cry even
though I want to 21 0 I have not noticed any recent changes in my interest
in sex
11 0 I am no more irritated now than I ever am 1 I am less interested in sex than I used to be
1 I get annoyed or irritated more easily than I used to 2 I am much less interested in sex now
2 I feel irritated all the time now 3 I have lost interest in sex completely
3 I don't get irritated at all by the things that used to
irritate me
On this questionnaire are groups of statements.  Please read each group of statements carefully.  Then pick out the one 
statement in each group that best describes the way you have been feeling the PAST WEEK, INCLUDING TODAY.  Circle 
the number beside the statement you picked.  If several statements in the group seem to apply equally well, circle each one.  
Be sure to read all the statements in each group before making your choice.
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Thank you for agreeing to participate in our research. Depression and heart disease are common 
health problems, with heart problems increasing the risk of depression whilst depression may 
increase future cardiac risk.  In our research we are interested in identifying early biological 
markers that predispose people to depression.  To measure levels of stress, and the response to 
stress, we analyse hormones present in saliva.  This valuable data can be used in conjunction with 
previously gathered data to search for effects on heart disease progression and treatment. 
 
Please find enclosed six cotton swabs, with instructions for use.  There is one swab for each 
sampling time: 
1. At time of waking (tube marked 0) 
2. 15 minutes after waking (tube marked 15) 
3. 30 minutes after waking (tube marked 30) 
4. 60 minutes after waking (tube marked 60) 
5. At 2pm (tube marked 2) 
6. At bedtime (tube marked B) 
 
To prevent any void samples, please could you leave the cotton swab in place for two minutes.   
 
I would be grateful if you could also fill in the enclosed questionnaires at the time of sampling, 
to be returned with the completed samples, within 2 weeks of this letter.   
 
Many thanks for your continuing support that makes this valuable research possible. 
 
Yours sincerely, 
Dr. Livia A Carvalho, INFLAME-BEAT Program Leader 
Enc.  Cortisol instructions 
 Sampling questionnaire 
 Beck questionnaire 
 Return stamped addressed envelope 
Any questions please call on 07824 701249 – thank you. (Jennie Parker). 
Dr Livia Carvalho 
CCBB, The James Black Centre  
Institute of Psychiatry, 
Kings College London  
125 Coldharbour Lane  
London SE5 9NU  
Tel    + 44 (0) 207 848 0352 









Appendix-G How to Collect the Saliva Samples 
How to Collect the Saliva Samples 
 
You should have six tubes, each with a different number, relating to saliva collection 
times.  Only one sample is required at each of the specified times. 
  
x 6 plus questionnaire, “measuring your biological levels of stress”. 
 
1.  Take the test tube marked with the appropriate number and remove 
the lid: 
 
2.  Remove the inner tubing to expose the cotton roll: 
       
3.  Place the cotton roll in your mouth and chew on it; it is essential that you keep it there 
for 2 minutes to ensure a sufficient sample is collected. 
4.  Place the cotton roll back into the inner tube and replace the lid/label. 
5.  Immediately place the sample tube in the fridge. 
6.  Repeat the above at 15, 30 and 60 minutes after the waking sample, and again at 2pm 
and bedtime. 
Please remember to fill in the questionnaire at the time of each sample. 
 




Appendix-H A Step by Step Guide for the Saliva Collection 
Measuring your biological levels of Stress:  
 
A step by step guide for the saliva collection  
Date of saliva collection: _____________ Name: ____________________________  
Saliva Code____________ GAP ID: _____________  GAPBarcode______________ 
Baseline □     3 Months Follow up □    12 Months Follow up □ 
 
Wake up (before 10 a.m.).  
Immediately after waking up collect your saliva putting the Sorbette under the tongue 
and leaving it for 60 seconds, then put it back in the tube marked 0.  
 
Write here the EXACT TIME OF AWAKENING: _____________________________ 
 
Try to sit down and relax in the next hour. YOU CANNOT BRUSH YOUR TEETH 
AND CANNOT HAVE ANYTHING TO EAT OR DRINK FOR THE NEXT 
HOUR. If you need, you can drink water, but only immediately AFTER you have taken 
the sample.  
 
15 minutes after waking up, collect your saliva using the tube marked 15. 
 What time is it now? ________________________________________________ 
 What were you doing before giving the sample?___________________________ 
_____________________________________________________________________ 
 Did you accidentally have anything to eat or drink before taking the sample? If 
yes, please describe it here: _______________________________________________ 
_____________________________________________________________________ 
 Did you have any difficult or tense situation, unpleasant thoughts or any kind of 





30 minutes after waking up, collect your saliva using the tube marked 30. 
 What time is it now? _________________________________________________ 
 What were you doing before giving the sample? ___________________________ 
_____________________________________________________________________ 
 Did you accidentally have anything to eat or drink before taking the sample? If 
yes, please describe it here: _______________________________________________ 
_____________________________________________________________________  
 Did you have any difficult or tense situation, unpleasant thought or any kind of 




60 minutes (1 hour) after waking up collect your saliva using the tube marked 60. 
 What time is it now? _________________________________________________ 
 What were you doing before giving the sample? ___________________________ 
_____________________________________________________________________ 
 Did you accidentally have anything to eat or drink before taking the sample? If 
yes, please describe it here: _______________________________________________ 
_____________________________________________________________________ 
 Did you have any difficult or tense situation, unpleasant thought or any kind of 











At 2pm collect your saliva using the tube marked 2.  
You should not eat or drink anything, or do not brush your teeth in the 30 minutes before 
noon. 
 What time is it now? _________________________________________________ 
 What were you doing before giving the sample? ___________________________ 
_____________________________________________________________________ 
 Did you accidentally have anything to eat or drink before taking the sample? If 
yes, please describe it here: _______________________________________________ 
_____________________________________________________________________ 
 Did you have any difficult or tense situation, unpleasant thought or any kind of 






At bedtime collect your saliva using the tube marked B.  
You should not eat or drink anything, or do not brush your teeth in the 30 minutes before 
bedtime. 
 What time is it now? _________________________________________________ 
 What were you doing before giving the sample? ___________________________ 
_____________________________________________________________________ 
 Did you accidentally have anything to eat or drink before taking the sample? If 
yes, please describe it here: ______________________________________________ 
_____________________________________________________________________ 
 Did you have any difficult or tense situation, unpleasant thought or any kind of 





Store the tubes away from the heat and direct sunlight and put them into the fridge 
as soon as possible.  
 
Please note name and time of any medication taken today (including the contraceptive 
pill): ___________________________________________________________________ 
________________________________________________________________________ 
Do you have any medical problem? If so, please list them here_____________________ 
________________________________________________________________________ 
If you are female: Please indicate the age of your first menstrual cycle: ______________ 
And please indicate the date of the first day of your last menstrual cycle:  _____________ 
 
 
If you have any questions about any of these instructions please call Dr Livia Carvalho 














Appendix-I Salivary Cortisol Guideline for the Researcher  
Salivary Cortisol Guideline: 
Sample Collection 
 SWABS should be used to collect saliva samples; that changes according to age:   
 
- Up to 6 months, Salimetrics Infant's Swab (SIS) 
- Between 6 months and 6 years, Salimetrics Children's Swab (SCS) 
 
Both of these are ordered from Salimetrics  
(http://www.salimetrics.com/collection-supplies) 
 





 The salivettes should be labelled by numbers: 1, 2, 3, 4, 5 and 6; and then below 
the number the indicated time: 0 min, 15 min, 30 min ,60 min, 12 noon, 8 pm, 
respectively. 
 
 The researcher should encourage the participant to wake up between 5-10 am on 
the day they intend to collect the sample. It should be explained to the 
participants that the awakening sample should not be taken earlier than 5 am or 
later than 10 am; and if that is the case, they should leave the collection of 
samples for another day. 
  
 It is highly recommended that the researcher should ask all participants to take 
the awakening sample as soon as they wake up followed by recording the exact 
time of awakening. It should be make clear to the participant that if the first 
sample has not been taken immediately after awakening or maximum 5 minutes 
after, the collection must be left for another day. 
 
Dealing with Time Errors: 
 It is highly important that the researcher explain to all the participants and make 
them understand about the necessity of recording the exact time for collecting 
each sample. However if:  
 
- The time record is missing for one or more points, the researcher should 
contact and check immediately with the participant in case they might 
remember the time of the sample collection (at least approximate time). 
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- The time sheet is missing completely and no information in regards to the 
time of sample collection could be obtained; the sample will be 
considered and included as normal using the standard time. 
 
Dealing with Sampling Errors: 
 It is important for the researcher to go through the saliva cortisol data for each 
participant to double check the sampling time recorded for each data point. In 
cases that any sample has not been collected exactly at the expected time, the 
data can be included if the sample  has been taken within the following range : 
 
- For 15 min sample: ± 5 min 
- For 30 min sample: ± 10 min 
- For 60 min sample: ± 15 min 
- For 12 noon sample: ± 1 hr 
- For 8 pm sample: ± 1 hr 
 
 
 For the samples that the cortisol level is above or below the detectable range, the 
following values should be considered: 
 
- 82.7   for high values 
- 0.33   for low values 
 
 
 Please note that if a sample contains less than 5ul saliva it will not be measured, 
as results would not be reliable enough. The values will be only reported for the 
samples that can be used.  
 
Dealing with Missing Data: 
 If the data for the time point 0 from awakening is missing, the CAR cannot be 
calculated, but the diurnal cortisol can be calculated considering the data for 15 
min as the first sample.   
 
 If the data for 15 min or 30 min is missing, the average of the two points before 
and after the missing data should be used (For missing the data for 15 min, the 
average of awakening and 30 min can be used; and for 30 min, the average of 15 
min and 60 min). If the data for both 15 and 30 min are missing, CAR cannot be 
calculated, but the sample can be included for calculating the diurnal cortisol. 
 
 If the data for 60 min is missing, the sample is excluded for calculating the CAR 
but included for diurnal cortisol. 
 
 If the data for 12 noon and/or 8 pm is missing, the sample is excluded for diurnal 
cortisol but included for calculating the CAR. 
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Appendix-J PBMC Isolation, Freezing and Storage  
Peripheral Blood Mononuclear Cell (PBMC) Isolation Using Ficoll Paque, Freezing 




This instruction describes peripheral blood mononuclear cell (PBMC) isolation using 
Ficoll Paque, freezing and storage of viable cells. 
Necessary materials 
15-25 ml of Heparinized blood             9 ml sodium heparin tubes; Greiner 455051 
- PBS, sterile, pH 7.4   stock 10X PBS; Lonza BE17-517Q 
- 1:10 diluted in milli-Q water 
- check osmolarity (must be 260 - 320) 
- check pH (must be 7.3 - 7.5) 
- fill out and autoclave 
- after opening, expired after 1 month 
- Ficoll-Paque PLUS   GE Healthcare 17-1440-03 
- RPMI 1640, with 25 mM Hepes,  Lonza BE12-115F/U1 
with Ultraglutamin-1 
- Fetal Bovine Serum (FCS)  Lonza DE14-801F,  
- PEN-STREP (10.000 U Penicillin/ml, Lonza DE17-602E 
10.000 U Streptomycin/ml) stock 
- Dimethylsulfoxid (DMSO)  Merck 8.02912.1000 
 
- Culture fluid 1    90% RPMI 1640, with 25 mM Hepes, with                        
                                                                        Ultraglutamin-1 
+ 10% FCS 
+ 1% PEN-STREP (i.e. 5 ml PEN-STREP 
stock solution to 500 ml of Culture fluid) 
- store at 4°C 
- expired after 1 month 
 
- Culture fluid 2    80% Culture fluid 1 
+ 20% DMSO 
- prepare fresh, on ice 
- expired after 1 day! 
 
- 50 ml polypropylene tubes   BD Biosciences (Falcon) 352070  
 
- Cryovials, 1.2 ml, certified Rnase,  Simport, Canada T309-1A 
Dnase, Pyrogen and DNA-free 
- Lab-durable vinyl labels, 50mm x 16mm eg. Brady B-427 
 
- Suitable label printer   eg. Brady BP-4000 
- Cryo 1ºC Freezing Container   Nalgene 5100-0001 
- filled with 250 ml propanol-2 





Personal and environmental protection 
Wear gloves when working with human blood or serum. Work in a flow cabinet level II. 
Dangerous materials 






toxic, inflammable, explosive 













Note: Make sure that peripheral blood, PBS, Ficoll and centrifuge are at room 
temperature (~18 - 22°C). 
 
Place Culture fluid 1 and Culture fluid 2 on ice.  
1. Determine the White Blood Cell count, using a cell counter. 
2. Dilute sodium-heparinized blood 1:1 with PBS at room temperature. 
3. Carefully layer diluted blood on top of Ficoll (2:1, eg. 30 ml of diluted blood on 
15 ml of Ficoll) in 50 ml polypropylene tubes. 
4. Centrifuge 15 min at 1000 g, at room temperature, without break (light off). 
5. Draw off the upper (plasma) layer, leaving the PBMC layer undisturbed at the 
interface. 
6. Using a sterile Pasteurs pipette transfer the PBMC layer to a clean 50-ml 
polypropylene tube. 
7. Add PBS to a total volume of 50 ml. 
8. Centrifuge 10 min at 800 g. 
9. Remove the supernatant. 
10. Place the tube, containing the cells on ice. 
11. Resuspend the cells in a certain volume of cold Culture fluid 1, eg 1.0 ml. 
12. Determine the PBMC cell count. 
13. Determine the exact amount of cells to freeze per vial: 
Preferably store 2 vials (15 - 25 *10
6
 PBMC in a total volume of 1.0 ml per vial). 
14. Label the Cryovials to be used in a proper way (5 lines on a 50mm x 16mm label): 
 
eg. BD-UG-5023 <Disease code1-Short name participant2-patientID of the 
Institute> 
 BD 10-MAY-83 <Birth Date, dd-mmm-yy, 2nd characteristic> 
 PBMC 
 19.2*10E6 <amount of cells> 
 12-JUL-08 <date (dd-mmm-yy) of sampling> 
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Note: In case of a follow up sample: use the same patient ID, but different date of       
sampling! 
 
15. Slowly, in droplets add cold Culture fluid 2 (1:1) to the cell suspension. 
16. Aliquot: 1.0 ml of cell suspension per cryovial. 
17. Immediately put the vials in a Cryo 1ºC Freezing Container into the -80°C freezer. 




- Complete the whole procedure on the same day of blood drawing. 










































PBMC Cell Culture Protocol 
 
1        INTRODUCTION 
  
This instruction describes an assay to defrost PBMC frozen (see the PBMC isolation 
using Ficoll Plaque, freezing and storage of viable cells Protocol) analyse GR function in 
vitro. 
 
2        DEFINITIONS AND ABBREVIATIONS  
 
3        THEORY  
 
4        SAFETY  
 
5        NECESSARY MATERIALS   
 
● FALCON 3077, 96 well 
 
● PBS x1, sterile, pH=7.2 
 
● LPS (Sigma, Ref#L2880; 10mg) 
 
● Dexamethasone (Sigma, Ref#D1756; 500mg, MW:392.46) 
 
● Clomipramine (Sigma, Ref#C7291-1G; 500mg, MW:351.3) 
 
● Citalopram hydrobromide (Sigma, Ref#C7861-10MG, MW: 405.3) 
 
● Methyl all-cis-5,8,11,14,17-eicosapentaenoate (Sigma, Ref#E2012-1MG,    




● Culture fluid 1       90% RPMI 1640, with 25 mM Hepes, with Ultraglutamin-1 
                                                + 10% FCS 
                                                + 1% PEN-STREP (i.e. 5 ml PEN-STREP stock solution to     
                                                500 ml of Culture fluid) 
- store at 4°C 




6     In vitro experiment PBMC 
 
Final concentrations:   
                          
LPS                                                               1 ng/ml 











Clomipramine                                              10
-5 
M 
Citalopram                                                   10
-5 
M 






Experiment day 1 
 
Concentration Dilution (L) CF1 volume (L) Final total volume (L) 
LPS 20 ng/mL 20 980 1000 
DEX 2 x 10
-4
M 8 995 1000 
DEX 2 x 10
-5
M 100 900 1000 
DEX 2 x 10
-6
M 100 900 1000 
DEX 6 x 10
-7
M 300 700 1000 
DEX 2 x 10
-7
M 335 665 1000 
DEX 2 x 10
-8
M 100 900 1000 
CLOMIPRAMINE 7.1 993 1000 
CITALOPRAM 8 992 1000 
EPA 33 467 500 






6.1–LPS (FREEZER -20) 
           
Product: Sigma (10mg) - Ref # L2880 
 
 
a) To prepare the stock solution: Take 10 mg of LPS and add 10 mL of PBS 7.2 and 
stock in -20
0
 C Freezer (Final concentration: 1mg/mL). Stock 3 L per eppendorff. 
 
b) To prepare the solution for use in the culture: 
 
b.1) Take 1 L of the LPS stock solution (1mg/mL) and add to 1000 L of PBS. Use the 
vortex in solution. (Final concentration: 1g/mL) 
 
b.2) Take 20 L of the LPS working solution (1g/mL)) and add to 980 L of CF1. Use 








6.2 – DEXAMETHASONE (FRIDGE)    
 
Product: Sigma (500 mg) – Ref # D1756-1G – MW: 392.47  
 
 
a) To prepare the stock solution: Take 10 mg of dexamethasone and add 1 mL of 
alcohol (Final concentration: 10mg/mL or 25.48 x 10
-3
 M).  
 
 
b) To prepare the solution to use in the culture: 
 
b.1) Take 7.8 L (8 L) of the dexamethasone stock solution (25.5 x 10
-3
 M) and add to 




b.2) Take 100 L of the dex solution (2 x 10
-4
 M) and add to 900 L of CF1. 




b.3) Take 100 L of the dex solution (2 x 10
-5
 M) and add to 900 L of CF1. 




b.4) Take 300 L of the dex solution (2 x 10
-6
 M) and add to 700 L of CF1. 
(Final concentration: 6 x 10
-7
 M)  
 
b.5) Take 335 L of the dex solution (6 x 10
-7
 M) and add to 665 L of CF1.  




b.6) Take 100 L of the dex solution (2 x 10
-7
 M) and add to 900 L of CF1. 
(Final concentration: 2 x 10
-8
 M) 




6.3 – CLOMPIPRAMINE (FRESH)        
 
Product: Sigma (500 mg) – Ref # C7291-1G – MW: 351.3 
 
 
Prepare CMI solution always fresh (0.028M or 10mg/mL) by adding 1 mL of PBS to the 
10 mg CMI weighed powder, or equivalent. Use the vortex in solution. 
 
To prepare the solution for use in the culture 
 














 6.4 – CITALOPRAM (FRESH)        
 
Product: Sigma (10 MG) – Ref # C7861-10MG – MW: 405.3  
 
 
Prepare CIT solution (0.025M or 10mg/mL) by adding 1 mL of ethanol to the 10 mg CIT 
powder, or equivalent. Use the vortex in solution. Store in -20ºC. 
 
 
To prepare the solution for use in the culture 
 









6.5 – METHYL ALL-CIS-5,8,11,14,17-EICOSAPENTAENOATE   
 
Product: Sigma (1MG) – Ref #E2012-1MG 
 
 
Prepare EPA solution (0.003M or 10mg/mL) by adding 1 mL of ethanol to the 1 mg 
EPA, or equivalent. Use the vortex in solution. Store in -20ºC. 
 
 
To prepare the solution for use in the culture 
 









6. 6 – Ethanol solution for adding to the control culture wells 
 
















7       In vitro Peripheral Blood Mononuclear Cells (PBMC) Experiment: 
  
Prepare LPS, Dexamethasone, Clomipramine, Citalopram, EPA and ETOH 
dilutions. Add 10μl of the dilutions to the required wells. 
 
Take one tube of frozen PBMC from liquid nitrogen/-80
0
 C freezer and transfer 
immediately to a 37
0
 C bath. Warm up 10ml CF1 in a 15 ml tube in the water bath. While 
the cells still have a little bit of ice inside, transfer them to the 15mL tube with 10mL of 
CF1 inside. Centrifuge 800g, 5 min, RT and discard the supernatant. Then, add 1mL of 
CF1 and proceed to cell count.  
 
COUNTING CELLS: to prepare the hemacytometer, first clean the hemacytometer with 
H2O and then with 70% ethanol. Dry it off with a Kimwipe. Put 90μl PBS on a well, add 
10 μl of cell suspension (using 10-100 uL pipette) and 100uL of trypan blue Mix well 
with pipette. Cell count: Place hemacytometer on the counter. Centre a cover glass over 
the hemacytometer chambers. Fill one chamber with 10 μl of the cell dilution using a 10-
100μl pipette.  
 
Count the amount of cells to be added to each well (100K). Calculate and add CF1 for the 




8       INCUBATION 
  
The plate will be incubated on a plate shaker at 37 
0
C with 5% CO2 for 24 hours. 
              
 
 
9       AFTER 24 HOURS 
 
Centrifuge the plate 1000g, 10 min, 4 
0
C. Transfer the supernatant from each well to a 
labelled eppendorf and store in -80
0





10     REMARKS   
 
 
11     REFERENCES 
 
 






Appendix-L IL-6 ELISA Assay 
IL-6 ELISA ASSAY   
For Culture Supernatants 
 
 
1. INTRODUCTION  
 
This instruction describes an assay to analyse any human cytokine with ELISA 
for less than 2 euros/sample. This method has been used in the past for TNF-
alpha, IL-1alpha, IL-1beta, ril-1RA, INF-alpha, IL-4, IL-6, IL-8, IL-10, and IL-
12p40. 
 
2 DEFINITIONS AND ABBREVIATIONS  
 
IL-6, interleukin 6; BSA, bovine serum albumin; PBS, phosphate buffer saline 
 
 
3 THEORY  
 
 
4 SAFETY   
 
 
5 NECESSARY MATERIALS 
   
● Costar 3590, 96 well 
● PBS pH=7.8 (PBS pH7.8, Gibco 20012019) 
● NaCl (BDH Chemicals Ltd. Poole England, Prod. 10241 / 9092083C) 
● Tween 20 (Fisher Scientiffic, BP-337100) 
● BSA (Sigma A9647, 50G) 
● Capture antibody 
   Invitrogen: Ms mAb Anti-Hu IL-6  
   (REF: AHCO562 / LOT 72575914A) 
● Recombinant human IL-6  
   R & D system: Recombinant Human IL-6  
   (Catalogue Number 206-IL / LOT OJZ0410052) 
● Detection antibody 
   Invitrogen: Ms mAb Anti-Hu IL-6 Biotin 
   (REF:  AHCO469 / LOT 72682798A) 
● Required dilutions to be checked through website 
● Streptavidine poly HRP (Thermo Scientific, Prod # N200)  
● TMB Substrate (Thermo Scientific Prod  #3402)  











Preparation of the wash buffer: 
 
MilliQ water + 0.9% NaCl + 0.05% Tween20 per plate (9g NaCl & 500uL Tween 20 in 




Preparation of blocking buffer & working buffer: 
 
PBS pH=7.8 + 0.5% BSA (0.5mL BSA in 100mL PBS). Can be kept for 24 hours. If you 
wish to keep it for up to 2 weeks, increase the amount of BSA to 5%. (30ml PBS 7.8 + 




To coat the plate: 
 
After the capture antibody incubation overnight, take it out and pipette 300uL on block 
buffer. Do not wash it. Take the excess out by flipping the plate. Dry it upside down in a 











1. Capture antibody dilution (1:1000, 10uL in 10ml) in PBS (pH=7.8).  
Correct dilution has to be checked for each cytokine. 
2.  Coat 96 well flat bottom plates with 100uL of the diluted capture antibody. 
Seal the plate and incubate over night at 4 C. 
  
 
             Day 2 
   
3. Prepare wash and blocking buffer. 
4. Empty wells by tapping it on a paper filter quickly. Add block buffer 300uL 
and incubate for 2h in room temperature. In the meantime prepare the 
standards. 
5. Wash the plates 4 times with 300uL of washbuffer per well, using the plate 
whasher machine.  
6. Prepare the standard curve in the same CF1 you have used for your culture 
by diluting the stock (500, 250, 125, 62.5, 31.25, 15.75, 7.8, 3.9, 1.95, 0) to 
make 9 points plus blank in duplicate. Dilute it in your samples in 10ml of 
working buffer. 
7. Prepare the detection antibody in working buffer (1:500), the recombinant 
human cytokines and your samples to the plates. 




9. Add 50uL of the diluted detection antibody to each well. 
10. Incubate 2hr on a plate shaker at room temperature. 
11.Wash the plate 4 times with 300uL of wash buffer per well, using the plate 
washer. 
12. Dilute the streptavidin poly HRP 1:15000 (66uL in 10ml) in working buffer 
and add 100uL to each well. 
13. Incubate 30 minutes on a plate shaker at room temperature. 
14. Put the substrate at room temperature. 
15. Wash the plates 4 times with 300uL of wash buffer per well, using the plate 
washer machine. Make sure to tip it well! 
16. Just before use, prepare TMB solution by mixing substrate A and peroxidise 
solution substrate B (1:1). Then pipette 100uL per well. For an entire plate 
mix 5mL substrate A + 5mL substrate B. 
17. Incubate on a plate shaker at room temperature until you see a clear standard 
curve (or when the BLANK will start to be slightly blue). 
18. Stop the reaction with 100uL of 1M H2SO4 per well. 










- BSA30%, Capture Ab, Detection Ab, TMB are kept in the fridge. 
- Recombinant IL-6 is diluted 1:10000 ng/ml (5 ml R&D in 50 ml WB) for     
standard curve. The standard curve aliquots (700uL) are kept at -80°C   
                       labelled SC24/05/11. 
- Streptavidin is diluted 1:100 (250uL in 25ml PBS), aliquoted (75uL) and  




8 REFERENCES   
 
 








Appendix-M RNA Isolation from PAXgene 
RNA ISOLATION FROM PAXGENE 
1. Defrost samples for 3 hours before beginning processing. 
 
2. Invert PAXgene tubes twice and then centrifuge for 15 min at 3000x g with 
break. 
 
3. Remove the supernatant by decanting into waste bottle containing trigene. 
 
4. Add 4 ml RNase-free water to the pellet, and close the tube using a fresh 
secondary Hemogard closure. 
 
5. Vortex  until  the  pellet  is  visibly  dissolved,  and  centrifuge  for  15  min  at 
3000 x g with break. Remove the entire supernatant by decanting and discard. 
 
6. Add 350 µl Buffer BM1, and pipette up and down until the pellet is visibly 
dissolved then pipette the sample into a 1.5 ml eppendorf tube. 
 
7. Add 300 µl Buffer BM2 and 40 µl proteinase K. Mix by vortexing for 5 s, and 
incubate for 10 min at 55°C in an incubator (PSDL space). 
 
8. Pipette (use 700 µl setting)  the  sample  into  a  PAXgene  Shredder  spin  
column  (lilac)  placed  in  a  2  ml processing tube, and centrifuge for 3 min at 
full speed 16,000 x g (PSDL space). 
 
9. Remove inner lilac part. Carefully  transfer  the  entire  supernatant  of  the  
flow-through  from  the  PAXgene Shredder spin column to a new 1.5 ml 
eppendorf tube without disturbing the pellet in the processing tube. (Re 
centrifuge is pellet is disturbed). 
 
10. Add 700 µl of isopropanol (100%, purity grade p.a.), and mix by vortexing for 
15seconds. 
 
11. Pipette  700  µl  sample  into  the  PAXgene  RNA  spin  column  (pink)  
placed  in  a  2  ml processing tube. Close the lid gently, and centrifuge for 1 
min at 16,000 x g. 
 
12. Place the spin column in a new 2 ml processing tube, and discard the old 
processing tube containing flow-through. 
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13. Pipette the remaining sample into the PAXgene RNA spin column (pink). 
Close the lid gently, and centrifuge for 1 min at 16,000 x g. Place the spin 
column in a new 2 ml processing tube, and discard the old processing tube 
containing flow-through. 
 
14. Add 350 µl Buffer BM3 to the PAXgene RNA spin column. Close the lid 
gently, and centrifuge for 15 s at 16,000 x g. Place the spin column in a new 2 
ml processing tube, and discard the old processing tube containing flow-
through. 
 
15. Add 10 µl DNase I stock solution to 70 µl Buffer RDD in a 1.5 ml 
microcentrifuge tube (this is per sample so multiply amounts by number of 
samples). Mix by pipetting up and down or by gently flicking the tube. 
      Note: DNase I is especially sensitive to physical denaturation. Do not       
      vortex.               
 
16. Pipette the DNase I incubation mix (80 µl) directly onto the PAXgene RNA 
spin column membrane (without touching the membrane), and incubate on 
the bench top (20–30°C) for 15 min. 
 
17. Add 350 µl Buffer BM3 to the PAXgene RNA spin column. Close the lid 
gently, and centrifuge for 15 s at 16,000 x g.  Place the spin column in a new 2 
ml processing tube, and discard the old processing tube containing flow-
through. 
 
18. Add 500 µl Buffer BM4 to the PAXgene RNA spin column. Close the lid 
gently, and centrifuge for 15 s at 16,000 x g. Discard the flow-through. Place 
the spin column in a new 2 ml processing tube, and discard the old processing 
tube containing flow-through. 
 
19. Add another 500 µl Buffer BM4 to the PAXgene RNA spin column. Close the 
lid gently, and centrifuge for 2 min at 16,000 x g. 
 
20. Discard the processing tube containing flow-through, and place the PAXgene 
RNA spin column in a new 2 ml processing tube (supplied). Centrifuge at 
16,000 x g for 1 min. It  is  important  to  dry  the  spin  column  
membrane,  since  residual  ethanol  may  interfere with downstream 
reactions.   
 
21. Discard the processing tube containing flow-through. Place the PAXgene 
RNA spin column in a new 1.5 ml microcentrifuge tube, and pipette 40 µl 
Buffer BR5 directly onto the PAXgene RNA spin column membrane 
(without touching the membrane). Close  the  lid  gently,  and  centrifuge  for  





22. Collect ice and for the following steps keep samples on ice. 
 
23. Collect the flow-through and pass through the spin column again by pipetting 
directly onto the PAXgene RNA spin column membrane (without touching 
the membrane). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
